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RÉSUMÉ 
Le cartilage articulaire hyalin recouvre l’extrémité des os longs. Sa capacité de guérison 
intrinsèque est faible puisqu’il n’est pas vascularisé. Suite à une blessure, la guérison n’a 
généralement pas lieu, ou demeure de faible amplitude. Une dégénérescence des lésions peut 
également survenir suite au relargage de cytokines et autres facteurs inflammatoires. Un 
déséquilibre entre les activités anaboliques et cataboliques peut éventuellement induire l’érosion 
du cartilage, l’exposition de l’os sous-jacent et l’ostéoarthrite. 
Les techniques de stimulation de la moelle osseuse sont une façon de stimuler la guérison du 
cartilage en perçant l’os situé sous les lésions du cartilage. Les canaux percés permettent aux 
cellules progénitrices qui se trouvent dans la moelle osseuse (bone marrow progenitor cells en 
anglais) de migrer vers les lésions. Ces cellules progénitrices se différencient et synthétisent un 
tissue de granulation qui sera remodelé en tissue de guérison. Les techniques de stimulation de la 
moelle osseuse sont beaucoup utilisées en clinique puisqu’elles sont simples et peu coûteuses à 
effectuer, que les patients se rétablissent rapidement après la chirurgie et qu’elles sont efficaces 
pour diminuer la douleur. Cependant, les bienfaits ressentis ne sont pas durables puisque le tissu 
de guérison est un tissue fibrocartilagineux qui ne possède pas les propriétés biologiques et 
mécaniques du cartilage hyalin. Les inconvénients les plus communs observés au cours d’études 
pré-cliniques et cliniques portant sur les techniques de stimulation de la moelle osseuse sont une 
guérison incomplète, une grande variabilité inter-individu, et des résultats insatisfaisants, surtout 
chez les individus plus âgés. Il a déjà été démontré dans des études pré-cliniques que 
l’emplacement de la lésion ainsi que l’âge de l’animal sont deux paramètres qui affectent 
grandement la guérison. Plus spécifiquement, chez le lapin, les lésions situées sur la trochlée 
guérissent mieux que les lésions situées sur le condyle fémoral médial, ce qui suggère que les 
cellules progénitrices de la moelle osseuse présentes aux deux emplacements ne possèderaient 
pas les mêmes propriétés biologiques intrinsèques. 
L’objectif de la première étude de cette thèse était de déterminer l’effet de l’emplacement et de 
l’âge de l’animal sur les propriétés biologiques intrinsèques des cellules progénitrices de la 
moelle osseuse. Pour ce faire, les propriétés biologiques des cellules isolées à partir de la trochlée 
et des condyles chez des lapins jeunes et âgés ont été caractérisées. Ensuite, puisque de 
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précédentes études chez le lapin ont démontré qu’un perçage profond à 6 mm favorise la guérison 
du cartilage dans la trochlée en comparaison à un perçage peu profond, les propriétés biologiques 
de cellules progénitrices isolées à partir de la moelle métaphysaire (région profonde) et de la 
moelle épiphysaire (région peu profondes) ont été caractérisées. Deux méthodes d’isolation des 
cellules progénitrices ont été utilisées, soit la digestion enzymatique à la collagénase et la culture 
d’explants osseux. Pour chaque population de cellules progénitrices, le rendement cellulaire, le 
potentiel clonogénique et l’expression de différents marqueurs ont été déterminés in vitro. Le 
potentiel chondrogénique a, quant à lui, été déterminé en stimulant les cellules progénitrices avec 
un milieu de culture chondrogénique contenant de l’ascorbate, ITS et TGF-III. Enfin, le 
potentiel ostéogénique a été déterminé en stimulant les cellules progénitrices avec un milieu de 
culture ostéogénique contenant du dexamethasone, de la β-glycerophosphate et de l’ascorbate. 
Une comparaison entre les propriétés biologiques obtenues pour les cellules progénitrices 
provenant des condyles, de la trochlée profonde, ou de la trochlée peu profonde, pour les lapins 
jeune ou âgés et pour les cellules isolées par digestion enzymatique ou par culture d’explants a 
ensuite été effectuée. Selon les critères établis par l’International Society for Cell Therapy, les 
cellules progénitrices isolées lors de l’étude pouvaient être décrites comme une population de 
cellules souches mésenchymateuses. Les condyles avaient un faible rendement cellulaire en 
comparaison à la trochlée et les cellules progénitrices isolées à partir des condyles avaient 
également de faibles potentiels clonogénique et chondrogénique. En revanche, les cellules 
progénitrices isolées à partir de la trochlée possédaient un haut rendement cellulaire, des 
potentiels clonogénique et chondrogénique élevés et exprimaient beaucoup de 
glycosaminoglycanes et de collagène type II, deux molécules présentes dans le cartilage 
articulaire hyalin. Le site d’isolation ou l’emplacement était donc un facteur déterminant pour les 
propriétés biologiques des cellules progénitrices, ce qui suggère que le potentiel de guérison 
élevé observé dans la trochlée du lapin serait dû à la présence d’une population nombreuse de 
cellules progénitrices ayant un fort potentiel chondrogénique. L’âge des lapins s’est aussi avéré 
être un facteur important puisque le rendement cellulaire, l’expression de marqueurs pour cellules 
souches et la différenciation chondrogénique et ostéogénique étaient meilleurs chez les lapins 
jeunes que chez les lapins âgés. Enfin, il n’y avait pas de différence entre les cellules isolées par 
digestion enzymatique ou par culture d’explants. 
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L’objectif de la deuxième étude de cette thèse était de déterminer s’il existe une corrélation entre 
les propriétés biologiques intrinsèques des cellules progénitrices de la moelle osseuse et la 
capacité de guérison du cartilage sus-jacent. Pour ce faire, un modèle bilatéral a été effectué chez 
8 lapins. Pour chaque lapin, des lésions cartilagineuses ont été créées sur un genou à deux 
emplacements (la trochlée et le condyle fémoral médial) puis traitées par microperçage, tandis 
que l’autre genou demeurait intact. Après 3 semaines de guérison, les lapins ont été sacrifiés et 
des sections histologiques ont été récoltées du genou traité par microperçage afin d’évaluer la 
guérison. Parallèlement, les cellules progénitrices du genou intact ont été récoltées et leurs 
propriétés biologiques caractérisées tel que décrit ci-haut. Chez tous les lapins, la guérison induite 
par stimulation de la moelle osseuse était compromise dans le condyle fémoral médial, où très 
peu de tissu de guérison était présent après 3 semaines. En revanche, une guérison modérée à 
excellente était apparente dans la trochlée de 6 lapins sur 8, alors que 2 lapins ont été classifiés 
comme faisant partie d’un groupe ayant un plus faible potentiel de guérison. Tout comme pour la 
première étude, les cellules progénitrices de la trochlée avaient un meilleur rendement cellulaire 
et de forts potentiels clonogénique et chondrogénique que les cellules des condyles. Une 
variabilité inter-individu était également présente dans le cas des propriétés biologiques des 
cellules progénitrices. Les tissus de guérison de la trochlée ainsi que la matrice extracellulaire 
synthétisée par les cellules progénitrices isolées à partir de la trochlée contenaient une grande 
quantité de glycosaminoglycanes et de collagène type II. Des analyses statistiques ont permis de 
déterminer qu’il existait de fortes corrélations positives entre les propriétés intrinsèques des 
cellules progénitrices de la moelle osseuse et la capacité de guérison du cartilage sus-jacent. Les 
propriétés biologiques ayant le plus d’impact sur la guérison ont été identifiées.  
L’objectif de la troisième étude de cette thèse était de développer un modèle animal représentatif 
de la situation clinique, et d’y tester une nouvelle méthode de guérison. En clinique, les lésions 
du cartilage sont rarement détectées rapidement, ce qui complique le traitement. Une grande 
variabilité de la réponse et une guérison compromise sont également observées chez les patients 
plus âgées souffrant de lésions dégénératives chroniques. La rétraction du caillot sanguin qui 
remplit les lésions cartilagineuses suite au microperçage et sa perte subséquente sont une raison 
qui pourrait expliquer les résultats insatisfaisants observés en clinique. Il a été démontré que le 
chitosane permet d’inhiber la rétraction du caillot sanguin et, par le fait même, qu’il promeut la 
guérison du cartilage en ayant des effets sur le recrutement cellulaire, la vascularisation and le 
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remodelage osseux. Le plasma riche en plaquettes (PRP) contient une concentration élevée de 
facteurs de croissance capables de stimuler le recrutement cellulaire et la différenciation 
chondrogénique. Il a été démontré que le chitosane favorise la stabilité du PRP et le relargage de 
facteurs de croissance. Un modèle de lésions cartilagineuses chroniques a d’abord été développé 
chez le lapin. Deux chirurgies était nécessaire pour effectuer ce modèle. Au cours de la première 
chirurgie, des lésions cartilagineuses bilatérales ont été induites dans la trochlée de 8 lapins et 
laissées sans traitement pendant 4 semaines afin qu’elles dégénèrent à un stade chronique. Au 
cours de la deuxième chirurgie, ces lésions cartilagineuses ont été traitées par microperçage et par 
l’implantation de chitosane lyophilisé solubilisé dans du PRP autologue, ou par injection de PRP 
seul, comme contrôle. Le tissu de guérison a été récolté après 2 mois et des sections histologiques 
ont permis d’évaluer la quantité et la qualité du tissu de guérison. La guérison osseuse ainsi que 
le remodelage osseux ont également été caractérisées par analyse micro-CT. Les implants 
chitosane-PRP favorisaient la guérison des lésions cartilagineuses chroniques comparées au PRP 
seul. La composition biochimique de la matrice cartilagineuse ressemblait plus à du cartilage 
hyalin en présence des implants chitosane-PRP. Finalement, l’analyse micro-CT démontrait que 
les implants chitosane-PRP favorisent le remodelage osseux mais que le phénomène est toujours 
en cours après 2 mois de guérison. 
En résumé, le contenu de cette thèse nous a permis d’identifier certaines variables liées à 
l’emplacement, au donneur et à l’âge qui expliqueraient partiellement la variabilité inter-individu 
et les résultats décevants parfois obtenus suite à une stimulation de la moelle osseuse. Le modèle 
de lésions chroniques décrit dans cette thèse contribuera grandement au développement de 
nouvelles techniques et de nouveaux produits pour favoriser la guérison du cartilage articulaire. 
Enfin, les implants chitosane-PRP étudiés au cours de cette thèse constituent une approche 
prometteuse qui pourrait éventuellement servir à soulager des patients souffrant de lésions 
chroniques ou dégénératives. 
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ABSTRACT 
Articular cartilage is a thin layer of hyaline cartilaginous tissue covering the ends of long bones. 
Due to its avascular nature, it possesses very limited regeneration potential. In the event of an 
injury, the repair is either very limited or not initiated at all. As a result, cartilage lesions 
degenerate extensively under the influence of damaging cytokines and proinflammatory factors 
released. An imbalance in anabolic and catabolic activities continues to erode the cartilaginous 
surface exposing subchondral bone leading to osteoarthritis.   
Bone marrow stimulation (BMS) initiates repair by fracturing or drilling into subchondral bone. 
The channels created provide access to the underlying subchondral progenitor cells  that are 
recruited into the defect. Granulation tissue thus formed undergoes a complex cascade of events 
to generate a repair tissue. BMS is considered a gold standard of cartilage repair strategies since it 
is easy, relatively less invasive with swift recovery, more economical and appreciable short-mid 
term relief. However, long term outcome is generally discouraging due to poor durability of 
repair tissue. The quality of repair tissue is generally fibrocartilagenous with inferior mechanical 
and biological characteristics compared to hyaline cartilage. The most common drawbacks of the 
procedure include incomplete regeneration, high inter-individual variability and poor repair 
outcome especially in older individuals in preclinical as well as clinical studies. Earlier studies 
have shown that defect location and animal age affect the cartilage repair outcome observed in 
vivo, suggesting a strong influence of biological characteristics of progenitor cells (Bone Marrow 
stem cells; BMSCs or mesenchymal stem cells; MSCs) present in subchondral bone. Specifically, 
rabbit trochlea showed a superior repair and chondrogenic potential compared to the medial 
femoral condyle. Inspired by these observations, we carried out a study for comprehensive 
analysis of progenitor cells present in the subchondral bone of condyle and trochlea in young and 
old rabbits in order to determine the influence of location and age on the properties of progenitor 
cells. Earlier we had found that drilling to 6 mm improves the repair outcome in rabbit trochlea 
possibly by providing access to metaphyseal marrow and thus higher progenitor cell population. 
As a result, MSCs were isolated from epiphyseal (trochlea upper) and metaphyseal (trochlea 
lower) regions of the trochlea. Collagenase-derived MSCs originated from collagenase digest of 
bone chips while the digested explants were subsequently cultured to obtain explant-derived 
MSCs via cell outgrowth. In vitro characterization assays were used to determine the cell yield, 
clonogenic potential and surface marker expression profile. Chondrogenic differentiation was 
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stimulated using pellets of condylar and trochlear MSCs in the presence of chondrogenic media, 
rich in chondrogenic stimulating factors such as ascorbate, insulin-transferrin-selenium (ITS) and 
TGF-βIII. Finally, MSCs were differentiated into osteogenic lineage in presence of osteogenic 
media containing osteogenic stimulants such as dexamethasone, β-glycerophosphate and 
ascorbate. The aforementioned MSC characteristics were compared for trochlea vs. condyle, old 
vs. young and collagenase- vs. explant-derived cultures. MSCs isolated from distal femur 
epiphyseal bone had stem cell characteristics and fulfilled the stem cell criteria outlined by 
International Society for Cell Therapy. Location was an important factor influencing the 
properties of MSCs indicated by low cell yield, clonogenic potential and inferior chondrogenic 
potential of condylar cells. Results showed that rabbit trochlear vs. condylar subchondral bone 
yielded a greater number of progenitors with superior cartilaginous matrix expression under 
chondrogenic conditions suggesting higher intrinsic capacity for cartilage repair compared to 
condylar subchondral bone. Trochlear MSCs displayed superior chondrogenic differentiation 
evidenced by higher glycosaminoglycan (GAG) and collagen type II deposition. Age of the donor 
was an additional factor with significant bearing on the inherent properties of MSCs since growth 
rate, cell yield, expression of stem cell markers and osteogenic differentiation were found to be 
significantly superior in younger animals. As expected, no significant difference was observed 
between collagenase- and explant-derived cultures. 
Continuing our exploration of the mechanisms underlying variability in BMS procedure, we 
carried out the next study to verify if the cartilage repair outcome in condyle and trochlea 
correlated with the pre-existing properties of progenitor cells present in these two sites. A 
bilateral rabbit model was used to test this hypothesis. For each rabbit, full thickness acute 
defects were created in one knee and treated by BMS by microdrilling, while the second knee 
was left intact. Animals were sacrificed 3 weeks later and transverse sections of repair tissue 
from the treated knee were used to analyze the quality and quantity of repair macroscopically and 
by safranin- O (Saf-O) and immunostaining. At the time of animal sacrifice, distal femurs were 
separated and MSCs were isolated from condylar and trochlear regions of the intact contralateral 
knee for biological characterization of cell yield, clonogenic potential, cell surface marker profile 
and differentiation potency. BMS induced inferior cartilage repair in condyles of all donors 
studied further underlining the implication of location in influencing repair outcome. 
Macroscopic examination revealed extremely poor fill in condylar defects. In contrast, moderate 
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to excellent fill was observed in six out of eight trochlear defects. This led us to identify a donor-
dependent variability in repair outcome and the donors were classified as good trochlear 
responders and poor trochlear responders. In another observation, trochlear MSCs were 
characterized by increased cell yield, higher clonogenic potential and superior chondrogenic 
potential. Histopathological analysis indicated better matrix composition, rich in GAG and 
collagen type II in trochlea both in vivo and in vitro. Donor related variability in repair outcome 
was also observed in vitro through biological characterization of MSCs. Statistical analysis 
provided substantial evidence to identify strong, positive location- and donor-dependent 
correlations between inherent properties of MSCs and cartilage repair outcome in condyle and 
trochlea and factors with maximum influence on the repair outcome were identified.  
By this stage, it became imperative to seek after a clinically relevant application of our 
understanding based on current and past findings. Cartilage lesions are rarely detected in early 
stages, unfortunately reducing the efficacy of BMS procedure. Unpredictable, highly variable 
repair of poor quality is observed in degenerative defects, especially in older patients. Platelet-
mediated retraction of the blood clot that fills cartilage lesions following BMS is believed to be 
one underlying cause of inferior quality and durability of repair tissue. Chitosan inhibits this 
blood clot shrinkage and leads to the formation of a voluminous, adherent and stable clot and 
thereby enhances cartilage repair by promoting cell recruitment, transient vascularization and 
subchondral bone remodeling. Platelet-rich-plasma (PRP) contains a 2-10 fold concentration of 
growth factors and cytokines and has been shown to improve recruitment and chondrogenic 
potential of subchondral MSCs. Chitosan increases the stability of PRP and promotes the release 
of platelet-derived growth factors in a more sustained manner. Using a more clinically relevant 
chronic defect model, we tested the efficacy of implants composed of freeze-dried chitosan 
solubilized in PRP in improving marrow stimulated cartilage repair outcome compared to BMS 
augmented with just PRP. Two surgeries were performed in skeletally mature rabbits to create a 
bilateral trochlear defect model. Defects created in the first surgery were allowed to degenerate 
over 4 weeks and repaired in a second surgery by BMS. Treatments included BMS augmented 
with chitosan/PRP implants in one knee and BMS with PRP in the other knee. Repair tissue was 
harvested 2 months later and transverse sections were used to characterize the quality and 
quantity of repair by assessing the GAG and coll-II deposition. Subchondral bone repair was 
analysed by micro-CT. Augmentation of BMS with freeze-dried chitosan/PRP implants in 
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chronic defects improved cartilage repair compared to PRP by increasing quantity and quality of 
repair tissue and promoting subchondral bone repair. Matrix composition was improved in 
presence of chitosan/PRP indicated by increased GAG and collagen deposition. MicroCT 
analysis showed further evidence of increased, albeit incomplete, subchondral bone remodeling 
induced by chitosan/PRP.   
In summary, these studies led us to recognize significant donor-, age- and location-dependent 
variability which might help in understanding the mechanism underneath the unpredictability and 
inter-individual variability observed with BMS. Needless to say, these observations would be 
extremely valuable in improving the consistency, durability and quality of BMS repair procedure. 
Moreover, the innovative chronic model studied here is expected to make significant 
contributions in progress of cartilage repair field. Finally, chitosan/PRP implants investigated in 
this research are a promising approach to treat chronic cartilage lesions and could eventually 
provide relief to osteoarthritic patients with challenging, degenerative defects.  
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CHAPTER 1  INTRODUCTION  
1.1 Introduction 
The ends of long bones such as femurs are covered by a thin layer of cartilaginous tissue known 
as articular cartilage [1]. It is a highly specialized skeletal tissue and derives its unique 
biomechanical and physiological properties from an intact matrix comprised of proteoglycans 
and collagen type II [2]. Since this tissue lacks blood, nervous and lymphatic supply, in the event 
of an injury, the regeneration process is either not initiated or is insufficient to restore healthy 
tissue. Chondrocytes, the primary cell type of cartilage- are embedded in copious amount of 
ECM and are unable to migrate to populate the region of defect. Negligible blood supply further 
aggravates the problem since the stimulatory signals required to drive a repair process fail to 
propagate [3]. Full thickness lesions which reach sub-chondral bone undergo a limited repair 
process due to the access to the progenitor cells in the bone marrow stroma, though the quality of 
the repair tissue is mainly fibrocartilagenous with inferior mechanical and physiological 
properties  On the other hand, partial thickness defects are not repaired at all [4, 5].  
The knee joint is the most commonly affected joint and accounts for 75% of all lesions observed 
in articular cartilage. In an early study involving over 31,000 patients, it was found that while 
63% knees had chondral lesions, 20% suffered from full thickness lesions [6]. It is expected that 
60% of the patients who develop cartilage lesions will have osteoarthritis (OA) within 20 years 
of generating an articular cartilage defect [6]. Cartilage loss generally occurs due to age-related 
wear and tear and the likelihood of its degradation increases with increasing age. In a population 
with increasing life expectancy, up to 40% of population above 70 could be expected to be 
affected by OA leading to a burden of 5-20 billion dollars on the Canadian government [7]. 
However, trauma related osteoarthritis is not uncommon and although focal at onset, may 
progress into OA if not addressed swiftly. Cartilage degeneration is multifactorial and involves 
femoral, patellar and synovial compartments. Catabolic activities mediated by pro-inflammatory 
cytokines such as IL-1 and TNF-α are not balanced by anabolic growth factors like IGF-1 and 
TGF-β and anti-inflammatory cytokines like IL-4 and IL-10 [8, 9]. The disrupted equilibrium 
leads to degeneration of matrix exposing the subchondral bone and causing patient discomfort 
[1-5]. 
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Bone marrow stimulation (BMS) initiates cartilage repair by fracturing or drilling into 
subchondral bone at the base of a debrided cartilage defect, typically leading to the formation of 
a fibrocartilagenous repair tissue providing varied levels of clinical relie-f. It is relatively easy, 
economical, associated with swift recovery and provides appreciable short to mid term relief. 
Due to advantages offered by the procedure, BMS is adopted as first line of treatment globally. 
However, repair outcomes are affected by defect location and age, suggesting a strong influence 
of the structural and biological factors in the knee joint. These differences may include 
anatomical differences in the structure of knee as well as biological properties of mesenchymal 
progenitor cells in the subchondral bone. It is well known that human trochlear defects are rarer 
but harder to treat compared to condyles [10], while animal models present varying scenarios. In 
an earlier study, rabbit trochlea showed a superior repair and chondrogenic potential compared to 
medial femoral condyle [11, 12]. On the other hand, quality of repair was better in condyle than 
trochlea in a sheep model [13]. Taken together, these studies emphasize the need to address the 
inconsistent repair outcomes arising from location-dependent factors. Unfortunately, BMS 
procedures are also severely affected by increasing age leading to incomplete regeneration, high 
inter-individual variability and poorer outcome in older individuals. Therefore, identification of 
mechanism for reduced potential of progenitor cells in cartilage repair is required in order to 
understand fundamental causes of poor repair in older individuals. The exact mechanism of 
donor-, location- and age-dependent variability still eludes us since our knowledge about 
underlying factors such as bone structure and mechanics, load-bearing conditions and the role of 
subchondral bone progenitor cells is still extremely limited. A better understanding of the 
underlying causes and mechanism of variability in the marrow stimulated repair outcomes will 
enable us to make the approach more predictable, clinically efficient and personalized to 
patient’s needs. In addition, it will be pave the way to develop strategies to enhance the quality 
of repair, especially in hard to treat cases.  
BMS provides access to the underlying bone marrow stroma rich in bone marrow progenitor 
cells (BMPCs)/bone marrow stem cells (BMSCs)/mesenchymal stem cells (MSCs) by creating 
channels in the subchondral bone [14]. BMSCs are characterized by a unique potential of self 
renewal and ability to differentiate into cells of multiple lineages [15]. When recruited to the site 
of defect, they differentiate into chondrogenic phenotype leading to the formation of a repair 
tissue with varying amounts of hyaline and fibrous cartilage [16]. Since BMS mediated repair of 
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soft and hard tissues relies on recruitment of underlying BMSCs, it is logical to explore the 
properties of these progenitors in order to provide important mechanistic insights into variability 
present in marrow stimulated repair outcomes. It is reasonable to assume that differences in 
number, stemness and differentiation potential of BMSCs will influence the chondrogenesis in 
vitro and cartilage repair in vivo. Biological characterization can be carried out in vitro by means 
of several assays including determination of cell yield, CFU-f, expression of cell surface markers 
and multilineage differentiation assays. In a previously published study, our group demonstrated 
superior repair when trochlea was drilled to provide access to metaphyseal marrow [17]. Due to 
likely differences in the progenitor cell population in the epiphyseal and metaphyseal regions of 
bone, and their subsequent influence on repair response, the cells derived from these locations 
need to be characterized individually. Cells participating in BMS include cortico-spongious bone 
and marrow spaces and therefore characterization of cells originating from both these sources is 
warranted.  
Though repair response induced by BMS along with characterization of BMSCs has been 
investigated in animal models before [18-21], a study designed to correlate the repair response in 
different anatomic locations with biological properties of BMSCs is lacking. Needless to say, 
inherent differences in the properties of BMSCs can be expected to influence cartilage repair 
outcomes in a profound manner. A statistically sound study designed to investigate the influence 
of location- and donor-dependent factors on cartilage repair outcomes is more likely to elucidate 
the underlying mechanism of inter-individual variability observed in cartilage repair. Inferences 
from such an analysis will probably aid clinicians in developing repair strategies on a more 
patient-relevant basis.  
Another reason for poor quality of BMS repair is the compromised residency and stability of 
marrow-derived blood clot that fills cartilage lesions following bone fracturing [13, 18, 19]. Due 
to platelet-mediated clot retraction and serum exudation, the clot can lose more than half of its 
original volume. A retracted clot will eventually lead to early detachment of repair tissue from 
bone bed undermining the efficacy of this procedure. In contrast, a voluminous, physically 
adherent and stable clot is generated when chitosan - a biocompatible and biodegradable polymer 
comprised of glucosamine and N-acetyl glucosamine residues - is mixed with autologous blood 
prior to clotting and leads to an improved osteochondral repair [13]. Platelet-rich-plasma (PRP) 
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containing concentrated platelets is a rich source of growth factors, cytokines and chemokines 
[22-24] and has been shown to provide adequate stimulation for recruitment and chondrogenic 
differentiation of BMSCs [25, 26]. However, PRP clots are even more prone to retraction which 
might lead to insufficient chondrogenesis and hyaline cartilage restoration as reported by some 
authors [27]. A combination of freeze-dried chitosan and PRP would increase the stability and 
bioactivity of PRP likely improving cartilage repair outcomes in challenging cases. Liquid 
chitosan in aqueous solution suffers from limited shelf life due to poor stability during storage 
[28]. Therefore, freeze-dried chitosan offers the advantages of improved stability, longer shelf 
life and easier sterilization.  
The principle of augmented marrow-stimulation relies on the enhanced recruitment of 
mesenchymal progenitor cells to the lesion accompanied by increased stability of growth factors 
and BMSCs in the defect milieu. It is important to bear in mind that cartilage repair does not 
occur in isolation and inflammatory mediators in defect milieu are likely to complicate the 
healing process. Therefore, it becomes imperative to examine cartilage repair strategies in a 
model which is a more realistic depiction of clinical situation. Interplay of catabolic factors 
including damaging cytokines and pro-inflammatory factors are more likely to be represented in 
a model with degenerative, chronic lesions [29, 30]. To ensure successful clinical translation, it 
is critical to explore the potential of chitosan and PRP in improving the repair outcome in 
chronic lesions which are harder to treat compared to acute lesions.  
The objective of the study presented here is to make significant contributions to enhance the 
existing understanding of variability and unpredictability in marrow stimulated repair outcomes. 
The research aims to address the gap in our current comprehension of the underlying 
mechanisms of donor-, age- and location-dependent inconsistency observed with BMS, likely 
arising due to inherent properties of mesenchymal progenitor cells. Correlation of intrinsic 
biological properties of progenitor cells and cartilage repair outcome will eventually enable 
clinicians to perform BMS in a more patient-specific basis where intrinsic repair capacity is 
highly variable and unpredictable. Finally, conclusions from analysis of BMS augmented with 
chitosan/PRP implants in a chronic lesion will likely offer a promising strategy specifically 
designed to enhance the cartilage repair outcome in demanding cases. 
  
5 
 
 
 
1.2 Research Hypotheses and Objectives 
1.2.1 General objective 
The research presented here was carried out with an objective to explore the underlying 
mechanism of variability in marrow stimulated repair outcome by identifying location-, age- and 
donor-dependent factors influencing the inherent properties of subchondral bone progenitor cells 
(or mesenchymal stem cells, MSCs). Furthermore, strategies to improve cartilage repair outcome 
mediated by augmented BMS techniques were investigated in animal studies designed for a more 
accurate representation of the chronic lesions present in the clinical situation.  
1.2.2 Study 1 
The aim of this study was to carry out a comprehensive analysis of the progenitor cells present in 
the subchondral bone of rabbit condyle and trochlea, taking into account location and age 
revealing a likely mechanism for variability in marrow stimulated cartilage repair seen in vivo.  
1.2.2.1 Hypothesis1 
We hypothesized that the inherent biological properties of bone marrow progenitor cells 
(BMPCs; or mesenchymal stem cells, MSCs) including number, clonogenicity, surface marker 
profile and multilineage differentiation potential will be influenced by location and age while 
origin of the cells will have no significant bearing on these properties. Specific hypotheses tested 
through this study included the following: 
 In-vitro biological properties including P0 cell yield, clonogenic potential, expression of cell 
surface markers, chondrogenic and osteogenic differentiation potential will be superior for 
BMPCs/MSCs isolated from rabbit trochlea compared to condyles.  
 Cell yield, stemness markers, clonogenic, chondrogenic and osteogenic potential of 
BMPCs/MSCs will decrease with increasing age.  
 The aforementioned in vitro biological properties of BMPCs/MSCs will not be affected by the 
method of isolation and will be similar for collagenase- and explant-derived BMPCs/MSCs.  
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1.2.2.2 Objective 1 
Isolate progenitor cells (BMPCs/MSCs) from condyles and trochlea of young and old rabbits by 
collagenase digestion of marrow and explant culture followed by comprehensive analysis of their 
biological properties including- a). Cell yield, b). CFU-f, c). Expression of surface markers 
characteristic of bone marrow progenitor cells and d). Multilineage differentiation potential - in 
order to identify the factors influencing inherent properties of progenitor cells and likely to 
impact marrow stimulated repair outcome.  
1.2.3 Study 2 
The aim of this study was to determine the location- and donor-dependent correlation between 
marrow-stimulated cartilage repair outcome and inherent biological properties of BMSCs in order 
to identify the association between cellular behaviour of progenitor cells and variability in 
marrow stimulated repair response.  
1.2.3.1 Hypothesis 2 
Cartilage repair outcome in trochlea will be superior to condyles in an acute rabbit defect model 
and correlate to the pre-existing in vitro biological properties of the BMSCs at the two sites in the 
contralateral knee. Specific hypotheses tested were:  
 The quality as well as quantity of condylar repair tissue will be inferior to trochlear repair 
tissue indicated by lower volume of repair tissue and reduced GAG and collagen type II 
deposition. 
 Inferior repair outcome in condylar defect will correlate positively with reduced cell yield, 
lower clonogenic and inferior multilineage differentiation potential of condyles determined in 
vitro. 
1.2.3.2 Objective 2 
Develop a bilateral model for repair of acute full thickness defect in condyle and trochlea in one 
knee and biological characterization of cells isolated from these 2 sites in the contralateral knee. 
Using appropriate statistical model, correlate the biological properties of BMSCs isolated from 
condyles and trochlea with early (3 weeks) repair outcome assessment parameters. 
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1.2.4 Study 3 
This study was carried with an aim to develop a strategy to enhance cartilage repair response, 
especially in challenging conditions of extensive damage and degeneration. Role of PRP and 
Chitosan/PRP implants in augmentation of marrow stimulated cartilage repair outcome was 
investigated in a chronic defect model using quality and quantity of repair tissue as outcome 
assessment parameters. 
1.2.4.1 Hypothesis 3 
Repair outcome will be better with BMS augmented with freeze-dried chitosan/PRP implants 
compared to BMS augmented with recalcified PRP in an adult chronic trochlear defect model. 
1.2.4.2 Objective 3 
Optimize rabbit chronic defect model and apply it to analyze the outcome of cartilage repair as a 
result of BMS augmented with freeze-dried chitosan/PRP implants. Use macroscopic 
regeneration and matrix composition of repair tissue along with subchondral bone regeneration to 
assess and compare the repair outcome.  
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2. CHAPTER 2  LITERATURE REVIEW 
 
2.1 Articular Cartilage 
2.1.1 Overview 
Articular cartilage is a highly specialized tissue, avascular, aneural and alymphatic and at 
maturity of very low metabolic activity [1]. The main functions of articular cartilage include: a. 
Act as a shock absorber and withstand the compression, tension and shearing forces characteristic 
of a highly active joint such as knee, b.  Distribute load, c. Provide a smooth, frictionless 
articulating surface and prevent damage to the underlying bone. Articular cartilage lacks any 
blood or lymphatic supply and derives its nutrition through synovial fluid present in the synovial 
joint as well as the underlying bone [31]. The exchange of the metabolites, gases and waste 
products also takes place through synovial fluid.  
 
2.1.2 Composition of articular cartilage 
2.1.2.1 Zonal organization   
The medial condyle in young adults is ~2.4 mm thick lying on top of a ~130 µm thick calcified 
cartilage layer followed by a subchondral bone plate ~190 µm thick [32]. The biochemical and 
biophysical properties of cartilage are well adapted to bear repetitive mechanical forces which 
may even reach up to 65 times body weight. The articular cartilage is composed of a network of 
collagen fibres and a proteoglycan matrix within which reside cartilage cells. Healthy cartilage is 
organised into four zones comprising a superficial tangential zone characterized by flattened 
chondrocytes, a middle zone which is comprised of rounded chondrocytes, followed by a deep 
zone where the chondrocytes are spherical and columnar. Calcified cartilage comprised of very 
small chondrocytes forms the fourth inner most zone which is the region of extensive shear stress 
[2].  
 
2.1.2.2 Cells 
The articular cartilage is unique in being composed of mainly just one type of cell, i.e. 
chondrocytes which secrete the ECM that provides the tissue’s structure and contributes to the 
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functional, mainly mechanical role of cartilage. Chondrocytes represents only about 1% of the 
volume of articular cartilage. Chondrocytes also modify matrix properties in response to loading 
due to various mechanotransduction mechanisms [33]. Chondrocytes are mesenchymal in origin 
and differentiate from mesenchymal stem cells in bone marrow. During development the BMSCs 
differentiate into chondrocytes with those at the periphery of the bone and cartilage developing 
into hypertrophic chondrocytes and bringing about calcification and endochondral ossification. 
[1, 33].  
 
2.1.2.3 Extracellular Matrix 
The cartilage matrix is particularly rich in collagens and proteoglycans. The tissue possesses high 
tensile strength owing to the presence of collagen while the proteoglycan matrix which can hold 
up to 75-80% water contributes to the tissue’s capability of resisting compressive forces, one of 
the most important functions of articular cartilage [34]. Collagens form up to 75% of dry tissue 
weight. 90-95% of matrix collagen is type II, which due to associated carbohydrates; promotes 
interaction with water that is a critical requirement for the functional property of cartilage. Type 
X is mainly present in calcified cartilage and is secreted by hypertrophic chondrocytes [34]. 20-
25% of cartilage matrix is composed of proteoglycans such as HA, chondroitin sulphate, keratin 
sulphate, heparin sulphate [1, 33]. The proteoglycans are composed of 95% polysaccharides and 
5% proteins. The glycosaminoglycans associated with proteins play a major role in interaction 
with water. The interaction of these GAGs with water lends the property of flexibility to cartilage 
in addition to displaying excellent mechanical strength and shock resistance properties. 
2.1.3 Development of articular cartilage 
The embryonic development of cartilage begins from mesenchyme at the 5
th
 week of gestational 
age by aggregation of mesenchymal cells to form blastema. These cells express cartilage matrix 
and develop into chondroblasts. The increasing amount of matrix pushes the cells further away 
from each other. The cells become encased in the dense and copious amount of matrix and 
become chondrocytes. Meanwhile, perichondrium is formed by the mesenchymal tissue 
surrounding the blastema [35]. In their study using New Zealand White rabbit model, Hunziker et 
al revealed important insights into post natal development and growth of bone and articular 
cartilage [36]. A temporal trend was clear in the structural maturation of the articular cartilage 
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layer. The growth activity of the articular cartilage layer was highest in the period following birth 
and declined quickly between the first and third months. The growth ceased when the animal 
achieved the puberty between the third and fourth months. The growth activity in the true 
metaphyseal growth plate continued until sexual maturity-8 months in rabbit indicating 
independent regulation of the surface growth plate and metaphyseal growth plate. They found 
that the postnatal reorganization of articular cartilage from an immature isotropic to a mature 
anisotropic structure results from resorption and neoformation of all zones except the most 
superficial zone and not by a process of internal remodelling where the superficial zone was 
comprised of slowly dividing stem cells with bidirectional mitotic activity. The stem cells in this 
zone drive the lateral expansion of the AC layer in addition to replenishing the stem cell pool. In 
addition, the zone is also responsible for the postnatal growth phase of the articular cartilage layer 
by providing rapidly dividing, transit-amplifying daughter-cell pool that feeds the transitional and 
upper radial zones. Therefore, mammalian articular cartilage not only as an articulating layer but 
also as a surface growth plate in the post natal development [37]. 
2.1.4 Articular cartilage defects 
In a review with 993 arthroscopies, 66% of knees contained cartilage pathologies as measured by 
ICRS scoring system [6]. In the US, approx. 900,000 individuals are affected by chondral lesions 
per annum as a result of which more than 200,000 surgical procedures are needed to treat grade 
III and IV defects [38]. In another study with 31,000 arthroscopic procedures, an alarming rate of 
63% incidence of cartilage defects was noted with 41% grade III and 19% grade IV incidence 
[39]. In 1,000 knee arthroscopies evaluated by Hjelle et al., chondral and osteochondral lesions 
were identified in 61% patients, 55% grade III and 5% grade IV [40]. The occurrence of cartilage 
lesions was most frequently observed in the 40s while young adults developed full thickness 
defects in their 30s [41]. Interestingly, weight bearing medial femoral condyle is the most 
commonly affected zone accounting for 58% of all cartilage lesions in the knee.  
 
The International Cartilage Repair Society has developed a method for classification of chondral 
injuries: Grade 0-Normal cartilage, Grade I: Superficial fissures, soft cartilage, Grade II: minor 
tears, lesions extending less than half of the cartilage depth, Grade III: Deep lesions, lesions 
extending more than half but not extending into subchondral bone, Grade IV: severe erosion of 
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cartilage surface penetrating into subchondral bone and exposure of subchondral bone. Cartilage 
defects can be classified into chondral and osteochondral defects depending upon the depth. 
Chondral defects can be either partial thickness or full thickness [42]. Full thickness defects 
which penetrate the subchondral bone are considered osteochondral defects. While repair of 
chondral defects is limited or non-existent, osteochondral defects have some repair potential 
attributed to the mesenchymal progenitors recruited from the subchondral bone. In any case, the 
repair is generally fibrocartilagenous with inferior structural and functional properties with 
extremely compromised functionality (Fig. 2.1) [42-44]. The treatment modalities are dependent 
on defect size, depth and location, chronicity, age of patient, previous treatment among others 
[38]. 
 
Figure 2.1: An arthroscopic view of the knee joint revealing a full thickness cartilage lesion on 
medial femoral condyle leading to exposure of subchondral bone. 
(http://stemcelltreatmentclinic.com/indications/cartilage-defects/) 
2.2 Osteoarthritis 
Osteoarthritis (OA) is the most prevalent form of arthritis affecting up to 15% of population [45]. 
It is characterized by progressive loss of articular cartilage and formation of osteophytes which 
cause chronic pain reducing the quality of life of patients and loss of functional quality of the 
joints. OA is primarily caused by traumatic events, commonly referred to as post traumatic 
osteoarthritis (PTOA). Other causes include flawed position of joints, ageing and genetic 
predisposition [46]. The molecules of interest with respect to OA include agents with a direct 
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bearing on the matrix turnover such as matrix metalloproteinases (MMPs), aggrecanases and 
tissue inhibitors of proteinases (TIMPs) in addition to matrix components collagen and GAGs.  
 
Martinek et al classified the pathophysiology of OA into three stages [47]. The first stage is 
characterized by the degradation of matrix network on a molecular level. An increase in the water 
content is accompanied by loss in aggrecan. This leads to destruction of collagen network and 
cartilage starts to lose its stiffness. In the next stage, chondrocyte clusters are generated as a result 
of cloning of cells which get surrounded by newly synthesized matrix. This is a result of an 
increase in the proliferation and metabolic activity of chondrocytes in order to compensate for the 
ongoing damage to the ECM. Finally, the cartilage tissue is completely degenerated since the 
anabolic activities of chondrocytes are unable to match the degradation processes. This stage is 
further characterized by subchondral bone cysts, formation of osteophytes and osteochondral 
nodules.  
 
As mentioned before, an imbalance in the anabolic and catabolic processes in the articular 
cartilage leads to an increase in degradation as well as synthesis in the cartilage matrix (Fig. 2.2). 
The overexpression of matrix degrading enzymes results in steady loss of collagen and 
proteoglycans which causes the chondrocytes to proliferate and increase synthesis of matrix 
components. The disease progresses because these repair attempts are unable to balance ongoing 
cartilage degeneration [48]. The inflammatory cytokines-such as IL-1, IL-17 and TNF-α- lead to 
an increase in the expression of MMPs accompanied by a decrease in the expression of their 
inhibitors [49]. The damaging cytokines are released by synovial cells as well chondrocytes 
themselves [50]. Simultaneously, anabolic factors such as IGF-1, TGF, FGF and BMPs attempt 
to rescue matrix degradation by inciting ECM synthesis [48]. The degradation is further 
aggravated by the action of degradation fragments of fibronectin and collagen type II [51].    
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Figure 2.2:  Schematic diagram depicting the inhibitory role of inflammatory mediators IL-1β, 
TNF-α and IL-17 in chondrogenic differentiation of BMSCs. BMP-Bone morphogenetic protein, 
TGF-Transforming growth factor, Runx-Runt related gene, Sox-SRY box. [Image copied from 
Kondo et al- 52] 
 
OA also has a bearing on the BMSCs present in bone marrow. Reduction in the proliferation rate 
of BMSCs was reported by Murphy et al [53]. However, other studies suggest that the inhibitory 
effect of OA on BMSC proliferation is not absolute [54]. The effect of OA on the chondrogenic 
potential of BMSCs is equally controversial. CD105+/CD166+ population of BMSCs isolated 
from OA patients were shown to have similar chondrogenic potential as healthy BMSCs [55] 
[56]. In another study, BMSCs from OA patients had reduced chondrogenic potential and poor 
GAG deposition [53]. Kruger et al showed that synovial fluid from patients with OA delayed but 
did not completely inhibit the chondrogenic of BMSCs [57]. However, the limited literature on 
the effect of OA on functional behaviour of BMSCs suggests that OA BMSCs do not lose the 
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chondrogenic potential completely [58]. Progenitor cells also tend to migrate into the defect 
through the cracks in the subchondral bone and carry out a limited repair [59]. The inflammatory 
mediators released during OA are also detrimental for BMSC behaviour. The prominent 
mediators include IL-1α, IL-1β and TNF-α [60, 61]. The inhibitory action of IL-1β and TNF-α in 
inhibiting chondrogenic differentiation of BMSCs was shown to be proceeding through NF-κB 
mediated pathway leading to suppression of Sox-9 through TGF-β II receptor suppression 
accompanied by increase in Smad-7 levels and inhibition of Smad 2/3 [62, 63]. BMSC 
differentiation is also suppressed by another major inflammatory cytokine IL-17 mediated by 
inhibition of Sox-9 phosphorylation [64]. Il-1β also alters the expression of miRNAs-such as 
miR-140, miR-145, miR-199a- involved in chondrogenic differentiation of BMSCs leading to 
suppression of chondrogenic differentiation of BMSCs [62, 64]. Presence of inflammatory 
mediators also enhances calcification due to preferred osteogenic differentiation of BMSCs 
leading to increase occurrence of osteophytes and ectopic calcifications [61, 62]. Application of 
anti-inflammatory agents in such cases is expected to maintain functional and cellular behaviour 
of BMSCs leading to better cartilage repair outcome.  
 
2.3 Bone marrow stem cells (BMSCs)/Mesenchymal stem cells (MSCs) 
2.3.1  Introduction and history 
Bone marrow (BM) is a complex interacting system mainly comprised of hematopoietic, 
endothelial and stromal components [65]. The hematopoetic compartment of BM is made up of 
multipotent stem cells, committed progenitor cells of myeloid and lymphoid lineages and 
maturing cells [66]. A wide array of cells including macrophages, adipocytes, osteogenic cells 
and reticular cells make up the marrow stroma  [67]. In vitro culture of marrow stroma is 
comprised of a mixture of fibroblastic cells, macrophages, adipocytes, endothelial cells, and 
smooth muscle cells [68]. In addition, two distinct populations of stem cells co-exist in marrow, 
the hematopoetic stem cells (HSCs) and BMSCs [69]. The matrix is primarily composed of 
fibronectin, collagen, vitronectin and tenascin [70]. In addition to soluble factors such as stem 
cell factor, granulocyte-macrophage colony-stimulating factor and granulocyte colony-
stimulating factor, stroma is also characterized by presence of adhesion molecules such as VLA-
1-6 [71]. BMSCs secrete several trophic factors with paracrine effects. In addition to 
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differentiation, the trophic factors, including growth factors, adhesion molecules and cytokines 
have been shown to alter tissue microenvironment leading to tissue repair and regeneration [72]. 
Stem cells can be defined as cells with ability to self renew and proliferate indefinitely without 
differentiating (Fig. 2.3) [70]. Friedenstein et al were the first to identify stem cells (progenitor 
cells) in hematopoetic microenvironment of bone marrow in 1970s [73] although Julius 
Cohnheim in 1867 had proposed the existence of non-hematopoetic stem cells when he observed 
the presence of fibroblast like cells in repairing wound which were derived from circulation [74]. 
The cells were recognized as “mesenchymal stem cells” by Caplan in 1991 [75]. The bone 
marrow niche for BMSCs was proposed by Owen in 1985 who suggested that stromal cells reside 
in a niche of their own with self renewal property and capability to generate mature stromal cells 
[75]. These cells originate from the mesenchyme, which can be defined as loose connective 
tissue, mostly derived from mesoderm of developing embryo [76]. The trilineage potential of 
BMSCs was demonstrated by Pittenger et al in 1999 [77]. BMSCs are characterized by their 
intrinsic self-renewal capacity i.e. the ability to remain in an undifferentiated and unspecialized 
state after each division. In vitro cultures of BMSCs can proliferate and maintain differentiation 
potential until 40 population doublings [78, 79]. In adult tissues, MSCs carry out the function of 
replacing and regenerating local cells that are lost to normal tissue turnover, injury or ageing. In 
addition, they maintain hematopoiesis by providing growth factors and promoting cell-cell and 
cell-matrix interactions owing to several cytokines released by them [69]. As shown by Pittenger 
et al, these cells are extremely rare and form a mere 0.01 to 0.001% of the mononuclear fraction 
isolated from bone marrow [80] which is primarily made up of macrophages, adipocytes, 
osteogenic cells and reticular cells [68]. Several studies carried out in the recent past have 
indicated a perivascular niche for MSCs and that they exist as pericytes at several locations 
throughout body [81, 82]. Chagastelles et al showed close proximity between pericytes and 
MSCs which had similar expression of Stro-1, α-smooth muscle actin, CD44, CD90 and CD105 
[83]. In addition to serving as a pool of cells for regeneration and repair of tissues during an 
organism’s lifetime, MSCs also play several important roles owing to their paracrine effects 
resulting from secretion of cytokines, growth factors, chemokines, angiogenic and 
immunosuppressive factors [84]. 
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Figure 2.3: Schematic representing the properties and role of stem cells. [ Copied image -67] 
2.3.2 Isolation of BMSCs 
Initially contaminated with cells from hematopoetic origin, the cultures are almost 100% pure by 
second passage [85]. Upon isolation, cells form foci of 2-4 cells and grow as colonies in P0. The 
cells may take variable amount of time for adherence depending upon method of isolation, age of 
the donor and other factors like source of cells (fast for suspended cells and slower for cells 
derived from explants). The proliferation begins only after a dormant phase of 2-4 days after 
adherence [86]. Despite being “stem cells”, MSCs possess limited proliferative potential and can 
be passaged for 25-40 population doublings over 8-15 passages. The signs of ageing include 
reduced proliferation potential and change of morphology to large, loosely packed cells [87-89]. 
Tuan et al showed that cells in trabecular bone chips (explants) reacted positively with CD73, 
Stro-1 and CD105 antibodies while were negative for CD34 and CD45 suggesting presence of 
multipotential cells in bone [90]. The population isolated from explants is mostly homogenous 
and 100% positive for CD73, CD105 and Stro-1 unlike the population isolated from bone 
marrow which is more heterogenous. It will be interesting to explore if this difference has an 
implication on the differentiation potential of these cells as well.  
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BMSCs can be isolated from bone marrow (BM) using several methods including density 
gradient centrifugation, direct plating and explant culture of bone chips. Since stromal matrix is 
primarily composed of collagen type I (Col-I) and IV (Col-IV), collagenase enzyme is used for 
isolation of stromal BMSCs [91, 92]. Collagenase enzyme has been typically used to remove soft 
connective tissue from the trabecular bone for the isolation of progenitor cells from subchondral 
regions of bone which include the marrow stroma and bone lining cells [93]. The efficiency of 
digestion process depends upon the conditions used during collagenase treatment. Collagenases 
used in R&D are crude mixtures of interstitial (E.C.3.4.24.7) and neutrophil (3.4.24.34) 
collagenases. The former is a type MMP-1 while the latter is a type MMP-8 enzyme. The enzyme 
isolated from C.histolyticum typically contains a mixture of collagenase, clostridiopeptidase and 
non-specific protease (IUBMB- www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/24/3.htm). 
Although, several protocols are used for isolation of BMSCs using collagenase digestion, the 
yield is generally higher when enzymatic digestion is used as a method of isolation as opposed to 
BM aspiration [94]. While some believe that enzymatic isolation alters the characteristics of 
BMSCs [95], others claim that these cells are phenotypically similar to cells obtained from BM 
aspirate [94, 96]. Expansion of BMSCs has been shown to have a negative impact on 
differentiation potential with increasing passages [97]. The media used for in vitro expansion of 
BMSCs is typically comprised of a basal media containing glucose, amino acids, ions, and fetal 
animal sera [98]. An ideal culture of BMSCs would be characterized by a). Maintenance of 
original phenotypic and functional characteristics, b). Indefinite proliferation, c). Multilineage 
differentiation potential [70].  
In vitro characterization of BMSCs is important in order to understand the cellular and functional 
behaviour of BMSCs (Fig. 2.4). In vivo analysis is difficult owing to low frequency and lack of 
markers for their in vivo localization [70]. The culture systems primarily aimed at identification 
of BMSCs may be classified into CFU-f assay, analysis of BM stroma, and culture of BMSCs 
[70]. Clonal analysis has shown that BMSC populations are a heterogenous mixture of tri-, bi- 
and unipotent subpopulations with varying levels of lineage commitment [87, 99, 100]. BMSCs 
also possess limited transdifferentiation capacity dependent on culture conditions [101].  
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Figure 2.4.: In vitro characterization of BMSCs depicting their surface marker profile and 
differentiation potential. [Image copied from Si et al - 102] 
Since the isolated BMSC population is highly heterogenous with regards to morphology, 
physiology and expression of markers, International Society of Cell Therapy (ISCT) in 2006 
proposed a standard set of criteria to identify and characterize these cells in vitro [15]. First, 
BMSCs must adhere to tissue culture plastic, a property which is commonly applied for their 
isolation. Second, more than 95% BMSC population must express a specific set of membrane 
molecules such as CD105, CD73 and CD90 in addition to lacking the expression of hematopoetic 
markers like CD34, CD45, CD14, CD11 and HLA-DR as determined by flow cytometry. 
Interestingly, CD105 was originally described as SH2 antibody raised against human BMSCs 
which reacted with epitope present on TGF-β receptor endoglin CD105 [103]. Similarly, SH3 
and SH4 antibodies recognize membrane bound ecto-5’-nucleotidase CD73 [104]. It is important 
to note here that due to lack of an exclusive marker of BMSCs, their in-situ localization still 
eludes us [105]. Trilineage differentiation potential is the final ISCT criterion according to which 
BMSCs must differentiate into cells of osteogenic, chondrogenic and adipogenic phenotype upon 
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suitable stimulus. In order to differentiate BMSCs, a whole range of growth factors such as FGF, 
TGF and BMP, hormones such as dexamethasone, vitamins such as ascorbic acid and chemicals 
like β-glycerophosphate play an important role. Apart from the growth factors and cytokines, 
signaling molecules like Wnt, Notch, Runx2, Ihh also contribute in determining the fate of 
BMSC differentiation [106]. The multilineage differentiation potential is evidenced by the role 
these cells play in remodeling of bone under normal physiological conditions and fracture repair. 
The long bones in the body grow by means of a cartilaginous intermediate. The adipogenic 
potential of BMSCs is demonstrated when they increasingly lose bone forming potential with 
advancing age and more and more tissue in bone is replaced by adipocytes [107].  
 
2.3.3 Colony forming unit assay (CFU-f) 
In addition to above properties, clonogenic capability is another property used to characterize 
BMSCs [108, 109]. CFU-fs have been described as rapidly adherent, non-phagocytic clonogenic 
cells with ability of extended proliferation in vitro [110]. Cells from BM are seeded at low 
density and individual colonies are scored as an indicator of clonogenic potential or stemness of a 
culture since each colony is presumed to have been cloned from a single precursor cell [65]. 
Several groups have used the assay to suggest that CFU-fs occur at a frequency of one in 10
4
 to 
10
5
 of marrow mononuclear cells [65]. Upon isolation from bone marrow, the adherent cells have 
a heterogenous morphology due to which it is difficult to clone them [87]. It is therefore ideal to 
carry out the CFU-f assay at passage 1. It is essential to carry out the CFU-f assay at low density 
since the colonies grow in isolation at low density and represent clonal expansion of a single 
CFU-f or mesenchymal progenitor cell thus being a measure of the number of BMSC population 
[111]. Friedenstein was the first to propose the concept of colony forming units and demonstrated 
that each colony in BMSC culture was derived from a single fibroblastic colony forming cell. 
These CFU-fs are heterogeneous in morphology [87] as well as differentiation potential as 
confirmed by several other authors [112]. Cells in a colony are not necessarily genetically similar 
and have been shown to be heterogeneous in their lineage commitment and multilineage 
differentiation potential in vitro as well as in vivo [113, 114]. The CFU-f forming capability of an 
BMSC culture has been shown to be influenced by several factors including media composition 
but is also an indicator of bonafide differences existing in vivo [69]. 
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2.3.4 BMSC surface marker expression  
Stro-1 is an important marker which has found application in enriching the mesenchymal 
precursors [115]. Expression of CD34 is lacking in culture expanded BMSCs and cells isolated 
from CFU-fs [80]. However, a low level of CD34 has been detected in BMSCs isolated from 
some species, making it a controversial negative marker [116]. It is likely that CD34 expression 
is lost upon in vitro expansion. The CFU-f precursor has been shown to be positive for 
expression of Thy-1 (CD90), integrin family (CD29, CD49) and VCAM-1 in addition to 
receptors for PDGF, IGF and EGF [117].  
It is critical to carry out the characterization assays in early passages as long term culture of 
BMSCs have been shown to have detrimental effect on their fundamental phenotype. This 
becomes an important consideration in a scenario where in vitro characterization of BMSCs is 
supposed to be reflective of their in vivo phenotype. In vitro culture and expansion has been 
shown to affect the stemness, senescence and genetic stability [118] as well as expression of cell 
surface markers and differentiation potential. It is also important to consider that application of 
anti-human antibodies for characterization might lead to variation in expression of these markers 
[119]. 
2.3.5 Heterogeneity of BMSCs 
As mentioned before, BMSC cultures are highly heterogeneous with regards to morphology and 
function. The in vitro cultures are generally composed of a population containing both single 
stem-cell like cells and progenitor cells with different lineage commitment [120]. In this 
heterogeneous population, only a fraction of cells are truly multipotent and possess the capability 
of self renewal [121]. The problem is further compounded due to presence of donor-to-donor and 
intra-population heterogeneity [77]. Phinney et al observed striking heterogeneity in growth rate, 
alkaline phosphatase levels and osteogenic potential [77]. Donor dependent heterogeneity is 
attributed to several factors including sampling bias, age of donor and method of culture [99, 
122-124].  
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Figure 2.5: Schematic illustrating the hierarchical program of lineage specification and evolution 
of tri-, bi- and unipotent progenitors [Image copied from Phinney at al-77]. 
BMSC phenotype was identified to be made up of 113 transcripts and 17 proteins [125]. Since 
BMSCs have been shown to lose multipotential differentiation capacity without a corresponding 
loss in surface phenotype, a combination of assays are needed to evaluate growth, proliferation 
and functional behaviour including differentiation potency [87, 97, 126]. In their pioneer work, 
Muraglia et al [100] analysed 185 huMSC clones to demonstrate a dominance of tri-potent, 
osteo-chondrogenic and osteogenic progenitor. This indicated the maximum propensity towards 
osteogenic lineage while the BMSC clones were more likely to lose adipogenic commitment. 
This phenomenon is recognized as linear progression which follows a hierarchical program of 
lineage specification (Fig.2.5). In a later study, approx 50% of population was found to be truly 
tripotential cells while 5% were lacking differentiation potential. Tripotent cells were also 
characterized by high proliferation potential and low apoptosis [127].  
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2.3.6 Differentiation of BMSCs 
2.3.6.1 Chondrogenic differentiation 
While osteogenic potential of progenitor cells was demonstrated for the first time by Friedenstein 
in his pioneer work, chondrogenic potential was revealed much later in 1998 in critical works of 
Johnstone and Mackay [128, 129]. Johnstone et al illustrated that chondrogenesis can be induced 
in BMSCs in aggregate cultures in the form of pellet which has since become the gold standard to 
differentiate BMSCs into cartilaginous phenotype [128]. It is now known that pellet cultures 
provide the critical cell-cell and cell-matrix interactions which resemble microenvironment in 
precartilage condensation bud and promote chondrogenesis while maintaining chondrogenic 
phenotype. Mackay et al provided evidence that upon stimulation by TGF-βIII and 
dexamethasone, the stem cells differentiated and acquired chondrogenic phenotype. In this 
important study, Mackay et al found that cells failed to differentiate into chondrocytes when 
either TGF or dexamethasone was omitted from the media emphasizing the roles of these factors. 
In fact, one of the earliest activities of TGF-βIII was found to be its capability of inducing 
chondrogenesis in rats [128, 130, 131]. In addition, chondrogenesis was found to be superior 
when TGF-βIII was used instead of TGF-βI [132]. Dexamethasone, a synthetic glucocorticoid 
supports viability, inhibits hypertrophy and increases the expression of Col-II, aggrecan and 
COMP [128, 129, 133]. Ascorbate is responsible for hydroxylation of proline and lysine residues 
required for collagen synthesis [134]. On comparison of DMEM containing low v/s high 
concentration of glucose (1g/l v/s 4.5 g/l), increase in pellet size was higher in the case of latter. 
This effect could be due to protective action of higher concentration of glucose against cell death 
thus increasing viability. Moreover, a hypoxic environment is created due to respiratory 
inhibition caused by high concentration of glucose which promotes chondrogenic differentiation. 
High glucose also alters cell metabolism and makes cells less susceptible to apoptosis [129]. 
Since cartilaginous matrix was not observed in pellets from all donors when cultured for a period 
less than three weeks, this period has been considered as the most optimum duration for inducing 
chondrogenic differentiation [129]. The increase in the size of the pellets at the end of this period 
was found to be due to accumulation of matrix and not increase in cell number since DNA 
content was found to be fairly constant for the period of differentiation. Although Col-I is not 
found in normal articular cartilage, a peripheral zone of Col-I is detected in pellets where cells are 
flattened and resemble perichondrium [129]. 
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In their study on the events of chondrogenic differentiation in pellets, Yoo et al found that after 
an initial reduction in size, matrix synthesis kicks in which leads to a gradual and constant 
increase in the pellet size thereafter [135]. Sekiya et al analyzed 12000 genes during 
chondrogenesis and found marked changes in the expression of matrix proteins and transcription 
factors such as Col2a1, Agc1, COMP, Col-IX, Col-X, Sox-9, Sox-5, Sox-6, BMPs, PTH, PTHrP 
etc indicating their importance in chondrogenic differentiation of BMSCs [136].  
 
Pellets are highly heterogeneous tissues possibly due to the radial expansion of the cells which 
exert biomechanical forces on the tissue. Chondrogenic differentiation requires presence of 
interaction between cells and absence of adhesion to substrate [137]. Differentiation starts 
simultaneously at several sites and spreads gradually throughout aggregate [138]. The size of 
aggregates starts to increase 203 times after first week. A 2-3 cell layer deep outer layer 
resembling perichondrium is made up of flattened, undifferentiated BMSCs. The matrix in this 
zone is rich in Col-I and poor in Col-II and proteoglycans. Below this, the chondrocytes are 
rounded and resemble the native cartilage. They secrete a matrix that is rich in Col-II and 
aggrecan. The innermost core is last to differentiate and is normally comprised of poorly 
differentiated or necrotic zone [128, 129, 135]. Since PCR can detect mRNA long before the 
expression of protein, a histopathological analysis of pellets is carried out to determine the 
phenotype. Safranin-O staining remains to be the simplest and most efficient method to detect the 
presence of glycosaminoglycans (GAGs) in matrix. A more extensive immunochemical study to 
detect the presence of Col-I and Col-II is carried out to generate a complete profile of 
chondrogenic differentiation [139, 140]. TGF-β superfamily plays an important role in regulation 
of chondrogenesis and TGF-β, BMP-2 and GDF-5 have been implicated in chondrogenic 
regulation [141-143].  
 
TGF-β has been reported to be the most essential factor required for chondrogenic differentiation. 
TGF-βIII induced ERK1/2 pathway was activated for 1-14 days during chondrogenesis 
suggesting its importance in chondrogenic differentiation of BMSCs [144]. This pathway has a 
significant bearing on the expression of collagen type II in pellet cultures of BMSCs [144]. It is 
also believed to inhibit hypertrophy, an undesirable phenomenon during chondrogenesis [129]. In 
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a study carried out using chick wing bud mesenchymal stem cells, Jin et al showed that 
expression of Wnt 5α was upregulated in the presence of TGF-βIII by modulating PKC-α and 
p38 mitogen activated protein kinase (MAPK) activity. Activation of Wnt 5α led to the 
upregulation of synthesis of adhesion molecules like fibronectin and integrin α5 [145]. A 
crosstalk between Wnt, SMAD, MAPK and pathways induced by PTHrP and Ihh regulate the 
genes required for chondrogenesis including Sox9 which is master regulator of chondrogenic 
determination of BMSCs. Aggrecan gene expression on the other hand was shown to be 
dependent on a cross talk between Smad, ERK1/2 and MAPK pathways (Fig.2.6) [146]. The 
potential of BMSCs for cartilage repair was reported for the first time by Wakitani et al in 1994. 
BMSCs dispersed in collagenous matrix when implanted in full thickness defects in rabbits 
formed cartilage by two weeks [147]. 
 
Figure 2.6: Schematic of stages in condensation phase of embryonic limb formation. Adapted 
from Maeda et al [67]. 
 
Differentiation of BMSCs into cells of cartilaginous phenotype in pellets under in vitro 
conditions and during formation of repair tissue in vivo closely resembles the events of formation 
of limbs during embryonic development [148]. The cells from lateral plate mesoderm migrate to 
the site of skeletogenesis, characterized by expression of hyaluronan and upregulation of cAMP. 
25 
 
 
 
In the next stage, cell-cell interactions are encouraged due to N-cadherin and N-CAM under the 
influence of TGF-βIII. Syndecan and Tenascin set limit to this condensation where cells 
proliferate further under the influence of cfkh-1 and mfh-1. Sox-9 induces the expression of 
col2a1 gene at this stage. In order to induce differentiation, expression of proliferation and 
adherence related genes are downregulated under influence of BMPs, noggin and Syndecan. In a 
series of events influenced by multiple effector molecules such as Ihh, PTH/PTHrP, Sox-5/6/9, 
BMPs, Hox, and pathways including ERK1/2, Smad and MAPK, mature chondrocytes are 
formed which lay down a matrix rich in Col-II and aggrecan (Fig. 2.7) [146]. According to some 
reports, extracellular matrix components modulate differentiation and regulate BMSC adhesion. 
Matrix metalloproteases and tissue specific inhibitors of metalloproteases have been implicated in 
regulation of commitment by BMSCs [149].   
 
 
Figure 2.7: Molecular regulation of mesenchymal stem cell differentiation programs. 
Differentiation is transduced as a result of interaction between extracellular molecular signaling 
and mechanical inducers and putative receptors, channels, and/or other cell-surface-associated 
mechanisms. The downstream lineages arise from crosstalk of signaling pathways, including that 
between distinct mitogen-activated protein kinases (MAPKs) and R-Smads. GDF- growth and 
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differentiation factor; TGF- transforming growth factor; BMP, bone morphogenetic protein; FA- 
fatty acid; βcat- β-catenin; PPAR- peroxisome proliferator-activated receptor; MSK- mitogen- 
and stress-activated protein kinase; PCAF- p300/CBP-associated factor; Ac- acetyl; c- 
chondroblast; o- osteoblast; a- adipoblast; m- myoblast; cm- cardiomyoblast; t- tenoblast. [Image 
copied from Kolf et al-150]. 
 
2.3.6.2 Osteogenic differentiation 
Friedenstein had first demonstrated the osteogenic potential of CFU-f isolated from bone 
marrow. Bone tissue formation was observed in diffusion chambers filled with CFU-fs and 
implanted in donor animals [138]. In vivo, osteoblasts and bone lining cells are believed to 
originate from multiple sources including Nestin(+) endosteal BMSCs [151], periosteal stem 
cells, pericytes and other cells from vascular walls, and common endothelial/osteoblast 
progenitors that may be in the circulation [152-154]. In vitro osteogenic assays can be derived 
from fetal calvarial cells, BMSCs and cells originating from bone explants [155]. Osteogenic 
differentiation of BMSCs is typically carried out in a media comprised of α-MEM containing 
dexamethasone, ascorbate and β–glycerophosphate (GP). BMP-2 and 7, FGF-2 and PGE2 are 
known stimulators of osteogenesis [156, 157] while LIF, oncostatin, EGF and calcitrol are some 
of the inhibitors [67, 158, 159]. It is characterized by alteration in morphology to polygonal, 
active basophilia in the cytoplasm, increase in alkaline phosphatase (APase) activity and 
deposition of calcium (Ca) rich matrix which is illustrated by Alizarin Red S and vonKossa 
staining [160]. The matrix deposition could be nodular as in rats or uniform as in humans [78]. In 
a study carried out by Cheng et al, physiological concentration of dexamethasone was found to 
be an absolute requirement for osteogenic differentiation [161]. Dexamethasone enhances self-
renewal and survival and induces the expression of APase (initially, then decreases it) and Ca 
mineralization mediated by induction of Runx 2 and osterix [155] [162]. β-glycerophosphate has 
no effect on proliferation and increases matrix mineralization by donating inorganic phosphate 
[163]. Ascorbate promotes collagen synthesis [162]. During embryonic development, formation 
of long bones takes place by endochondral ossification. Post condensation and overt 
differentiation into chondrocytes, Ihh induces further differentiation characterized by expression 
of Col-X. BMPs upregulate expression of osteogenic inducers cbfa-1 and Runx-2. This is 
accompanied by activation of MMPs which degrade the cartilage matrix. Col-I, osteopontin and 
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osteocalcin genes are upregulated leading to synthesis of bone matrix. In the last stages, VEGF 
mediated angiogenesis leads to vascularization. MMP-9, 13 and 14 bring about further 
degradation of non-ossified matrix which is then replaced by calcified bone matrix. Under in 
vitro conditions, osteogenic differentiation is comprised of an initiation phase which is 
characterized by increase in proliferation followed by enhanced expression of ATPase and Col-I. 
In the maturation phase, matrix mineralizes primarily with hydroxyapatite aligned with collagen 
fibers. Calcium deposition is an important event in osteogenesis and indicates terminal 
differentiation. Smad pathway mediated by Runx2 and BMPs is the most important pathway 
underlying osteogenic differentiation [36, 164]. Several pathways have been implicated in 
osteogenic differentiation of BMSCs. The ERK pathway is activated in early stages by binding of 
laminin 5 to cell which leads to phosphorylation of osteogenic transcription factor cbfa-1 [165]. 
Activation of JNK pathway occurs later once the ECM is in mineralization phase [166]. Other 
factors which promote osteogenesis include Wnt3A and Cadherin 11 which increase the 
expression of tissue growth factor and alkaline phosphatase respectively. Sortilin and FGF-2 are 
needed for mineralization of matrix [167, 168].   
 
The osteogenic differentiation can be characterized by evaluating alkaline phosphatase and 
mineral deposition as end points (Fig. 2.8). The primary alterations during osteogenesis are 
change in morphology of cells from spindle to oblong and expression of non-mineralized matrix 
rich in collagen [155]. ALP activity increases by 2-6 fold when cultured in presence of 
dexamethasone, BMP-2 or vitamin D3 [169, 170]. Dexamethasone is the most potent osteogenic 
stimulator which is an agonist of glucorticoid receptors found on BMSCs [171]. Exposure to 
dexamethasone stimulates cuboidal morphology, ALP mRNA and suppresses bone sialoprotein 
[172, 173]. A concentration of 10 nM of dexamethasone is more conducive for stimulation of 
osteogenic phenotype [174, 175] since concentration of 100 nM was found to inhibit expression 
of osteopontin [175, 176]. In the first phase of development spanning 1-2 week, slow 
proliferation of cells is accompanied by expression of ALP activity, and assembly of collagen 
matrix along with expression of bone specific marker genes. The second phase occurs in week 2 
or 3, calcium phosphate is expressed causing matrix mineralization [177-179]. Presence of Pi is 
necessary during this phase and inorganic phosphate is usually provided by addition of 3mM Pi 
or 5-10mM disodium beta glycerophosphate [180]. The functional endpoint of advanced cell 
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differentiation is the mineralization. The calcium component of the matrix can be analysed by 
alizarin red staining while Von Kossa staining can be used to detect the presence of phosphate 
component. The mineral formed during osteogenesis may be substituted hydroxyapatite or non-
hydroxyapatite. The former exists with collagen fibrils and appropriate ratio of calcium and 
phosphate. The latter is characterized as cell-associated precipitate with higher calcium/phosphate 
ration than collagen [163, 177, 181, 182]. 
 
Figure 2.8: Representative osteogenesis cultures cultured in control media (CCM) and osteogenic 
media (OSM) containing dexamethasone. The osteogenic phenotype was represented by cuboidal 
cells and detected by Alizarin Red S and alkaline phosphatase staining. [Image copied from 
Hoemann et al- 155]. 
 
The mechanisms for in vitro differentiation of BMSCs have been explored in various species and 
similar protocols can be applied for osteogenic differentiation of BMSCs in presence of 
dexamethasone, vitamin D3 and BMP-2. Osteoblastic differentiation was accompanied by 
upregulation of 83 proteins and downregulation of 21 proteins [183]. Overexpression of cbfa-
1/Runx2, ostrix and lipoprotein related factor 5 induce osteogenic differentiation [184-186]. 
Kassem et al compared the EGF and PDGF mediated osteogenic pathways and found that EGF 
and PDGF utilized more than 90% signaling proteins while PI3K was only activated by PDGF 
alone [187].  
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2.4 Bone marrow stimulation for cartilage repair 
 
 
 
Figure 2.9: Stages in BMS procedure. A. Arthroscopic images of a trochlear defect. B. 
Debridement of the calcified layer in the defect using a curette. C. BMS procedure using an awl 
to create multiple perforations in the subchondral bone. D. Second look at 1.5 years after BMS 
showing asymptomatic lesion in the same patient. [Image copied from Gill et al-188]. 
 
Amongst several techniques existing for cartilage repair which include autologous chondrocyte 
implantation, mosaicplasty and osteochondral autograft/allograft transplantation (OATS), bone 
marrow stimulation (Fig. 2.9) by means of drilling, abrasion arthroplasty or microfracture 
remains most popular, especially for young patients with smaller defects. While drilling was 
introduced by Pridie in 1959 [189] and continued to be a widely accepted method for decades, 
Microfracture (MFX) has become more prevalent ever since being introduced by Steadman in 
90s [16, 190]. The spontaneous repair of cartilage can proceed through intrinsic or extrinsic 
mechanism. The former relies on the limited proliferation capacity of chondrocytes in the region 
adjacent to defect and is usually insufficient for repair. In the latter, new connective tissue is 
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formed from subchondral bone progenitor cells which undergo metaplastic changes to form a 
cartilage repair tissue [191]. Although small foci of hyaline cartilage are formed over the 
intertrabecular surfaces exposed due to erosion of subchondral bone, it is insufficient to develop a 
repair tissue [192]. Instead, frank defects created in subchondral bone by means of drilling [189] 
or MFX [16] lead to generation of a cartilaginous repair tissue. Both events rely on the 
subchondral bleeding caused by fracture of subchondral bone and recruitment of marrow derived 
progenitor cells which repair cartilage and bone in a sequential manner [192].  
 
Preparation of cartilage defect during human surgeries as well as creation of an animal model is 
an important first step to ensure success of this procedure. The cartilage defect must have clean 
90 degrees wall of normal cartilage and all the calcified cartilage must be removed taking care 
not to injure the subchondral bone. MFX is performed with a specialized awl that is used to 
create 1-1.5mm holes 3-4 mm apart in the subchondral bone. In the case of microdrilling a drill 
burr with diameter of 1-1.5 mm is used to create drill holes. While the former procedure leads to 
bone compaction and necrosis adjacent to holes, the latter generates a lot of heat [193]. However, 
accompanied by cooling irrigation system, microdrilling is a favorable procedure since it removes 
bone debris and creates clean holes thus improving the repair outcome [11, 12, 16, 189]. On 
comparison of one day postoperative acute events in a rabbit model, MFX brought about heavy 
fracturing of bone matrix and dense, compact bone was observed surrounding MFX holes. This 
was overcome in drilling due to employment of a twist drill which removes bone debris. In 
addition, more viable osteocytes were observed around microdrill holes. Drilling which was 
accompanied by cooled irrigation does not produce heat necrosis maintaining viability of 
adjacent bone. In the same study, when the drilling was performed to 6 mm compared to 2 mm, 
greater subchondral hematoma was observed with increased access to marrow stroma [21]. In 
addition, deeper drilling also enhances repair and remodeling of subchondral bone in a rabbit 
model. Increased bone activity and remodeling achieved through deep drilling improves the 
cartilage resurfacing. Since the volume of subchondral bone participating in the repair increases 
as a result of deeper drilling, the quality as well as quantity of cartilage repair is improved [194]. 
This was confirmed in another study where the quality of cartilage repair as a result of deeper 
drilling was investigated in a rabbit model. The outcome of cartilage repair indicated by %fill, 
%Saf-O, %Col-I and %Col-II was significantly better than shallow drilling [17].  
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The biological response induced by BMS is divided into 3 phases-necrosis, inflammation and 
repair [195]. Necrosis characterized by varying levels of tissue death begins immediately after 
injury. In the next phase of inflammation, a dense fibrin network is formed by transudation and 
cellular exudation mediated by reactive hyperemia and increased capillary permeability. Finally, 
the repair begins by invasion of fibrous tissue with neovascularisation followed by formation of 
granulation tissue. In a complex cascade of events, the granulation tissue remodels into the 
cartilage repair tissue. The repair in marrow stimulated procedures begins with formation of a 
blood clot in the drill holes and the lesion as a result of subchondral bleeding. The wound repair 
is initiated by formation of a vascularized granulation tissue accompanied by infiltration of 
leukocytes. This phase is also characterized by migration of mesenchymal progenitor cells 
derived from subchondral bone into the defect and increase in their proliferation. The cells then 
commit to a chondrogenic lineage as condensation of mesenchymal progenitor cells is initiated 
under influence of PTH/PTHrP. Cell-cell interactions are further promoted by N-cadherin 
promoting chondrogenesis [18, 192, 196-198]. Chondrogenic foci are detected at this stage, 
mostly present adjacent to the edges of drill holes, in close proximity to the intact bone. The 
hyaline cartilage is formed by appositional growth of these foci [18, 196]. Col-I is present in 
abundance throughout the new repair tissue in the beginning. The matrix gradually witnesses a 
shift in expression of collagen from type I to type II since the expression of Sox-9 upregulates 
Col2a1 gene. This is accompanied by rounding of chondrocytes. The organization and 
constitution of matrix gradually begins to resemble the natural cartilage and there is an increase 
in the deposition of GAGs and col-II which are abundant in the intermediate and deeper zones of 
the repair tissue. The col-I content is gradually reduced to few layers on the surface. The 
chondrocytes in the basal zone undergo hypertrophy induced by expression of Runx2 in later 
stages of repair. While Sox-9 is a master regulator of chondrogenesis, Runx2 regulates terminal 
differentiation of chondrocytes and osteoblast differentiation [199]. The foci in the deeper zone 
are resorbed, accompanied by increased vascularization and bone remodeling bringing about the 
repair of subchondral bone restoring its porosity and continuity [196, 198].  
 
The origin and differentiation of cells during a BMS repair were outlined in rabbit model by 
Shapiro et al [14]. Fibrinous arcades were seen in the first few days with mesenchymal cell in 
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growth oriented along long axes. At day 10, proteoglycan content appeared in the matrix 
followed by presence of a fibrocartilagenous tissue by 2 weeks. The cells progressively 
differentiated into chondroblasts, chondrocytes, and osteoblasts at week 6, 8 and 10 respectively. 
Cartilage and bony matrices were formed by week 12 and the regeneration was completed by 
establishment of tidemark and subchondral bone by week 24. 
3
H-Thymidine and 
3
H-cytidine 
labelling showed that the cartilage repair was entirely mediated by subchondral mesenchymal 
cells and not from the residual adjacent cartilage [196].  
 
The repair tissue formed after BMS could be a cartilaginous tissue with chondrocyte like cells 
and cartilaginous matrix. In other cases, a non-cartilaginous tissue is formed which might be 
fibrous, intermediate or chondroid with increasing restoration of cartilaginous phenotype [192]. 
On the examination of structure of early repair tissue in BMS, cartilage appears as focal plaques 
instead of a continuous layer. In most of the cases the repair tissue has a streaky, fibrous 
appearance. The arrangement of cells is random with a zone of flattened cells just below the 
surface resembling the natural cartilage. Calcified cartilage and tidemark are not clearly distinct. 
Although the proportion of repair tissue increases with time, the results are variable and 
influenced by age and species of the animal in addition to location and size of lesion [192]. 
Young animal defects are healed better than old probably due to higher number of mesenchymal 
progenitor cells with superior differentiation potential [192]. In addition, smaller defects show 
superior healing in the initial stages but suffer from rapid breakdown later on due to poor 
subchondral bone healing [200]. In other animals, poor repair was observed in weight bearing, 
large defects despite a good healing in the beginning. Weight bearing, large defects are more 
likely to be affected by opposing articular surfaces which impinge on the fragile repair tissue 
leading to its poor attachment [199].  
 
In a systematic review of existing clinical data, Mithoefer et al reported that MFX provides 
effective short term functional improvement and patient relief [201]. The improvement was 
observed as early as six months and improved consistently for a period up to 24 months. Limited 
hyaline repair tissue, variable repair cartilage volume and possible functional deterioration are 
some of the shortcomings of the procedure. Younger patients had better clinical outcome scores 
which was a result of better cartilage repair fill. Medial femoral condyle was found to repair 
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poorly in most of the studies. Most importantly, MFX is mostly recommended as a first line of 
treatment for defect sizes <4cm
2 
 [201]. 
Some of the primary causes of failure of MFX include clot retraction and presence of calcified 
cartilage at the base of defect [199, 202]. Age, location and size of defects are critical parameters 
to be considered while proceeding with MFX [199]. Poor subchondral bone repair, necrosis of 
adjacent articular cartilage and advancing of repairing subchondral bone are still other 
shortcomings that have been reported [203]. One of the reasons of failure of BMS is the poor 
integration of a well repaired tissue with the surrounding tissue leading to early degeneration 
[14]. Clefts that develop between reparative tissue and subchondral bone are a common cause of 
failure of marrow stimulated repair in long term [199]. Another probable cause of the failure of 
marrow stimulated repair was shown to be the presence of hypocellular adjacent matrix with poor 
restoration of matrix components, primarily its proteoglycan content. The incomplete matrix 
repair fails to support collagen fibres [199]. In addition to this phenomenon, BMS fails in weight 
bearing regions or larger lesions due to incomplete bone remodelling. The subchondral bone fails 
to support the newly formed cartilage tissue which needs to rely on still underdeveloped matrix 
proteoglycans [199]. Presence of calcified cartilage (CC) layer was shown to be detrimental to 
the repair and regeneration of cartilage repair tissue by Hurtig et al [199]. It acts as a barrier to 
invasion of fibrous tissue from subchondral bone. Frisbie et al carried out a detailed study to 
examine the effects of calcified cartilage on repair outcome and concluded that amount and 
attachment of repair tissue was enhanced upon removal of CC while retaining subchondral bone 
[204]. The remodelling of subchondral bone was also improved upon removal of CC by 
enchancing the diffusion of nutrients from subchondral bone [188]. 
 
2.5 Influence of ageing on proliferation and differentiation potential of 
BMSCs 
BMSC ageing has been described as irreversible arrest of cell division and expression of 
senescence associated β-galactosidase [105, 205, 206]. Older BMSCs usually undergo 
senescence which is different from apoptotic cells in that they are alive but cannot undergo 
anymore divisions due to irreversible G1 growth arrest [207]. Moreover, young cultures comprise 
more small, spindle shaped cells while there are more flattened, broad, slow dividing cells in 
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older cultures (Fig. 2.10) [208, 209]. This phenomenon was first coined the Hayflick limit by 
Leonard Hayflick in 1960s. Aged BMSCs show a decline in maximal life span and growth rate 
[210, 211]. In addition to altered morphology, senescent BMSCs display upregulated levels of 
p53/p21 and p16/Rb cell cycle inhibitors. In general, ageing induced changes in BMSCs can be 
broadly classified as: 1). Change in quantity, 2). Change in quality indicated by differentiation 
capacity, 3). Altered mobility [212]. BMSCs displaying senescence are characterized by limited 
differentiation potential, limited self-renewal capability, limited by Hayflick limit, and 
inactivated telomerase [205]. One of the most important factors affecting the number, 
proliferation and differentiation potential of BMSCs is ageing. While fetal bone marrow contains 
1 in 10,000 BMSCs, the number reduces to 1 in 250,000 in adults [213]. Since older BMSCs still 
remain metabolically active, senescence and not apoptosis is believed to be the primary cause of 
reduction in proliferation capacity [111]. Quarto et al in 1995 pointed out that CFU-f was 
inversely correlated to age leading to decrease in differentiation potential in senescent animals 
[214]. Muruglia et al provided evidence that frequency of tripotential clones reduces with 
increasing age replaced gradually first by bipotential and then unipotential clones thus reducing 
the differentiation potential [100]. In addition, the ability of cells to migrate in response to 
chemoattractants also reduced with increasing age. This may have a profound influence on 
cartilage repair since migration and recruitment of BMSCs will be reduced leading to poorer or 
slower repair in older individuals.  
 
 
 
Figure 2.10: Cellular morphology of (A) early and (B) senescent BMSCs. (A). Cells are narrow 
and spindle shaped in younger passage. (B). Large and flattened senescent BMSCs in late 
passage are shown by arrows. [Image copied from Wagner et al-215]. 
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In an interesting observation by Stenderup et al, human BMSCs were found to undergo lower 
number of population doublings before entering senescent phase compared to other species [210]. 
It is estimated that stem cells lose 17bp/yr and stop dividing when telomere length is reduced to 
10 kbp, thus reducing the proliferation in older individuals. Interestingly, according to some 
reports, MSCs possess very low levels of telomerase, the enzyme responsible for maintaining 
telomere length [216]. In fact, telomerase activity is not detected in huMSCs [217]. In addition, 
there is a downregulation of genes involved in DNA replication, cell cycle, mitosis and DNA 
repairs at older age [218]. Simonsen et al showed that overexpression of telomerase in MSCs 
abolished senescent phenotype and maintained their capacity to proliferate and differentiate 
[216]. Moreover, Liu et al showed that MSC without telomerase activity lacked the capability to 
differentiate into adipocytes and chondrocytes [219]. These studies suggest that telomerase is 
critical for cell replication and differentiation [105].  
In their study, Payne et al did not observe correlation between age and proliferation, however, the 
chondrogenic potential was reduced which was reflected by reduced sizes of pellets initiated from 
cells obtained from older individuals [220]. In yet another study, while there was poor expression 
of Col-II, GAGs were not deposited at all in old rats [221]. Moreover, the expression levels for 
mRNA for Col-II, aggrecan and link proteins were lowest in old animals. In the classic study of 
Meachim and Roberts, it was reported that the cartilage repair outcome improves with increasing 
time in an animal model and was better in younger animals [192]. Finally, younger patients were 
found to show better repair outcome in clinical studies comparing MFX and ACI, conducted by 
Knutsen et al and Saris et al [222-225]. It can thus be concluded that BMSCs lose proliferation as 
well as differentiation potential with increasing age which is expected to influence the cartilage 
repair outcome in marrow stimulated procedures. 
A significant decrease in the growth rate has been observed in BMSCs derived from aged donors 
[211, 226]. Moreover, older BMSCs also failed to show an increase in proliferation upon positive 
stimulation unlike young BMSCs [211]. Li et al showed a decrease in proliferation of BMSCs 
with increasing age and correlated it to decrease in the clonogenic potential [227]. Correlation 
between age and CFU is controversial since some studies have observed an effect of age on CFU-
f [211, 228-230] while others indicate CFU is unaffected by age of donor [231-233]. In another 
study, BMSCs from older donors displayed a reduced initial proliferation phase compared to 
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younger BMSCs [234]. Interestingly, Bustos et al reported a significant impairment in the 
migration potential of BMSCs derived from older donors [235]. Similar results were also 
reported by Naaldijk et al who observed a minor reduction in migration potential of BMSCs from 
old donors [236]. 
Several groups have worked with in vitro cultures of BMSCs derived from different species and 
reported that ageing influences multiple biological processes related to the BMSC function 
including: 1). Reduced yield of BMSCs in BM aspirate, 2). Reduced proliferation and 
differentiation potential, 3). Reduced CFU-f frequency, 4). Increase in frequency of senescent 
population, 5). Modification in morphology of BMSCs from spindle shape to flattened, 6). 
Altered expression of cell surface markers and finally, 7). miRNA expression and 
immunomodulatory potential [237-240]. Moreover, the therapeutic potential of BMSCs was 
found to be influenced in an age-dependent manner in recent in vivo studies as well including 
increased susceptibility to reactive oxygen species, altered immunomodulation and impaired 
angiogenesis [241-243]. Fehrer et al proposed influence of ageing to be similar to heirarchial 
model of lineage [105] since a progressive loss of clonal multipotentiality of BMSCs is observed 
in senescent BMSCs. Studies have also reported a reduction in the proportion of RS cells and 
CFU-f in the populations derived from older donors. Colony size of CFU-fs also reduced in 
BMSCs derived from older donors [244]. D’Ippolito proposed that aging of BMSCs is 
accompanied with loss in proliferation and multipotential differentiation [245]. 
Although telomere shortening is considered to be one of the most important factors contributing 
to age-dependent modified behaviour of BMSCs, other studies report several pathways involved 
in senescence. DNA damage, accumulation of cyclin-dependent kinase inhibitor p16INK4a and 
oxidative stress have been shown to have detrimental effect on properties of ageing BMSCs [246-
248]. Moreover, downregulation of genes involved in cell cycle, DNA replication, mitosis and 
DNA repair have been reported in higher passages indicating older BMSCs may have altered 
DNA repair and regulation mechanisms [215]. Stolzing et al reported an increase in nitric oxide, 
ROS, oxidized and glycated proteins levels in addition to reduction in superoxide dismutase 
activity in older patients [209]. Oxidative stress induced apoptosis and inhibition of 
differentiation was more pronounced in older BMSCs [209]. Other studies have shown oxidative 
damage to lead to BMSC apoptosis and senescence [249, 250] and inhibition of differentiation 
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[251]. Increased level of p53 levels has been associated with increasing age and inhibition of p53 
has been shown to have a positive impact on osteoblastic differentiation [252]. P53 mediated 
senescence is attributed to telomere dysfunction and DNA damage while p16 /RB mediated 
senescence pathway is impacted by oncogenes, chromatin disruption and stresses [206]. Ageing 
has also been shown to impair the HSP/stress response accompanied by reduced differentiation 
and proliferation [253]. In addition, the expression of cell surface markers such as CD105 and 
Stro-1 has been shown to be altered in older BMSCs [231]. Older BMSCs have also been shown 
to have reduced expression of TGF-beta and BMP 2/4 [254]. Reports suggest that ageing induces 
changes in composition and immunophenotype of BM which in turn may alter functional 
behaviour of BMSCs during development and post-natal life [58]. In vivo, increasing age causes 
increased cross-linking of collagen. Advanced glycation end (AGE) products inhibit in vitro 
adhesion and spreading of BMSCs on collagen [255]. Moreover, AGE modified BSA induces 
apoptosis while inhibiting proliferation and differentiation [256]. This observation is underlined 
by the fact that BMSCs isolated from fetuses and pediatric donors have higher proliferation 
potential and lesser population doubling time compared to adult BMSCs (Fig. 2.11) [257, 258]. 
 
The detrimental effect of ageing is mimicked in older long term cultures of BMSCs and reduced 
differentiation potential was observed in long term cultures [211, 259-261]. Murine and rat 
BMSCs have been reported to demonstrate karyotopic aberrations and malignant transformations 
upon long term culture [262-264]. Osteogenic potential was also reported to be diminished in 
older donors across several species [205]. In fact studies have shown that similar genes are 
upregulated in old long term cultures and older people [89, 265].  
Reports suggest epigenetic mechanisms as underlying causes of ageing dependent alterations in 
BMSCs [266]. DNA methylation is one of the most important epigenetic mechanisms studied in 
mammals. Several osteogenesis related markers have been shown to be influenced by DNA 
methylation patterns [267, 268]. Histone modifications have also been implicated in determining 
the functional behaviour of BMSCs. Histone modification pattern has been shown to be 
constantly modified during osteogenesis. Age related impact on these epigenetic mechanisms 
may have profound bearing on downstream differentiation of BMSCs. Yang et al implicated JNK 
pathway mediated reduction in the migration ability of BMSCs from aged donors [269].   
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Figure.2.11: Figure illustrating the relationship between adult stem cell and mesenchymal 
progenitor theories of aging and free radicals, telomeres, and accumulation of DNA damage. 
[Image copied from Fukada et al-270]. 
2.6 Influence of location of defect on the marrow stimulated cartilage repair 
outcome: Condyles v/s trochlea 
In clinical scenario, the medial femoral condyle (MFC) is the most commonly affected area 
accounting for 34–58% of chondral injuries [6, 271] compared to 6-8% cases where defects are 
located on trochlea. The pre-clinical and clinical studies reporting the influence of location of 
defect offer conflicting scenarios [272, 273]. While Steadman reported that there was no 
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association between location and cartilage repair [274]; other studies reported superior clinical 
scores in repair outcome of condyles [275, 276]. An ovine study conducted by our group also 
highlighted difference in the repair outcome between trochlea and condyle. Condyle 
demonstrated a higher %fill, better matrix restoration and subchondral bone healing. This 
indicates the existence of species specific factors which affect the repair outcome based on 
location of defect [13]. When deep drilling was employed for cartilage repair in a rabbit defect 
model, improved repair outcome was observed in trochlea compared to shallow drilling possibly 
because deep drilling provides access to metaphyseal marrow. However, this observation was not 
consistent in condyle. At the end of three weeks, volume density of chondrocytes and number as 
well as area of chondrogenic foci was higher in rabbit trochlea [12]. It is known by now that 
chondrogenic foci which arise from subchondral bone progenitors mediate the cartilaginous 
repair by transforming into cartilage repair tissue bringing about marrow stimulated cartilage 
repair in animal defect model [18]. Trochlea had more mature foci while nascent foci were 
observed in condyle although the volume fraction of marrow derived progenitor cells in surgical 
holes was similar in both cases. Moreover, woven bone formation was faster in condyle, but was 
comparable to trochlea in later stages [11, 196]. The observations were confirmed in a longer 
three month study where poorer repair outcome was observed in condyle. While Col-II 
expression in repair tissue was comparable, %fill was significantly lower in condyle accompanied 
by higher % Col-I indicating more fibrocartilagenous repair. Moreover, the subchondral bone 
density was completely restored in trochlea while condyle had lower subchondral bone fraction. 
Interestingly, even the shallow trochlear defects demonstrated superior repair than condyle 
indicating that the inability to access metaphyseal marrow in the case of condyle is not the only 
cause for poor repair in latter [11, 12].  
 
This difference in the repair outcome between condyle and trochlea could arise due to structural 
differences such as thicker cartilage and subchondral bone plate along with higher subchondral 
bone density observed with condyle which might reduce the recruitment of the progenitor cells 
from the subchondral bone [277]. Several intrinsic differences are observed between condyle and 
trochlea-the convex v/s concave surface anatomy, load-bearing features, biomechanical cues and 
biological factors including chondrogenic potential of marrow-derived precursors [223, 278]. 
Biomechanical cues such as dynamic compression is believed to improve chondrogenic 
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differentiation [279-281]. Rabbit condyle is weight bearing while trochlea is partially loaded. The 
concave surface of trochlea might shield the fibrin clot and granulation tissue from the shear 
forces to which condylar defects are continually exposed due to convex surface of the latter [19, 
196]. Finally, there could be the differences in the inherent properties of progenitor cells present 
at these locations which might be a function of age or cellularity influencing the number as well 
as differentiation potential. The differences in the biological properties of trochlea and condyle 
might arise as a result of intrinsic or developmentally derived biological properties or different 
load-bearing patterns. 
Moreover, the regenerative potential of MSCs has been attributed to their paracrine effect. 
Cytokines, adhesion molecules and growth factors play a critical role in healing role of MSCs 
[82]. It becomes imperative to wonder if it is likely that the reduced progenitor population in 
condyle might lead to poor regeneration of repair tissue. In addition, angiogenins expressed by 
stromal cells induce processes essential for bone growth including capillary proliferation, 
expansion of the sinusoidal space as well as vessel growth and remodeling, processes that are all 
essential for bone growth [282]. Thus, a lower yield of condylar BMSCs may also lead to poorer 
bone remodelling-an important aspect of osteochondral repair.  
 
Since methods for in vivo localization of BMSCs still elude us, it becomes imperative to utilize 
the in vitro assays to shed light on the underlying mechanisms of differences observed in cellular 
and functional behaviour of BMSCs. For example, donor age and disease stage have been shown 
to impact the proliferative and differentiation potential of BMSCs in several studies [283]. 
Moreover, BMSCs obtained from OA patients have been shown to have reduced potential for 
proliferation and chondrogenesis compared to healthy BMSCs [53].  
Bone marrow stimulation procedures rely heavily on the migration of BMSCs to the repair site. 
Although the mechanism of BMSC migration is still uncertain, many believe that chemokines 
and adhesion molecules play an important role in migratory behaviour of BMSCs [284]. For 
example, the chemokine receptor type 4 (CXCR4) and its binding protein stromal-derived factor 
1-α (SDF-1α) are essential role for the process [285]. An inherent difference in the migration 
potential of BMSCs arising due to differences in receptor profile may also lead to variability in 
cartilage repair outcome.  
41 
 
 
 
Hierarchichal structure of BMSC differentiation has been proposed [286]. Russell et al showed 
that tri-potent clones had a higher rate of proliferation and reduced apoptosis [127]. Currently, 
markers to distinguish multipotent BMSCs from more committed progenitor cells are not 
available. As a result, a difference in the lineage commitment profile of BMSCs is hard to 
ascertain. A difference in the lineage commitment of BMSCs in condyle and trochlea may impact 
their potential for proliferation and differentiation-both with a profound impact on cartilage repair 
potential.  
 
Studies have reported that histone modification patterns on BMSCs can be correlated to its 
multipotential state and eventually to the differentiation potential. It will be interesting to explore 
if there are any differences in the epigenetic mechanisms of regulation between condyles and 
trochlea [287]. In an important study it was reported that BMSCs obtained from different organs 
had very similar profiles with minor differences in differentiation potential and surface marker 
profile. Interestingly, it was proposed that this difference may arise due to influence of local 
environment of origin and may be niche-dependent [119]. The origin or location of BMSCs’ 
source therefore has a bearing on their properties.   
 
2.7 Application of chitosan in improving cartilage repair 
Platelets and chitosan were first decribed by G. Bizzozereo and C. Rouget respectively [288]. 
BMS procedures rely on the formation of a blood clot which is retracted to a fraction of its size 
due to clot retraction property of platelets and exudation of serum. The contraction leads to 
shrinkage of clot and detachment from lesion surface. Platelets are the central hemostatic 
component comprised of anuclear, discoid shaped cell and are rich in several growth factors 
including TGF-beta, PDGF, VEGF etc in addition to cytokines [289]. Exposure to collagenous 
subendothelial structures causes platelets to adhere and bind with each other. The aggregated 
plug retracts and releases components which in turn induce inflammation and wound repair 
[290]. The retraction of the clot is mediated by actin-myosin contractile apparatus in the platelets 
and leads to loss of more than half of the clot’s original volume through serum exudation [291]. 
This retraction is detrimental for cartilage repair since it leads of shrinkage of clot and ultimate 
detachment of repair tissue from the defect bed [13, 14, 19, 292].  
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Chitosan is a biopolymer derived by deacetylation of chitin obtained from shell of crustaceans 
[293]. It is a linear polysaccharide comprised of β (1-4) linked D-glucosamine and various groups 
of randomly located N-acetyl glucosamine residues (Fig. 2.12). The average weight of CS is 
dependent on the method of preparation and can range from 50 to 1,000 kDA. The degree of 
deacetylation is generally in the range of 50-90% [294].  
 
 
Figure 2.12: Schematic of structure of chitosan- cationic polymer of partly acetylated 
glucosamine, made up of β (1-4) linked D-glucosamine and various groups of randomly located 
N-acetyl glucosamine residues. [Image copied from Buschmann et al-295]. 
 
Its beneficial role in repair of skin, cornea and bone among other tissues has been shown in past 
[296-298]. CS is an ideal scaffold material since it is biocompatible, soluble at physiological pH 
and is resorbed in a reasonable time frame [295]. Moreover, it inhibits platelet mediated clot 
retraction while promoting coagulation due to its hemostatic properties attributed to its ability to 
chain erythrocytes and activate platelets (Fig. 2.13) [299-301]. Finally, due to polycationic nature 
and high charge density, CS has excellent adherence to negatively charged biological tissues 
including bone and cartilage. 
 
 
 
Figure 2.13: Chitosan inhibits the platelet mediated retraction of blood clot leading to negligible 
loss in volume (b) compared to > 50% loss in volume in clot formed by blood alone (a). [Image 
copied from Buschmann et al-295] 
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Chitosan has been shown to be extremely biocompatible in several studies. It invokes a minimal 
foreign body reaction with negligible fibrous encapsulation [302]. The beneficial role of chitosan 
with respect to tissue engineering and regeneration includes its ability to encourage healthy 
granulation tissue formation, accelerated angiogenesis, increased cell proliferation and improved 
integration of repair tissue with host tissue [294]. In addition CS has unique hemostatic properties 
and modulates the migration behaviour of immunomodulatory cells such as neutrophils and 
macrophages [303, 304]. The beneficial effects of CS can be briefly summarized to include the 
following-chemoattraction, enhancement of granulation tissue formation, restricted retraction, 
hemostatic property, activation of immunomodulatory cells including neutrophils and 
macrophages and promotion of ECM synthesis by release of glucosamine and N-
acetylglucosamine residues [305].  
Chitosan oligosaccharides have a stimulatory effect on macrophages due to acetyl residues and 
CS has been shown to exert chemoattractive influence on neutrophils in vitro as well as in vivo 
[306-308]. In vivo, CS induces a significant recruitment of neutrophils in its vicinity without 
developing a chronic inflammatory response [294]. This property likely attributes to increased 
local cell proliferation and better attachment of repair tissue.  
Owing to these properties, CS has been developed as an ideal scaffold material for tissue 
engineering application among others. In addition, N-acetyl moiety in CS has structural 
similarities with GAG and HA component of cartilage matrix and makes it application for 
cartilage TE even more ideal [294]. The structural similarity with GAGs increases its potential 
for bioactivities related to interaction with growth factors receptors and adhesion proteins [294]. 
Repair of cartilage lesions was improved when chitosan was used along with BMP-7 in a rabbit 
cartilage defect model [309]. Chitosan-HA hybrid showed significant improvement in 
chondrocyte adhesion, proliferation and synthesis of cartilage matrix proteins [310]. Moreover, 
CS based scaffolds ensure a controlled release of growth factors which promote cartilage repair 
by increasing chondrocyte proliferation, recruitment and biosynthetic activity [302]. 
Collagen/CS/GAG scaffold developed by Lee et al ensured a controlled release of TGF- I and 
promoted cartilage regeneration in vitro [311]. CS scaffolds maintained the rounded morphology 
of chondrocytes along with synthesis of cell-specific ECM molecules [312, 313]. When used 
with PLLA films, CS improved cell adhesion, proliferation and biosynthetic activity of 
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chondrocytes [314]. Along with chondrocyte proliferation, CS/HA scaffold improved the 
synthesis of collagen type II and aggrecan [310]. CS/HA/alginate scaffolds developed by Hsu et 
al showed neocartilage formation in vitro and improved repair upon transplantation in rabbit knee 
[315].  
In addition, CS scaffolds have also been used with GFs alone for improved regeneration. PDGF 
and FGF encapsulated within CS promoted the differentiation of adipose derived stem cells 
(ADSC) and GAG synthesis. Similarly, controlled release of GFs such as IGF-1 and BMP-2 from 
CS porous scaffolds improved bone regeneration in vivo [316]. Encapsulated VEGF and PDGF 
improved revascularization in a rabbit model [317] . CS scaffolds promoted chondrogenic 
differentiation of ADSC indicated by significant improvement in GAG and collagen type II 
deposition along with upregulation of cartilage markers including Sox-9 [318]. Osteogenic 
differentiation of ADSC was promoted by platelet lysate released from CS-Chondroitin sulfate 
nanoparticles indicated by increased mineralization [319]. Defects in cranial bone were repaired 
in 16 weeks by PRP-Ca3P2O8-CS scaffolds by newly formed lamellar and woven bone due to the 
beneficial effect of GFs released from the scaffold on the BMSC differentiation [320, 321]. 
BMSC differentiation into chondrocytes was shown in a thermosensitive water soluble CS poly 
(N-isopropylacrylamide) gel with ability to be injected into the site of defect in a liquid form 
followed by its solidification at physiological temperatures [322].  
The causes for the better repair observed with CS-GP/blood implants were investigated in a 
rabbit model. Chitosan clots improve the attachment of the repair tissue growing from marrow 
holes, since only as little as 1% of tissue was detached in case of treatment. In addition, chitosan 
clots increase the cell recruitment into drill holes resulting in elevated levels of progenitor cells in 
the lesion. The transient subchondral angiogenesis is promoted which results in increased 
vascularization including large blood vessels in deeper zones and small vessels in superficial 
zone leading to a porous and revascularized bone plate [19, 291]. Improved subchondral bone 
remodeling allows higher tissue regeneration and better attachment of repair tissue [19]. 
Interestingly, chitosan improves the bone remodeling and repair even when residual calcified 
cartilage layer is present [19]. Chitosan clots release IL-8 which increases neutrophil and bone 
marrow progenitor cell recruitment in addition to stimulating angiogenesis. Increased recruitment 
of neutrophils in turn escalates the infiltration of alternatively activated macrophages which 
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improve subchondral bone repair due to their pro-angiogenic property [323]. Moreover, the levels 
of osteoclasts were increased by 2-fold which led to better subchondral bone remodeling and 
superior bone repair [20]. Our group also observed that osteochondral repair is mediated by 
formation of chondrogenic foci which recapitulate MSC condensation and chondrogenesis in 
embryonic limb bud. Although delayed by treatment with chitosan-GP/blood implants, the 
number and area of mature foci was higher. Moreover, the foci were displaced towards articular 
surface leading to reduced resorption to bone [18]. Quality as well as quantity of repair tissue in 
lesions treated with MFX and CS-GP/blood implants indicated a superior outcome in ovine 
models at the end of 6 month period. In addition, the incidence as well as severity of subchondral 
cysts-a common occurrence in ACI as well as BMS procedure- was reduced in this model [13].  
 
In a study including 33 patients on a compassionate basis, chitosan-GP/blood implant (BST-
Cargel) was proven to be safe for human application. Moreover, 12 month WOMAC (Western 
Ontario and McMaster University Osteoarthritis Index) scores showed considerable 
improvements in pain, stiffness and function over the baseline scores [324]. In summary, the 
application of a chitosan-GP/blood implant increases the quality and quantity of cartilage repair 
tissue which integrates better with a porous and healthy subchondral bone compared to BMS 
alone. Stanish et al published the results of a 1 year randomized controlled trial comparing BST-
CarGel treatment with MFX alone in 80 patients. Lesion fill and repair quality were improved in 
the BST-CarGel group (41 patients) compared to MFX alone (39 patients) indicated by more 
hyaline cartilage like T2 values [325].  Osteochondral biopsies showed significant improvement 
in ICRS macroscopic score in BST-CarGel group compared to MFX alone indicating 
improvement in fill, integration and appearance of tissue. In addition, significant improvement 
was also observed in surface architecture, surface/superficial assessment and cellular parameters 
in BST-CarGel treated defects. Collagen stratification was improved and resembled native 
cartilage more closely in the BST-CarGel group. The MFX group did not show a significant 
improvement in any of the parameters studied indicating superiority of BST-CarGel treatement 
over MFX alone [326]. The 5 year results from the study showed significant improvement in 
lesion filling and T2relaxation times with BST-CarGel versus MFX alone. Although the clinical 
benefit by both the procedures was same, BST-CarGEl induced more sustained and significantly 
superior quality and quantity of repair tissue [327]. The technology was acquired by Smith and 
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Nephew and is currently available in 26 countries. Recognizing the need for a one-step cell based 
method, BST-Cargel was subsequently combined with bone marrow aspirate concentrate in order 
to utilize the cartilage regeneration potential of MSCs to treat challenging defects. In vitro 
properties of the product - including clot retraction, cell viability and morphology, clotting time 
and product degradation - were reported to be similar to the currently available BST–CarGel 
implant [328]. Steinwachs et al and Al-Qarni et al recently published reports on the arthroscopic 
use of the technique [329, 330]. Although minimally invasive, the arthroscopic technique is 
technically challenging and not suitable for lesions in certain locations.  
2.8 Application of PRP in improving cartilage repair outcome 
A possible means to further improve the above strategy of BST-CarGel product is by using 
platelet-rich plasma (PRP) instead of whole blood. The use of PRP for clinical application was 
suggested by Marx et al in 1998 [22]. PRP is prepared by sequential centrifugation of whole 
blood and is defined as a volume of the plasma fraction of autologous blood having a platelet 
concentration 4-6 times the baseline [22-24, 331]. The platelet concentrate is activated following 
the separation from erythrocyte supernatant using either calcium chloride or thrombin. As a result 
of activation, PRP’s secretome - which may contain up to 800 protein components- is released 
[332]. In addition to growth factors, PRP is primarily composed of soluble mediators involved in 
inflammatory response-such as IL-1RA, IL-4, IL-8, IL-10, TNF-α, α-2-macroglobulin and 
mediators with a modulatory role in angiogenesis and coagulation [333]. PRP preparations are 
highly heterogeneous arising from discrepancies related to starting number of platelets, use of 
anticoagulants, isolation method, presence of leukocytes and use of activators [334-337]. A 
method for classification of PRP has been developed in order to address the high variability in 
cell composition of PRP. The international classification system-PAW classifies PRP based on 
the following criteria: absolute platelet count-low (P1) to high (P4), manner of platelet activation 
and presence or absence of white blood cells [338]. Based on the method of preparation, PRP 
may contain cells from leukocytic lineage, and is known as L-PRP.  
PRP finds application in tissue engineering mainly due to being a rich source of anabolic growth 
factors and ease of availability of autologous PRP preparation. However, activated platelets tend 
to release GFs quickly leading to loss of activity and reduced clinical efficiency [305]. Moreover 
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hyperconcentration of platelets in PRP preparations aggravates the platelet activation leading to 
rapid reduction or loss in platelet function.  
The exact mechanism of PRP in cartilage repair is still poorly understood due to large number of 
mediators and complex interactions [339] and is likely attributed to the growth factors stored in 
α-granules of platelets [340]. PRP is safe for clinical application and no medical contraindications 
have been recognized as yet [340]. Autologous PRP is easy to prepare and easily available and 
reduces the risk for transmission of disease or rejection of graft [334]. PRP is easy to deliver and 
is a suitable candidate to increase the GFs concentration in the defect milieu to achieve more 
successful cartilage repair results. Moreover, the mitotic effect of PRP was found to be reversible 
following the withdrawal of PRP. This is important since the cells need to retain their normal rate 
of proliferation once the tissue is regenerated [341]. 
In an important study, Kutlu et al showed that CS was a suitable carrier for PRP application and 
ensured a sustained release of GFs [342]. Platelet aggregation was shown to be enhanced on a 
CS/PCL scaffold [343]. Porous freeze dried CS scaffold used for sustained release of TGF-βI 
from microspheres increased chondrocyte proliferation and ECM synthesis [344]. In another 
study by our group, it was found that chitosan coats blood-derived cells and fibers in CS/PRP 
clots and prevents clot retraction through physical inhibition of platelet aggregation. Moreover, 
the release of EGF and PDGF-AB is increased in vitro from CS/PRP clots compared to PRP 
clots. Based on these studies, CS seems to be an ideal candidate for development of medium 
which ensures a controlled release of GFs over an extended period of time thereby improving the 
repair and regeneration outcome.  
Studies have shown that growth factors such as TGF-β [345], BMP-7 [346], FGF-2 [347] 
encourage proliferation and chondrogenic differentiation of BMSCs. It is likely that application 
of these factors improve the BMS repair outcome. Studies have reported an increase in 
proliferation and ECM synthesis upon exposure to PRP. The beneficial effects of PRP likely arise 
from its capability to promote angiogenesis, recruitment of cells to site of defect and induce local 
GF production [340]. PRP also has a positive impact on bone regeneration since BMSCs contain 
receptors for growth factors released from PRP which enhance the rate of bone formation and 
bone density [22]. Lucarelli et al observed an increase in the proliferation of MSCs upon 
exposure to PRP [341]. Properties such as increased BMSC recruitment and angiogenesis can 
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find an application in cartilage repair to augment the marrow stimulated procedures [348, 349]. 
PRP also releases Nf-κB pathway mediators such as IGF and HGF thereby inhibiting the IL-1  
mediated inflammatory reaction [333, 350-352]. Several groups have used PRP to augment BMS 
with mixed outcome. An increase in proliferation and anabolic activity of chondrocytes as a 
result of culture in medium containing 10% PRP was observed by Akeda et al [353]. In addition, 
PRP also has beneficial effects on proliferation and viability of chondrocytes and BMSCs [133-
135]. Kruger et al pointed out that migration and chondrogenic potential of subchondral BMSCs 
was enhanced in presence of PRP [26]. Moreover, PRP inhibits the catabolic effects of IL-1β, 
TNF-α, NF-κB on chondrocytes in in-vitro conditions [354, 355]. In-vivo, PRP reduces 
inflammation related Col-II loss and synovial hypertrophy [352]. Finally, PRP is likely to exert a 
positive effect on the recruitment of BMSCs from the bone to the site of defect due to abundance 
of chemokines present such as CCL3, CCL 5, CXCL1, CXCL 12 and CCL 17 [356]. An 
autologous bone graft combined with PRP and MSCs accelerated subchondral bone remodeling 
in an animal model improving the subchondral bone healing [357, 358]. Huh et al showed that 
PRP improved the outcome of BMS compared to BMS alone in a rabbit model [340]. However, 
they did not evaluate the mechanical strength of their repair tissue vis-à-vis the natural cartilage. 
PRP was also found to enhance the chondrogenic differentiation of BMSCs [359]. In a study with 
14 patients, PRP injections provided relief in OA patients at 12 month follow up [360]. In their 
systematic review, Smyth et al concluded from 21 in vitro and in vivo studies that PRP increased 
the synthetic capacity of chondrocytes along with increased proteoglycan and collagen synthesis 
thus increasing the hyaline content of the repair tissue [25]. 
On the contrary, studies carried out in human, bovine and ovine cells have indicated that while 
PRP may enhance the proliferation, it has deleterious or no effect on the chondrogenic 
differentiation [361-363]. The downside of using PRP derives from the sudden burst release of 
GFs post activation of platelets. The platelets release the contents of α-granules within 10 
minutes of activation and release over 90% of their contents within 1 hour. Owing to the burst 
release of GFs, some authors have questioned whether it is possible to regenerate cartilage defect 
upon such a short exposure to GFs [24, 364]. The effect of PRP on the chondrogenic 
differentiation has been controversial where some studies found an increase in the deposition of 
GAGs and collagen type II [353, 365]. On the other hand, Drengk et al showed that increased 
proliferation of chondrocytes was accompanied by reduction in the chondrogenic phenotype in 
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the presence of PRP [363]. Similar results were seen by Gaissmaier et al who cultured 
chondrocytes in presence of PRP. Although PRP induced an increase in the proliferation in 
monolayer phase, the chondrocytes were dedifferentiated into a fibroblast like phenotype in 
association with downregulation of collagen type II, aggrecan and BMP-2 mRNA levels in 
addition to significant upregulation in collagen type I [362]. In their study, Li et al observed a 
sustained expression of stemness related markers while expression of lineage specific markers 
was reduced. While PRP induced proliferation in muscle derived MSCs, it maintained cells in a 
more undifferentiated state and cells did not show any change in the osteogenic or chondrogenic 
differentiation capacities [366]. Nasal septal chondrocytes were stimulated for proliferation but 
failed to redifferentiate in 3D cultures and expression of cartilage specific matrix components 
was not achieved in the presence of PRP [361]. Using an ovine chronic defect model, Milano et 
al showed that when used as an adjunct to BMS, PRP enhanced the repair response versus BMS 
alone [367]. Although the application of PRP improved the macroscopic and mechanical 
outcome, the hyaline nature of RT was lacking. 
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2.9 Considerations for suitable animal model 
In order to relate animal models with human repair and identify a model which not only 
corresponds to the older and degenerative human joints, but also can be used for development of 
strategies for better repair, it is crucial to choose the animal model carefully. Since subchondral 
bone is the source of repair in case of BMS procedure, it becomes important to consider the 
subchondral bone parameters as well as cartilage properties while choosing an animal model. 
Rabbit trochlea resembles human MFC more closely than any other species in subchondral bone 
porosity, thickness of bone plate as well as repair outcome [368].  
In this study, biological properties of rabbit BMSCs from condyle and trochlea will be 
determined. These will then be correlated with the repair outcome in a skeletally mature rabbit 
model. While developing the animal model, it is important to bear in mind a few considerations 
which include but are not limited to the following. Young animals have tremendous spontaneous 
repair potential and are an unsuitable candidate for development of models for cartilage repair 
studies [13]. Moreover, skeletally mature animals are more comparable to the patient population 
in need of cartilage repair treatment. The size of the defect is an important consideration. Defects 
less than 3 mm have been shown to repair spontaneously [199] and therefore, it is important to 
create critical sized defects to rule out the possibility of spontaneous repair. In the rabbit model 
developed by our group, 17-20% of defect area is perforated by drill holes by placing 4 holes in a 
4X4mm defect in rabbit. This simulates the clinical hole perforation density range of 13-49% 
used in humans. In addition, the rabbit defect size is approximately 1/10th of average clinical 
defect size of 1.5 cm
2
. As a result a scaling factor of 3 is used for linear dimensions reflected by 
the ratio of diameter of clinical tool (3 mm) and microdrill to be used in this study (1 mm) [21].  
Although rabbit knee has been widely used in experimental cartilage repair studies [194], it is 
imperative to take certain considerations into account while extrapolation of results. The model 
proposed in this study is an aggressive model since bilateral defects will be created on trochlea as 
well as condyle resulting in large surface being covered by defects which might lead to formation 
of osteophytes [223]. It is important to create bilateral models owing to high interindividual 
variability observed with rabbit model [194]. Also, rabbits have high degree of flexion as a result 
of which the load bearing region of MFC is more posterior than human. Bone marrow stimulation 
procedures rely on the recruitment of progenitor cells from the underlying subchondral bone. 
Drilling deep has been shown to provide access to metaphyseal marrow, richer in progenitor cell 
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population [17]. As pointed out by Hurtig, removal of calcified cartilage is an important step in 
cartilage repair studies in preclinical and clinical situation. Removal of CC provides increased 
access to progenitor cells. Several studies have shown presence of CC as a barrier to marrow 
stimulated repair across various species [199, 369, 370]. However, extreme caution needs to be 
exercised during CC debridement since insult to subchondral bone increases the likelihood of 
poor repair, subchondral cysts and poor clinical outcome [371-373]. Drilling accompanied with 
cooling irrigation prevents heat necrosis, bone compaction and ensures removal of bone debris. 
Increased access to marrow improves the long term repair outcome [21].  
Traditionally, the models used in the lab are generated from normal animals where fresh defects 
are treated to verify the cartilage repair strategies. In reality, the excellent pre-clinical results fail 
to translate successfully in a clinical setting. The failure may arise due to failed bonding between 
the repair tissue and surrounding cartilage, impartial restoration of repair tissue or inferior quality 
of repair tissue. This leads to instability of the newly generated repair tissue finally causing the 
procedure to fail. Chronic model provides an opportunity to study the impact of the altered joint 
mechanics on cartilage regeneration. Based on recent studies, it is clear that influence of 
synovitis, meniscal damage, ligament instability, and altered metabolism in joints cannot be ruled 
out while studying the pathogenesis of osteoarthritis or evaluation of cartilage repair strategies 
[374]. Using goat model, Verbout et al showed that early intervention proved to be more 
successful in maintaining normal joint homeostasis (Fig. 2.14). Metabolic alterations including 
degeneration of matrix and release of matrix components was more pronounced in the defects 
receiving late treatment. Chronic defects are more challenging to treat as seen by the comparable 
degeneration observed between untreated and chronic defects. The authors were able to conclude 
that cartilage regeneration was negatively influenced by the altered joint homeostasis in chronic 
defects. This study highlights the need for development of chronic defect model for evaluation of 
cartilage repair strategies in pre-clinical studies. Subchondral bone in chronic cartilage lesions is 
likely to be denser and more sclerotic accompanied by a reduction in the number as well as 
chondrogenic potential of progenitor cells [375]. Finally, it also important to evaluate the 
influence of chronicity of defects on the chondrogenic and osteogenic potential of mesenchymal 
progenitor cells in the subchondral bone [220]. In conclusion, the evaluation of cartilage repair 
techniques in chronic defect models is likely to simulate the clinical situation more closely and 
accurately thereby ensuring the successful translation of these techniques.     
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Figure 2.14: Comparison of cartilage repair outcome in groups treated “early” and “late”. (a). 
Repair response was better in acute defect group characterized by hyaline staining of matrix and 
evidence of SC bone remodeling. (b). Chronic defects were characterized by incomplete fill, 
hypertrophy, uneven staining and poor bonding with adjacent cartilage [Image copied from Saris 
et al-374]. 
 
Another important aspect while development of animal models is the duration of repair. Early 
time points are more suitable for monitoring of initial alterations occurring in the defect milieu. 
The early time point also assists in better understanding of the underlying mechanism of key 
events participating in the cartilage repair such as cell recruitment, vascularisation and 
subchondral events [19] with an important bearing on the eventual repair outcome. Moreover, it 
is important to study the short term outcomes before proceeding to larger studies since poor short 
term outcomes are rarely translated into successful outcomes in long term [374].  
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3. CHAPTER 3   ORGANIZATION OF ARTICLES 
The scientific contribution made through this thesis is presented here by means of this section. In 
previous studies by our group we had found substantial evidence of effect of location of defect on 
marrow stimulated cartilage repair outcome. In BMS, progenitor cells (Mesenchymal stem cells, 
MSCs) present in the subchondral bone are recruited into the drill holes and defect to give rise to a 
repair tissue via a complex cascade of events. The underlying mechanism of high inter-individual 
variability observed with BMS procedure remains unclear and warrants a better understanding of 
behavior of individual cells present in subchondral bone. The first part of the study will primarily 
focus on the characterization of mesenchymal stem cells isolated from condyle and trochlea of 
young and old rabbit. Since bone marrow stimulation procedure involves cells originating from 
marrow spaces, bone lining regions and bone; cells will be isolated using collagenase digestion to 
obtain first population of cells followed by explant culture to obtain second population of cells. The 
paper is entitled “Bone marrow progenitor cells isolated from young rabbit trochlea are more 
numerous and exhibit greater clonogenic, chondrogenic and osteogenic potential than cells isolated 
from condyles”. This paper will verify if MSCs exhibit location-dependent variability in their 
intrinsic biological properties. In addition, the influence of age on the aforementioned biological 
properties will also be determined. Comprehensive analysis of biological properties will be carried 
out in vitro to compare the cell yield, clonal potential, surface marker profile and potential to 
differentiate into chondrogenic and osteogenic lineage. This is the first study of its kind aimed at 
providing valuable insights into our understanding of location and age dependent factors influencing 
cartilage repair outcome. The paper has been published in the journal “Cartilage”. 
The results from this study then steered us towards second article where correlation between 
inherent biological properties of BMSCs and cartilage repair outcome in adult rabbit will be 
investigated. The results are presented in the article titled “Quality of cartilage repair from marrow 
stimulation correlates with number clonogenic, chondrogenic and matrix production potential of 
underlying bone marrow stem cells”. This novel study will attempt at exploring the underlying 
mechanism of donor- and location-dependent variability observed in marrow stimulated repair 
outcome. Acute defect in skeletally mature rabbits will be created in condyles and trochlea in one 
knee and repaired by BMS by microdrilling. The contralateral knee will be used for isolation of cells 
from condyle and trochlea followed by in vitro characterization of their biological properties. 
Characterization of repair tissue and BMSCs will help us establish influence of location and donor 
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on the cartilage repair outcome. In the most important step, the study will seek after donor- and 
location-dependent correlation between cartilage repair outcome and inherent properties of stem 
cells present in condyle and trochlea using suitable statistical models. This paper has been submitted 
to the journal “Osteoarthritis and Cartilage”. 
These two studies helped in establishing the donor-, age- and location-dependent factors with a 
significant impact on the outcome and variability of cartilage repair outcome. Inspired from our 
analysis of underlying mechanism of variation in cartilage repair, we finally proceeded to the 
final stage of this study, the results from which have been presented in the article titled “Freeze-
dried chitosan/PRP implants improve marrow stimulated cartilage repair in a chronic defect 
rabbit model”. Clinical translation of several cartilage repair strategies with promising preclinical 
results is unsuccessful since cartilage lesions in clinical situation are rarely detected in early 
stages and have already progressed to degenerative, chronic stage by the time surgical 
intervention is carried out. With this issue in mind, this paper will explore critical aspects in 
cartilage repair using a challenging chronic defect model to analyse the influence of augmented 
marrow stimulation on repair response. Chronic trochlear defects will be developed in skeletally 
mature rabbits and treated by microdrilling for BMS. The impact of stimulus provided by means 
of chitosan and PRP on BMSCs contributing to marrow stimulated cartilage repair will be 
examined. This article has been submitted to the journal “Biomaterials”. The studies presented in 
these three articles not only helped us in recognizing critical factors implicated in variability in 
marrow stimulated repair outcome but also present a promising approach to address the critical 
clinical osteoarthritic situation. 
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4. CHAPTER 4   ARTICLE 1: BONE MARROW PROGENITOR 
CELLS ISOLATED FROM YOUNG RABBIT TROCHLEA ARE 
MORE NUMEROUS AND EXHIBIT GREATER CLONOGENIC, 
CHONDROGENIC AND OSTEOGENIC POTENTIAL THAN 
CELLS ISOLATED FROM CONDYLES 
Bone marrow stimulation initiates repair by fracturing or drilling into subchondral bone at the 
base of a debrided cartilage defect, typically leading to the formation of a fibrocartilagenous 
repair tissue. The common drawbacks of the procedure include incomplete regeneration, high 
inter-individual variability and poorer outcome in older animals. Based on evidence in literature, 
we believe that cartilage repair outcomes are affected by defect location and age of donor, 
suggesting that the biological characteristics of progenitor cells (Bone Marrow Progenitor cells, 
BMPCs or mesenchymal stem cells; MSCs) present in underlying subchondral bone strongly 
influence the repair response. Chapter 4 focuses on comprehensive analysis of the BMPCs/MSCs 
present in rabbit condyle and trochlea, taking into account location and age. In this study, we 
established isolation and culture protocols for BMPCs/MSCs derived from rabbit distal femur. 
BMPCs/MSCs were isolated from condyles and trochlea of young and old rabbits using cultures 
derived from collagenase-digests of marrow stroma and explant culture of digested bone. 
Characterization of BMPCs/MSCs was primarily based on ISCT guidelines with assays added for 
better understanding of their inherent properties. P0 cell yield was used an indicator of initial 
population of cells present in subchondral bone. CFU-f assay provided an estimation of their 
clonogenic potential and thus stemness. Surface marker expression profile was carried out to 
confirm the composition of population as well as verify influence of age and location. Finally, 
cells were differentiated into osteogenic and chondrogenic phenotype. In vitro analysis of 
properties of BMPCs/MSCs is expected to shed light on the differences in inherent properties of 
BMPCs/MSCs present in condyle and trochlea including cell population, clonogenic potential 
and differentiation potency. We believe that the extensive characterization of BMPCs/MSCs 
presented here will improve our understanding of mechanism underlying the location-dependent 
variability in marrow stimulated repair outcome. By understanding the impact of ageing on the 
properties of BMPCs/MSCs, our results will also help in adapting the procedure to better suit the 
needs of older population. In Press, Cartilage. 
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Abstract 
 
Objective: Bone marrow stimulation procedures initiate repair by fracturing or drilling 
subchondral bone at base of cartilaginous defect. Earlier studies have shown that defect location 
and animal age affect cartilage repair outcome, suggesting a strong influence of structural and 
biological characteristics of subchondral bone. Here we analyzed comprehensive biological 
characteristics of bone marrow progenitor cells (BMPCs) in subchondral bone of young and old 
rabbit condyle and trochlea. We tested the hypothesis that in vitro biological properties of 
BMPCs are influenced by location, age of donor and method of their isolation. 
  
Design: In vitro biological properties including cell yield, colony-forming unit fibroblasts (CFU-
f), surface marker expression and differentiation potential were determined. Comparisons were 
carried out between trochlea versus (vs.) condyle and epiphyseal versus metaphyseal bone using 
old (N=5) and young animal knees (N=8) to generate collagenase and explant-derived BMPC 
cultures.  
 
Results: CFU-f, cell yield, expression of stem cell markers and osteogenic differentiation were 
significantly superior for younger animals. Trochlear subchondral bone yielded the most 
progenitors with the highest clonogenic potential and cartilaginous matrix expression. Trochlear 
collagenase-derived BMPCs had higher clonogenic capacity than explant-derived. Epiphyseal 
cells generated a larger chondrogenic pellet mass than metaphyseal-derived BMPCs. All older 
pellet cultures and 1 non-responder young rabbit failed to accumulate glycosaminoglycans 
(GAGs).  
 
Conclusion: Taken together, these results suggest that properties intrinsic to subchondral 
progenitors could significantly influence cartilage repair potential, and could partly explain 
variety in cartilage repair outcomes using same cartilage repair approach. 
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4.1 Introduction  
Articular cartilage present at the ends of long bones possesses very limited regenerative capacity 
and is frequently repaired using bone marrow stimulation typically leading to formation of 
fibrocartilaginous repair tissue. Channels created in subchondral bone, provide access to 
underlying bone marrow stroma rich in BMPCs which are recruited to cartilage defect site. They 
proliferate and differentiate into a chondrogenic phenotype leading to formation of a repair tissue 
with varying amounts of hyaline and fibrous cartilage [1]. In addition to mechanical and 
structural factors; differences in number, stemness and differentiation potential of BMPCs are 
expected to influence cartilage repair.  These properties can be characterized in vitro using 
assays for determination of cell yield, colony forming unit-fibroblast potential (CFU-f), 
expression of cell surface markers and multilineage differentiation potential. 
 
Previous studies have reported an influence of the defect location and age on cartilage repair 
outcome, suggesting a strong influence of biological characteristics of subchondral BMPCs [2-
4]. 34-58% of chondral injuries are observed in condyles while trochlea accounts for 6-8% cases 
[2]. Whereas human trochlear defects are harder to treat compared to condylar defects-likely due 
to anatomical and mechanical dissimilarities- [3-5], animal models present varying scenarios. 
While trochlea demonstrated superior repair potential in rabbit [3, 4]; quality of repair in a sheep 
model [2] was better in condyle as shown in earlier studies by our group reflecting important 
species- and site- dependencies. Primary goal of this study was to verify influence of location on 
in vitro properties of rabbit BMPCs which might impact in vivo repair outcome. Earlier, our 
group also showed that drilling to 6mm vs 2mm improves repair outcome in trochlea [6], 
possibly since it provides access to the metaphyseal red marrow rich in BMPCs. Therefore, we 
compared in vitro biological properties of BMPCs in upper and lower regions of trochlea in 
order to evaluate the influence of the depth of drilling on the repair response in clinical 
situations. We also explored influence of age on BMPC properties to improve our understanding 
of underlying causes of poor repair in older individuals. Finally, BMPCs were isolated from 
stromal spaces and bone lining regions (collagenase digestion) as well as outgrowths from 
explants since cells participating in bone marrow stimulated cartilage repair originate from both 
these sites. Human trabecular cells reacted positive for Stro-1 and CD105 and negative for CD34 
and CD45 suggesting presence of multipotential cells in bone [7]. Cells remaining in explants 
59 
 
 
 
most likely migrate out after collagenase treatment and demonstrate potential to form colonies  
[8-10] and form new bone and cartilage in vivo [11]. We optimized the concentration and 
duration of enzyme treatment for maximum yield and viability since collagenase digestion is a 
harsh treatment compared to explant culture with a damaging effect on in vitro properties of 
BMPCs [12, 13]. Owing to similar cell surface marker profile and trilineage differentiation 
potential, we expect that collagenase- and explant derived BMPCs would demonstrate 
comparable in vitro biological properties. 
 
Through this study, a comprehensive analysis of biological characteristics of BMPCs from 
young and old rabbit condyle and trochlea was performed to verify influence of location, age and 
isolation method on their in vitro biological properties. The specific hypotheses tested were: 1) 
Cell yield, stemness markers, clonogenic, chondrogenic and osteogenic potential are superior in 
trochlea compared to condyles. 2) Cell yield, stemness markers, clonogenic, chondrogenic and 
osteogenic potential decrease with age. 3) There is no difference in in vitro biological properties 
of collagenase and explant-derived BMPSCs. 
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4.2 Materials and Methods  
4.2.1 Necropsy 
 
Animal study protocols were approved by University of Montreal institutional committee 
“Comité de déontologie de l’expérimentation sur les animaux”. Female New Zealand White 
rabbits -young (4 months; n=8 knees) and retired breeders (12-36 months; n=5 knees) were used. 
Rabbits were anaesthetized with xylazine-ketamine and euthanized by an overdose of sodium 
pentobarbital. Both femurs were exposed, dissected of all soft tissues, and placed in ice-cold 
DMEM/F12 medium.  
 
4.2.2 Isolation of BMPCs 
 
Reagents were obtained from Sigma-Adrich (Oakville, ON, Canada) unless otherwise specified. 
Under sterile conditions, bone was rinsed with HBSS-Penicillin-Streptomycin (P-0781). 
Condylar and trochlear bone segments were obtained using isomet saw (Fig. 4.1a-1d). Trochlear 
segments were separated into Trochlea Upper (epiphyseal bone) and Trochlea Lower 
(metaphyseal bone) separated by growth plate in case of young animals or epiphyseal line in 
retired breeders (Fig. 4.1e). Following further fragmentation into 4-5 mm chips using flat blades 
(Fig. 4.1f), chips were weighed in order to determine cell yield/wet mass at end of P0. Bone 
chips were treated with 3 mg/ml collagenase type-XI (C-9697) for 2 hours/37⁰C/100rpm. Post-
digestion cell suspension was centrifuged and cells were used to obtain first population of 
BMPCs-“collagenase-derived”. Digested bone chips were rinsed twice with HBSS to remove 
residual collagenase and placed in flasks for 4 days to generate second population of cells-
“explant-derived”. Colonies of fibroblast-like-cells were cultured in growth medium comprised 
of DMEM/F12 (Gibco, 12500-062) containing 10% FBS and 1X penicillin-streptomycin 
solution. Following first medium change at 4-5 days to remove dead and non-adherent cells, 
medium was changed every 2-3 days.  
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4.2.3 Histology of bone chips 
 
Two bone chips were collected at three stages-before enzyme treatment (D0, pre-digested), 
immediately after enzyme treatment (D0, post-digested) and day 4 of explant culture (D4, post-
digested) for evaluation of collagenase digestion efficiency and migration of cells from explants. 
They were fixed in 10% normal buffered formalin (Fisher), decalcified in 0.1N HCl/0.1% 
glutaraldehyde, embedded in paraffin, sectioned at 5 µm and stained with Hematoxylin (Fisher, 
SH30-500D) and Eosin (Surgipath, CI 45380).  
 
4.2.4 Cell Yield 
 
For accurate comparison of initial BMPC population isolated from different locations of bone, 
all P0 samples were trypsinized at the same time ˗ when at least one of the samples reached 80-
85% confluency ˗ irrespective of other cultures’ confluency. While sufficient cells were obtained 
from all 3 locations in all 8 young knees, only 3 of older knees generated substantial cell yield 
for statistical analysis (n=8 knees and n=3 knees for young and old animals respectively). The 
cultures were trypsinized at d6-7 (collagenase-derived) and d10-11 (explant-derived) in young 
and d8-10 (collagenase-derived) and d11-13 (explant-derived) in older animals. Cultures were 
passaged twice using 0.25% Trypsin-EDTA (Invitrogen, 25200-072). Cell viability was 
determined with Trypan Blue exclusion and Countess system (Invitrogen). Cell yield was 
determined as follows:  P0 cell yield (10
6
/g) = viable cell count (10
6
)/ wet weight of bone chips 
(g) 
 
4.2.5 Flow cytometry  
 
P1 BMPCs (10
6
/ml) were blocked with 1% solution of BSA-PBS (A-7888) followed by 
incubation with non-conjugated monoclonal antibodies and goat anti-mouse IgG-FITC. MPC 
positive antigens used were CD29 (Millipore, MAB1951Z) and CD44 (Cell Marque, 144M-96). 
Hematopoetic marker CD34 (Cell Marque, 134M-16) and pan-leukocytic marker CD45 (Cell 
Marque, 145M-97) were used as negative markers. Mouse IgG isotype primary antibody served 
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as negative control. Stained cells were acquired using MoFlo cytometer and data was analysed 
using Summit software after appropriate gating to exclude cell debris.  
  
4.2.6 CFU-f 
 
P1 cells were trypsinized, replated as single cells at low density of 100 cells/well and cultured in 
complete growth medium for 6-7 days. Cultures were stained with 1% (w/v) solution of crystal 
violet (C-0775) and colonies containing more than 50 cells were counted.  
 
4.2.7 Chondrogenic differentiation assay 
 
Chondrogenesis was induced in 3-dimensional high density pellet cultures of BMPCs using P2 
cells. 0.25×10
6 
cells (in DMEM/F-12) were centrifuged in 15 ml polypropylene tubes at 300g/5 
minutes to form pellets. Tubes were placed at 37°C/5% CO2 with caps loosened to allow gaseous 
exchange. Next day, pellets were switched to 0.5 ml chondrogenic medium comprised of serum-
free high-glucose DMEM (Gibco, 12100-046) supplemented with dexamethasone (100nM, Cat. 
No. D-2915), ascorbate (50 µg/ml, A-8960), ITS (1X), sodium pyruvate (100ug/ml, Gibco) and 
BSA (1.25mg/ml, A-7888) for three weeks. Ascorbate was added fresh at the time of medium 
change on alternate days. Control and stimulated pellets were cultured in absence and presence 
of TGF-βIII (R&D, FB2712091) respectively. Low magnification images of fixed pellets were 
used to determine their gross structure and diameters (used as an indicator of amount of matrix 
synthesized) using Northern Eclipse software (Empix Imaging).  
 
4.2.8 Histology of pellets 
 
Pellets were fixed in 4% paraformaldehyde/0.1M sodium cacodylate/2.5%w/v cetylpyridinium 
chloride followed by sucrose infiltration, OCT embedding and sectioned at 8 µm using CryoJane 
tape-transfer cryosectioning system. Sections were stained with Safranin-O (Fisher, S670-25) 
and Fast Green (F-7252) to detect GAGs as previously described [14]. Collagen type-II 
expression was determined by immunostaining. Sections were treated with hyaluronidase (H-
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3506) and pronase (P-8811) and blocked with goat serum (G-9023) followed by anti-collagen-
type II (clone II6B3, DHSB, 1:10) antibody. Following treatment with biotinylated secondary 
antibody (B-7151) and Vectastain ABC kit (Vector, Cat. No. AK-5000), alkaline phosphate red 
substrate kit (Vector, SK-5100) was used to develop the stain. Images of Safranin O/Fast Green-
stained sections were scored using a 0 to 4 system by one blinded observer (AC). A 
chondrogenesis score of 0 was attributed to pellets which had no Safranin-O staining (Panel-a in 
Fig. 4.6). Chondrogenesis score of 4 was given to pellets which had a matrix that was rich in 
GAG and had cells with characteristic chondrocyte and hypertrophic chondrocyte morphology 
(Panel-b of Fig. 4.6). 
 
4.2.9 Osteogenic differentiation assay 
 
P2 cells were trypsinized and replated in 24-well plates and cultured in complete growth medium. 
Confluent monolayers were stimulated with osteogenic medium comprised of α-MEM (Gibco. 
12000-014) supplemented with dexamethasone (100nM, D-2915), ascorbic acid (L-) 2-phosphate 
sesquimagnesium salt (100µM, A-8960) and β-glycerophosphate (5mM, G-9422). Control 
cultures were cultured in absence of dexamethasone. Presence of osteogenic matrix was 
determined after four weeks by Alizarin Red S (AR) (A5533) staining. Absorbance of 10% acetic 
acid extract was recorded at 425 nm and used to quantify AR present in each sample using AR 
standard curve.  
 
4.2.10 Statistical Analysis 
Statistical analysis was performed using SAS Enterprise Guide 5.1 and SAS 9.3. Since several 
segments were collected from both legs of each rabbit, mixed model was used to account for 
influence of donor and age (n=8 young knees and n=3 or 5 old knees). Fixed effects were 
location (condyles, upper trochlea or lower trochlea), age (young or old), isolation method 
(collagenase- or explants-derived cultures), and treatment (for chondrogenic or osteogenic 
stimulation only), while donor was a random effect. Data in figures are presented as mean 
(circle); median (line); Box: 25
th
 and 75
th
 percentile;  
Whiskers: Box to the most extreme point within 1.5 interquartile range. 
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4.3 Results 
4.3.1 BMPCs can be isolated from different locations in rabbit femur  
 
Bone fragments displayed marrow stroma rich in cells before digestion (Fig. 4.1g-i) following 
which variable fractions of bone marrow stroma were released into supernatant and marrow 
spaces became clearer (Fig. 4.1j-l). Bone lining cells seen in pre-digested samples (arrows in Fig. 
4.1g-i) were no longer observed in post-digestion samples (Fig. 4.1j-l). Numerous lacunae were 
observed in bone matrix after 4 days of explant culture (dashed arrows in Fig. 4.1j-l). Upon 
seeding, BMPCs readily separated from cells of hematopoietic origin owing to their adherence to 
tissue culture plastic.  
In both collagenase and explant cultures, cells adhered as rounded cells, acquired characteristic 
fibroblastic morphology later and grew as colonies in P0 (Fig. 4.1m and n). No apparent 
morphological difference was observed in cells from condyles, upper trochlea and lower 
trochlea.                               
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Figure 4.1: Processing of rabbit femur. Femoral end secured on sample holder of Isomet saw 
while condylar segment is being sectioned off (a). Femoral end while distal trochlear segment is 
being sectioned off (b). Femoral end while proximal trochlear segment is being sectioned off (c). 
Three segments post-sectioning: Condyles, distal trochlea and proximal trochlea (d). Separation 
of a trochlear segment into Upper and Lower trochlea above and below the growth plate (in the 
young) and epiphyseal line (in the old) (e) All segments were fragmented with flat blades to yield 
3 groups: Condyles, Upper trochlea (pooled from distal and proximal segments) and Lower 
trochlea (pooled from distal and proximal segments) (f). H&E stained paraffin sections of bone 
fragments were collected at pre-digestion (g-i) and post-digestion after 4 days of explant culture 
(j-l). Marrow spaces are initially occupied by cells. Arrows point to the bone lining cells in pre-
digested samples (g-i). In post-digestion samples, marrow spaces are partly void, bone-lining 
cells are mostly absent. Dashed arrows point to empty bone lacunae in post-digestion samples (j-
l). Bone marrow progenitor cells growing as colonies from Collagenase-derived cultures (m) and 
Explant-derived cultures (n). Arrow in n points to an explant bone fragment. 
 
4.3.2 Cell yield, clonogenic potential and matrix production are highest in trochlear 
segments; and decrease with age 
 
In young animals, trochlea upper showed higher cell yield versus condyles for both collagenase 
(p<0.0001) and explant-derived cultures (p<0.0001) (Fig. 4.2a). In older animals, cell yield was 
highest for trochlear upper and lowest for condyles in collagenase-derived (p=0.0041) (Fig. 4.2b). 
Cell yield was lower in old versus young animals, significantly for explant-derived cultures (p = 
0.028) (Fig. 4.2a, b). Yield for collagenase- and explant-derived BMPCs was found to be 
comparable in young animals (Fig. 4.2a), while poorer yield was observed for explant-derived 
cultures in old animals (p = 0.0022) (Fig. 4.2b).  
 
All samples expressed BMPC markers CD29 and CD44 (Fig. 4.2c, d) with no apparent difference 
between condyles, trochlea upper and trochlea lower or collagenase- and explant-derived 
BMPCs. Substantial difference was observed between young and old animals (Fig. 4.2c vs. 4.2d). 
Expression of BMPC markers was poor in older animals with a considerable proportion of cells 
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showing no expression. All samples lacked expression of CD34 (Fig. 4.2e, f) and CD45 
indicating absence of cells of hematopoetic or leukocytic origin. 
 
 
 
Figure 4.2: Cell yield observed in young animals (a, n = 8 knees) versus old animals (b, n = 3 
knees) for collagenase- and explant-derived cultures. Cell yield was higher for Trochlea Upper in 
both collagenase- and explant-derived cultures in the young animals (a). Cell yield was also 
higher for Trochlea Upper in collagenase-derived samples in older animals (b). Data is presented 
as mean (circle); median (line); Box: 25th and 75th percentile; Whisker: Box to the most extreme 
point within 1.5 interquartile range. Horizontal lines show significant differences between pairs. 
Greater expression of stem cell marker CD44 was observed in young animals (c) versus old 
animals (d). CD34 was not expressed in young (e) or old (f) animals. 
 
CFU-f was strongly influenced by location, age and method of isolation (Fig. 4.3a-l and m, n). 
Upon macroscopic examination, trochlear colonies appeared more numerous and larger (Fig. 
4.3b, c vs. 4.3a and 4.3e, f vs. d). In young animals, both collagenase-derived trochlear segments 
had higher CFU-f than condylar segments indicating greater clonogenic potential (Fig. 4.3m) 
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(p=0.02-trochlea upper and p<0.0001-trochlea lower respectively). CFU-f was significantly lower 
in older animals for both collagenase (p=0.02) and explant-derived BMPCs (p=0.06). Finally, 
explant-derived BMPCs showed inferior clonogenic potential versus collagenase-derived BMPCs 
in young and old animals indicated by lower CFU-f (Fig. 4.3m, n) (p<0.0001).  
 
 
 
Figure 4.3: Clonogenic colonies stained with 1% (w/v) Crystal Violet stain show increased 
colony formation in the case of young (panels a to f) versus old animals (panels g to l). Higher 
CFU-f was observed for both trochlear segments versus condyles in collagenase-derived cultures 
in young animals (m, n = 8 knees), but not in old animals (n, n = 3 knees). CFU-f was 
consistently higher for collagenase-derived cultures compared to explant-derived cultures (m & 
n). Data is presented as mean (circle); median (line); Box: 25th and 75th percentile; Whisker: 
Box to the most extreme point within 1.5 interquartile range. Horizontal lines show significant 
differences between pairs. 
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In young animals, pellets cultured without TGFβ-III were smaller than those cultured in presence 
of TGFβ-III in both collagenase (Fig. 4.4a-c vs. d-f) and explant-derived cultures (p<0.0001) 
(Fig. 4.4 g-l). Pellets from upper trochlear BMPCs were largest in both collagenase (p=0.1) and 
explant-derived cultures (p=0.03) indicating maximum matrix production (Fig. 4.4m, n). 
Respective pellets from collagenase- and explant-derived BMPCs from same location were 
similar in size (Fig. 4m vs. n) (data not shown for explant-derived cultures). 
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Figure 4.4: Gross structure of pellets show increase in size upon culture in presence versus 
absence of TGF-βIII in young animals (a-f) but not in old animals (g to l). Pellets derived from 
collagenase-derived cultures are shown here. Pellets from trochlea upper samples were larger 
compared to pellets from condyles in young animals (m&n, n = 6 knees), and significantly so in 
the case of explant-derived cultures (n). All samples show low pellet diameter in old animals for 
collagenase- (o, n = 5 knees), and even lower in explant-derived cultures (p, n=2 knees). Data is 
presented as mean (circle); median (line); Box: 25th and 75th percentile; Whisker: Box to the 
most extreme point within 1.5 interquartile range. Horizontal lines show significant differences 
between pairs, unless otherwise indicated. 
 
4.3.3 Chondrogenic potential displays high inter-individual variability, is on average 
superior for trochlear segments and decreases with age 
 
Pellets cultured without TGF-βIII lacked expression of GAGs (Fig. 4.5) as well as Coll-II (results 
not shown). In young animals, enormous variation was observed in quality of matrix produced by 
pellets cultured in presence of TGF-βIII. In one young animal-a high responder- pellets expressed 
high levels of GAGs (Fig. 4.5-panels a&b) and Coll-II. Two young animals were labeled 
medium-responders (Fig. 4.5-panels c&d). In another young animal-a low responder- very little 
chondrogenesis was observed (Fig. 4.5-panels e&f).  While chondrogenesis scores reflect this 
variation and have large spread, on average, both collagenase- and explant-derived BMPCs 
derived from trochlea upper displayed increased chondrogenic potential (Fig. 4.5-i&j). By 
contrast, outcome in older animals was more consistent (Fig. 4.5-panels g&h). Poor matrix with 
negligible expression of GAG (Fig. 4.5-panels g&h) and Coll-II and corresponding low 
chondrogenesis scores (Fig. 4.5-k&l) was observed for all samples cultured in presence of TGF-
βIII, irrespective of location or method of isolation.  
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Figure 4.5: Safranin O/Fast Green staining of pellets derived from collagenase- and explant-
derived cultures, showing a high responder (panels a&b), medium responder (panels c&d) and 
low responder (panels e&f) in the young, as well as pellets derived from an older animal (panels 
g&h). TGF-βIII treatment only induced chondrogenesis in the young animals, as revealed by the 
chondrogenesis score (compare panels i&j to panels k&l). Cells derived from the trochlear upper 
sample displayed increased chondrogenic potential in both collagenase-derived and explant-
derived cultures in the young (i&j). Data is presented as mean (circle); median (line); Box: 25th 
and 75th percentile; Whisker: Box to the most extreme point within 1.5 interquartile range. 
Horizontal lines show significant differences between pairs. 
 
4.3.4 Osteogenic potential is higher in trochlear segments and decreases with age 
 
Osteogenic matrix expression was significantly influenced by age, location and treatment with 
dexamethasone. In young animals, cultures differentiated into osteogenic phenotype upon 
dexamethasone stimulation and matrix calcification was much stronger in presence of 
dexamethasone (p<0.0001) (Fig. 4.6 a, e vs 4.6b-d and 4.6f-h). Staining observed with AR was 
superior in trochlea upper for collagenase- (p<0.0001) and explant-derived cultures (p=0.0154) 
(Fig. 4.6q, r), while no apparent difference was observed between collagenase- and explant-
derived samples (Fig. 4.6q, r). Osteogenic differentiation was found to be attenuated with 
increasing age and even when cultured in presence of dexamethasone, a very poor osteogenic 
matrix was observed in case of old animals (Fig. 4.6j-l, 4.6n-p). AR extracted from cultures from 
older animals was much lower in all cases signifying poor osteogenic differentiation and no 
significant influence of location (Fig. 4.6s, t) or method of isolation (Fig. 4.6s vs 4.6t) was 
observed.  
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Figure 4.6: Osteogenic cultures stained with Alizarin Red S (AR) showed increased matrix 
synthesis in presence (panels b-d&f-h) versus absence (a&e) of dexamethasone in young animals. 
Poorer osteogenic matrix synthesis was found in old animals (i-p). In young animals (n = 4 
knees), AR accumulation was higher in upper trochlea samples in both collagenase-(q) and 
explant-derived cultures (r). Inferior AR accumulation was found in old animals (s&t, n=3 
knees). Data is presented as mean (circle); median (line); Box: 25th and 75th percentile; Whisker: 
Box to the most extreme point within 1.5 interquartile range. Horizontal lines show significant 
differences between pairs. 
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Table 4.1: Influence of location, age and isolation method on the different in vitro biological 
properties assessed. 
Property assessed Influence of 
location 
Influence of age Influence of 
isolation method 
Cell yield Higher in upper 
trochlea in young 
animals 
Decreases with 
age 
Lower in explant-
derived in old 
animals 
Significant 
difference (Y/N) 
Y for collagenase- 
and explant-
derived cultures in 
young 
Y for collagenase- 
and explant-
derived  
Y 
Expression of 
markers 
No effect Decreases with 
age 
No effect 
Significant 
difference (Y/N) 
N Y for collagenase- 
and explant-
derived 
N 
Clonogenic 
potential 
Higher in trochlear 
samples in young 
animals 
Decreases with 
age 
Lower in explant-
derived cultures 
Significant 
difference (Y/N) 
Y for collagenase-
derived in young 
Y Y 
Matrix synthesis 
(Size of pellets) 
Higher in trochlear 
samples in young 
animals 
Reduces with age No effect 
Significant 
difference (Y/N) 
Y in collagenase- 
and explant-
derived in young 
Y N 
Chondrogenic 
potential 
High inter-
individual 
variability; Higher 
in upper trochlea 
in young animals 
Decreases with 
age 
No effect 
Significant 
difference (Y/N) 
Y Y N 
Osteogenic potential Higher in upper 
trochlea in young 
animals 
Decreases with 
age 
No effect 
Significant 
difference (Y/N) 
Y for collagenase 
and explant- 
derived in young  
Y N 
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4.4 Discussion  
Clear biological differences were observed in biological properties of BMPCs from trochlea and 
condyles, with trochlear cells-more specifically trochlea upper cells-exhibiting increased cell 
yield, more clonogenic potential and differentiation potency, thus confirming our first hypothesis 
that location influence chondrogenic potential. Since P0 cell yields reflect in situ difference in 
initial number of progenitor cells present at these two sites, we can conclude that fewer 
chondrogenic progenitors reside in condyle compartment versus trochlea. Close interaction of 
densely-packed cells during condensation phase is critical for initiation of chondrogenic 
differentiation of BMPCs-since high number of cells are needed in initial stages- and a low 
density BMPC population in condyles could be directly correlated to poor repair outcome. Also, 
since the number of self-renewing cells possessing clonogenic potential is positively correlated 
with repair potential, lower CFU-f might reduce in vitro chondrogenic potential of condyles. At 
molecular level, a difference in the expression of Sox-9 -master regulator of chondrogenic 
determination of BMPCs [15] or response of BMPCs to TGFβ-III might be yet another factor 
responsible for poor chondrogenic differentiation with condylar BMPCs. Although MSCs niche 
is deemed to be dynamic, it is challenging to determine their mobilization and in situ behaviour 
in the absence of methods for their localization in vivo. As is common in in vivo studies, inter-
animal variation was also prominent in pellet cultures in young animals. Medium- and low-
responders showed significantly improved cartilaginous phenotype in trochlear pellets indicated 
by higher GAG and collagen type II expression, consistent with our earlier observations of better 
repair outcome in rabbits [3, 4]. Alternatively, high-responders consistently generated matrix rich 
in cartilage components in all samples. However, it is impossible to ascertain if this observation 
was due to inherent differences or influence of in vitro culture conditions on differentiation 
potency. For instance, the same number of condylar and trochlear BMPCs were used for pellet 
culture. In vivo, the number of cells participating in cartilage repair would depend on initial 
population of BMPCs which are scarcer in condyles, based on our cell yield assay. Moreover, an 
ideal and identical cocktail of growth factors and other cytokines was provided to BMPCs in 
vitro, unlike in vivo. Previous studies pointed out that TGF and BMPs released from the 
underlying subchondral bone influence cell migration and repair tissue formation [16, 17]. In vivo 
differences in production, release, and metabolism of these cytokines and responses from condyle 
vs trochlea would be less pronounced in vitro. MSC populations are known to be heterogeneous 
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mixture of uni-, bi- and tripotent subpopulations with varying levels of lineage commitment [20]. 
It is possible that a population isolated from a particular donor is richer in bi- and tripotential 
progenitors and might have higher chondrogenic potential. This might explain higher 
chondrogenesis seen in some condylar high-responders since even condylar BMPCs with low 
yield but relatively higher proportion of chondroprogenitors might have a superior differentiation 
potential. Finally, a clear influence of location was observed when cells were stimulated for 
osteogenic differentiation. Although, mineralization appeared comparable upon macroscopic 
examination, quantitative assay indicated a weaker osteogenic phenotype of condylar cells. Due 
to its role in cartilage repair, better subchondral bone repair in trochlea might positively influence 
the cartilage repair. It also re-emphasizes the superior differential potential of trochlea. 
Interestingly we did not observe any influence of location on expression of cell surface markers. 
Although used frequently for characterization, these markers are not specific MPC markers and 
do not indicate their levels of self-renewal or differentiation capacity. 
In our previous animal studies, cartilage repair outcome was superior when subchondral bone 
was drilled to 6mm compared to 2mm [6] motivating us to examine BMPCs isolated from 
epiphyseal (upper) and metaphyseal (lower) marrow. In this study we found yield and 
differentiation potential to be superior in trochlea upper versus lower, leading us to reject our 
hypothesis that more progenitors occur in the deeper metaphyseal marrow. It is important to 
consider here that volume of subchondral bone participating in repair in deep drilling is three 
times that of shallow drilling and therefore produces a larger volume of GAG+ callus [6]. In 
young animals, such a large callus could have potential to proliferate towards the articular cavity 
and produce articular repair cartilage tissue, while in older animals; callus with continued 
proliferation of senescent cells could lead to an outgrowth of fibroblasts into the articular cavity 
leading to a fibrous repair. One limitation of this study is that recruitment of progenitor cells in 
the clinical setting may be different than how cells were isolated here in vitro (collagenase or 
explant culture). 
Increasing age had a profound impact on all the biological properties studied here confirming our 
second hypothesis that age influences chondrogenic potential was true. Our data supported the 
earlier findings which report the reduction in differentiation potency of stem cells in older 
animals [18]. Older animals were characterized by reduced number as well clonogenic potential 
in addition to a weaker chondrogenic and osteogenic differentiation potential. CFU-f has been 
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reported to be inversely correlated to age leading to a decrease in differentiation potential in 
senescent animals [19]. Moreover, frequency of tripotential clones reduces with increasing age-
replaced first by bipotential and then unipotential clones- thus reducing differentiation potential 
[20]. Studies indicate reduction in pellet size with increasing age [21] and poor expression of 
Col-II accompanied by negligent GAGs expression in older rats [22]. BMPCs possess very low 
levels of telomerase-enzyme responsible for maintaining telomere length [23]. In addition, there 
is a downregulation of genes involved in DNA replication, cell cycle, mitosis and DNA repair 
with age [24]. Most importantly, expression of stemness related markers including Oct-4, Sox-2 
and Nanog has also been found to diminish with increasing age [25]. Taken together, the past 
knowledge combined with the observations in this study may be used in development of 
approaches to overcome this deleterious effect of age on stem cells and improve the repair 
outcome in clinical situations.  
 
Our third hypotheses-that biological properties of BMPCs are unaffected by method of isolation-
was partially supported, given that explant-derived and collagenase-derived cultures had similar 
differentiation potential though there were some striking differences in the clonogenic potential. 
Age had a more profound impact on the yield of progenitor cells derived from bone since the 
yield of explant-derived BMPCs was comparable to collagenase-derived cultures in young animal 
while reduced drastically in older animals. Bone chips from young rabbit still possess growth 
plate with on-going endochondral ossification. This could influence the type of cells growing out 
of the explant in young (chondrocytes and osteocytes) vs. old (osteocytes only). This 
heterogeneity might explain the reduced chondrogenic differentiation potential of explant derived 
BMPCs in old animals. In addition, decline in progenitor cell population or reduced migration 
potential of existing progenitors might lead to poor BMPC yield in explants from older animals. 
Clonogenic potential was found to be particularly depleted in explant-derived cultures which 
could be a function of both method of isolation and culture conditions. Moreover, since explant-
derived BMPCs are believed to originate from de-differentiation of osteoblast cells [8], it is 
possible that population of such cells is very low in the initial passage used for CFU-f assay. The 
homogeneity of cultures along with an increase in population of undifferentiated MPCs might 
lead to an improved chondrogenic and osteogenic differentiation potential comparable to 
collagenase-derived cultures in later passages. Cells recovered from old explants appear to be 
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senescent or to have lost TGF receptor expression or chondrogenic capacity, and may be only 
capable of generating fibrous tissue. This result could be related to the fact that young bone is 
undergoing remodeling and therefore probably contains progenitor cells embedded in the 
collagen type I matrix; inaccessible to collagenase. Moreover, in explant cultures, trace residual 
collagenase could more readily liberate cells from partly mineralized young bone matrix than 
heavily mineralized old bone. Along these lines, we speculate that remodeling bone could 
potentially liberate stem cells into the repair zone. Our findings are also supported by a recent 
study which reported comparable in vitro biological properties including proliferation and 
differentiation potential for collagenase- and explant-derived BMPCs isolated from several tissue 
sources [26]. In summary, despite differences in the initial passages, the origin of cells from 
explant versus collagenase-derived does not affect the differentiation potential of cultures and 
therefore is not expected to influence the in vivo cartilage repair outcome.   
 
4.5 Conclusion 
This study is first of its kind to carry out detailed analysis of biological properties of young and 
old BMPCs isolated from two locations of knee using cells obtained with two different isolation 
methods. Location of BMPCs was found to be an important factor influencing yield, 
clonogenicity and differentiation potential of BMPCs. A wide variation was observed in 
chondrogenic potential in younger animals, where some young animals showed the same loss of 
capacity for proliferation, stemness and potency as BMPCs isolated from older animals. The 
mechanisms to explain young non-responders remain elusive. Finally, biological properties-with 
an exception of clonogenic potential- were similar for explant and collagenase-derived cells. 
Owing to high spontaneous repair potential of young animals and limitations of in vitro models in 
simulating in vivo conditions, a study which directly correlates the properties of stem cells and 
repair outcome in an animal model might be the next step in understanding pre-existing 
differences at the two locations. Taken together, our data suggests an influence of location as well 
as age on the in vitro biological performance of BMPCs that could be directly responsible for 
location and age-dependent repair outcome seen in our previous animal studies. These results 
enhance our understanding location and age-dependent cartilage repair in humans and point 
towards effective approaches to improve repair outcomes, for example by stimulating cell 
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recruitment from subchondral sites via surgical techniques and biological factors as well as 
promoting subsequent proliferative and specific differentiation behaviours. 
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5. CHAPTER 5   ARTICLE 2: QUALITY OF CARTILAGE REPAIR 
FROM MARROW STIMULATION CORRELATES WITH CELL 
NUMBER, CLONOGENIC, CHONDROGENIC AND MATRIX 
PRODUCTION POTENTIAL OF UNDERLYING BONE MARROW 
STROMAL CELLS 
 
The previous study provided tangible evidence of influence of location and age on the properties 
of condylar and trochlear BMPCs/bone marrow stem cells (MSCs). Earlier studies have reported 
location-dependent variability in marrow stimulated repair outcome in multiple animal studies. 
However, correlation of repair outcome and properties of MSCs has never been reported before. 
The following chapter presents the first study designed to correlate the properties of subchondral 
MSCs with location dependent variability in the marrow stimulated cartilage repair. Defects were 
created on condyle and trochlea in one knee of skeletally mature rabbits and followed by 
treatment with BMS. Qualitative assessment of three week repair tissue was carried out to assess 
the repair outcome in condyle and trochlea. Collagenase and explant cultures of MSCs were 
derived from condyle and trochlea of contralateral knee. MSCs were characterized to determine 
the influence of location and donor on their number, clonogenicity and differentiation potential. 
Statistical analysis enabled us to determine the factors with maximum impact on the repair 
outcome likely revealing a mechanism of variability observed in BMS. Correlation analysis was 
applied to determine if location dependent variability in cartilage repair responses stem from 
inherent differences in the biological properties of subchondral MSCs including their number and 
differentiation potential. We believe that these observations will eventually contribute towards 
improving the outcome of BMS procedure and enable clinicians to develop it in a more patient 
relevant basis to maximize its efficiency. Submitted-Osteoarthritis and Cartilage. 
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ABSTRACT  
Introduction: Variable cartilage repair outcomes following bone marrow stimulation for 
articular cartilage repair suggest that subchondral bone marrow stem cells (BMSCs) in different 
donors and locations have different intrinsic capacity for cartilage repair. Using a rabbit model, 
we tested the hypothesis that in vivo cartilage repair correlates with in vitro biological properties 
of BMSCs. 
Methods: Full thickness cartilage defects were created in the trochlea and condyle in one knee of 
skeletally mature New Zealand White rabbits (N=8) followed by microdrilling. Three week 
repair tissues were analyzed by macroscopic ICRS scores, O’Driscoll histological scores and 
Safranin-O (Saf-O) and type-II collagen (Coll-II) % stain. BMSCs isolated from contralateral 
knees were assessed for cell yield, surface marker expression, CFU-f, %Saf-O and %Coll-II in 
pellet culture followed by correlation analyses with the above cartilage repair responses.  
Results: In vivo cartilage repair scores showed strong, positive correlation with in vitro cell yield, 
clonogenic potential, and chondrogenic matrix production (Coll-II, GAG) by TGF-βIII stimulated 
BMSC cultures. Trochlear repair showed clear evidence of donor dependency and strong 
correlation was observed for inter-donor variation in repair and the above in vitro properties of 
trochlear BMSCs. Correlation analyses indicated that donor- and location-dependent variability 
observed in cartilage repair can be attributed to variation in the properties of BMSCs in 
underlying subchondral bone. 
Conclusion: Variation in cell number, clonogenic, chondrogenic and matrix production potential 
of BMSCs correlated with repair response observed in vivo and appear to be responsible for inter 
animal variability as well as location-dependent repair. 
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5.1 Introduction 
Chondral lesions are a commonly occurring knee pathology and are more widespread in medial 
femoral condyle (MFC) than trochlea [1].  Bone marrow stimulation (BMS) procedures carried 
out by fracturing or drilling into subchondral bone typically produce a fibrocartilaginous repair. 
Repair outcomes are affected by defect location suggesting a strong influence of biological 
characteristics of progenitor cells in the underlying subchondral bone on repair response [2, 3]. 
Donor-, location- and age-related factors are increasingly being recognized to influence repair 
outcomes and may guide patient-specific treatment [4]. The mechanisms behind these sources of 
variable cartilage repair still elude us since underlying factors such as bone structure and 
mechanics, load-bearing condition and role of subchondral bone progenitor cells are largely 
unknown.  
 
Better repair and increased chondrogenic potential have been observed in rabbit trochlea 
compared to medial femoral condyle in previously published studies [5, 6]. BMS cartilage repair 
in rabbit trochlea was associated with more chondrocytes and larger chondrogenic foci 
suggesting greater chondrogenic potential of trochlear progenitor cells compared to condylar 
progenitors [5]. As evidence of location- and species-dependent cartilage repair, more fibrous 
repair was observed in ovine trochlea versus condyle with BMS as well as with autologous 
chondrocyte implantation [7, 8]. In vitro characterization of BMSCs isolated from condyle and 
trochlea of young and old rabbits showed evidence that trochlear BMSCs were more numerous 
with higher clonogenic and chondrogenic differentiation potential [9]. Since BMS relies on 
recruitment of underlying BMSCs for repair of soft and hard tissues, characterization of these 
progenitors and direct correlation with cartilage repair outcomes may provide important 
mechanistic insights into location-dependent cartilage repair.  
 
Here, in addition to validating the influence of location on early repair responses in an acute 
defect rabbit model, we sought to investigate the influence of biological properties of BMSCs 
isolated from condyles and trochlea on the repair response. Although repair responses induced 
by BMS along with characterization of BMSCs has been investigated in animal models before 
[10-13], this is the first study designed to correlate the early repair response with biological 
properties of BMSCs from the same location to elucidate the mechanism of location-dependent 
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and inter-animal variation observed in cartilage repair. Since cells participating in marrow-
stimulated cartilage repair originate from both stromal spaces and bone lining regions, BMSCs 
were isolated from both these regions by means of collagenase digestion and cell outgrowth from 
explants, respectively. Based on our earlier observations, we do not expect any significant 
difference in the properties of cells isolated by these methods of isolation [9]. The current study 
was carried out with the hypothesis that the quality of cartilage repair outcome in condyle and 
trochlea will correlate to the in vitro biological properties of underlying BMSCs at the same two 
sites in the contralateral knee. 
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5.2 Materials and methods 
 
5.2.1 Study design and rabbit surgical model 
 
The research protocol was reviewed and approved by an institutional ethics committee for 
animal research. Eight skeletally mature (8-9 month old) female New Zealand White rabbits 
were used. In order to examine the influence of inter-animal variation, a bilateral model was used 
for characterization of cartilage repair and in vitro biological properties of BMSCs [Fig.5.1]. On 
one knee (n=8 knees), full thickness cartilage defects measuring 4 X 4 mm were created on the 
medial femoral condyle (MFC) and central trochlear groove by complete debridement of non-
calcified and calcified cartilage using a flat blade to expose the underlying subchondral bone. 
Using drilling burrs, four subchondral drill holes, 0.9 mm diameter and 6 mm deep, were made 
in each defect in the trochlea and MFC [14]. Constant cooling irrigation was applied to prevent 
heat necrosis [14] and remove loose bone debris. The patella was repositioned and the knee was 
closed in sutured layers. No peri-operative antibiotics were administered but animals received 
extended analgesia with a fentanyl transdermal patch. Knees were allowed unrestricted motion 
and constantly monitored for infections and other complications until sacrifice three weeks later. 
The contralateral knee (n=8 knees) in each animal was intended for in vitro characterization of 
BMSCs from condyle and trochlea and received no treatment prior to sacrifice [Fig. 5.1].  
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Figure 5.1: Schematic representing the study design. Condylar and trochlear cartilage repair 
outcome in one knee from each animal was correlated with in vitro biological properties of 
BMSCs isolated from the condyle, upper trochlea and lower trochlea from the contralateral knee. 
 
5.2.2 Characterization of cartilage repair 
 
Animals were sacrificed by overdose of pentobarbital and the treated knee was characterized for 
cartilage repair. Photographs of harvested joints were scored using the macroscopic ICRS 
scoring system for cartilage repair [15]. Scoring was performed by two blinded readers (ICC 
0.95 for overall repair assessment). Decalcified samples were embedded in OCT and sections 
were obtained from three levels-through proximal and distal holes in addition to between holes. 
Sections were stained with Safranin O/Fast Green [16] and scanned using a Nanozoomer RS 
system (Hamamatsu, Japan). Two blinded observers scored the digital Saf-O stained sections 
using a previously published modified O’Driscoll histological scoring method (ICC 0.86 for total 
O’Driscoll score) [13]. The average score from two observers was used to determine final 
macroscopic ICRS and O’Driscoll score. All three sections collected from each defect were also 
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used to determine %Saf-O and %Coll-II in the chondral repair tissue using a previously 
described method of Hue-Saturation-Value thresholding with ImageJ and in-house Matlab 
routine software [16].   
5.2.3 Isolation and in vitro characterization of condylar and trochlear BMSCs 
The contralateral knee was used for isolation of BMSCs as previously described [9]. Briefly, 
distal femur ends were separated into condyles, trochlea upper and trochlea lower compartments 
[Fig.5.1] followed by fragmentation into bone chips (approx. 5mm) which were then digested 
with collagenase type XI (Sigma) [3mg/ml, 2hours] to obtain the population of collagenase-
derived cell BMSCs. Digested bone chips were then seeded as explants to generate a second 
population of explant- derived cell BMSCs. BMSCs were cultured for a maximum of 2 passages 
in DMEM/F-12 media supplemented with 10% fetal bovine serum and 1X penicillin-
streptomycin. The following biological properties were then characterized: P0 cell yield, CFU-f, 
cell surface marker expression and chondrogenic differentiation potential using previously 
reported methods [9]. P0 cell yield was used to estimate the population density of BMSCs 
originally present in condyles and trochlea. Stemness of trochlear and condylar BMSCs was 
characterized by CFU-f assay. Cell surface marker characterization was done for positive - CD44 
(Cell Marque, 144M-96) and CD29 (Millipore, MAB1951Z) and negative - CD34 (Cell Marque, 
134M-16) and CD45 (Cell Marque, 145M-97) stem cell markers [9]. BMSC pellets were used 
for chondrogenic differentiation for 3 weeks in a 15 mL conical tube in chondrogenic medium 
comprised of high glucose DMEM containing penicillin-streptomycin, ascorbate, 
dexamethasone, sodium pyruvate, BSA and TGFβ-III [9]. Size of pellets was measured to 
determine the amount of matrix synthesized as an indicator of chondrogenic differentiation. 
Safranin-O/fast green staining and collagen-type II immunostaining was done as described 
previously. Stained sections of pellets were used to determine the percentage area stained 
positively for Saf-O (% Saf-O_pellets) and Collagen-II (% Coll-II_pellets) using Image J and a 
Matlab routine as described above. 
5.2.4 Correlation of cartilage repair to BMSC properties 
Correlations between five in vitro assessed biological properties of BMSCs (P0 cell yield, 
CFU-f, Pellet Size (mm), %Saf-O + and %Coll-II + area in pellets) and four in vivo 
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assessed repair parameters (ICRS Score, O’Driscoll Score, %Saf-O + and %Coll-II + 
repair tissue) was carried out for collagenase- and explant-derived BMSCs.  
5.2.5 Statistical Analyses 
Statistical analysis was performed using SAS Enterprise Guide 5.1 and SAS 9.3. Since 
several segments were collected from both legs of each rabbit, a mixed model was used to 
account for the influence of donor. Fixed effects were location (condyles, upper trochlea or 
lower trochlea for in vitro characterization, n=8 knees and condyles and trochlea for 
cartilage repair characterization, n=8 knees) while donor was a random effect. Data in 
figures are presented as mean (diamond); median (line); Box: 25
th
 and 75
th
 percentile; 
Whiskers: Box to the most extreme point within 1.5 interquartile range. Correlations 
between in vitro BMSC properties and in vivo repair outcome were analyzed by calculating 
the Pearson correlation coefficients. p<0.05 were considered statistically significant. In 
order to determine the in vitro variables which best account for the variability in repair 
outcome, a general linear model (GLM) was applied. For each in vivo repair parameter, 
variables with the least influence (highest value of p) were sequentially removed in a step 
wise manner to yield variables with the most significant influence (p<0.05) on repair 
outcome. 
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5.3 Results 
5.3.1 Repair of trochlear defects was superior to condylar defects- and correlated with in 
vitro properties of BMSCs as function of location and donor  
We focussed on the early events in cartilage repair and found that quality and quantity of condylar 
repair tissue was markedly inferior in contrast to mostly excellent trochlear healing. At 3 weeks 
post-surgery, six out of eight trochlear defects were filled with glossy, white and smooth repair 
tissue flush with adjacent cartilage [Fig. 5.2a]. These donors were termed good trochlear 
responders. The majority of these repair tissues were homogenous with a smooth surface and 
appeared to bond well with adjacent tissue with occasional cases heterogeneous with slightly 
irregular surface and identifiable defect margins. Defects were significantly depressed and 
incompletely filled in two donors leading us to identify them as poor trochlear responders [Fig. 
5.2b]. In contrast, all eight condylar defects were severely depressed with very little fill in addition 
to distinct residual drill holes and defect margins [Fig 5.2c, d]. Mean ICRS macroscopic scores 
were significantly higher for trochlea versus condyles (p=0.0027) [Fig. 5.2e]. Moreover, ICRS 
grade II (nearly normal) was assigned to 5 out of 8 trochlear repair tissues while all 8 condylar 
repair tissues were scored ICRS grade IV (severely abnormal).  
 
Figure 5.2: Macroscopic appearance of repair tissue in good and poor trochlear responders at 3 
weeks post-operative. Acute trochlear defects treated with marrow stimulation were largely 
restored with repair tissue in six of eight donors termed good responders (a) while two donors 
had extremely poor repair outcome and were termed poor responders (b). Condylar defects were 
incompletely filled with distinct holes and defect margins in all 8 donors (inserts c,d are from 
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corresponding condylar repair outcomes in good and poor trochlear responders). Scale bar=1mm. 
Significantly higher mean macroscopic ICRS scores indicate superior early repair response in 
trochlea versus condyles (e). 
 
Saf-O stained sections of condyles showed thin, fibrous repair tissue with poor structural 
integrity in contrast to voluminous tissue with regular surface observed in trochlear defects [Fig. 
5.3a-h]. Average O’Driscoll scores were significantly reduced for condylar repair tissues versus 
trochlea (p<0.0001) [Fig. 5.3i] and associated with lower scores for surface regularity, thickness 
of repair tissue, cell morphology, health of adjacent cartilage and negligible GAG accumulation. 
Upon quantitative histomorphometric analysis, significantly reduced % Saf-O (p=0.002) [Fig. 
5.3j] and % Coll-II (p=0.0048) [Fig. 5.4i] were observed for condyles. 
 
Figure 5.3: Representative Saf-O/Fast Green (a-h) staining of repair response in sections 
collected between holes (a,b,e,f)  and through holes (c,d,g,h) in good (a-d) and poor (e-f) 
trochlear responders. Depleted Saf-O staining was evident in all condyles. Among good trochlear 
responders, abundant GAG expression was observed, more evident in sections from between 
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holes. Expression was reduced in poor trochlear responders. Arrow points to subchondral cyst 
observed in the condyle of a poor responder. Scale bar=1mm. Significantly higher O’Driscoll 
scores indicate superior early repair response in trochlea versus condyles (i). Trochlear matrix 
was more abundant in GAG indicated by significantly higher %Saf-O (j) in repair tissues 
 
Clear histological differences were observed between good and poor trochlear responders in 
vivo. In the sections taken from between holes, thicker repair tissue with abundant GAG was 
observed in good trochlear responders in contrast to thin, fibrous tissues in poor trochlear 
responders with negligible GAG expression. In trochlear repair tissue through the microdrill 
holes, Saf-O staining was observed in mid-deep regions of good trochlear responders with varied 
levels of hyaline and fibrocartilagenous tissue. In contrast, repair tissue was thinner and more 
fibrous in poor responders indicated by diminished Saf-O (Avg. %Saf-O-49.46+13.72 in good 
responders vs 26.62+8.1 in poor responders) [Fig 5.3b vs f and 5.3d vs h]. The only instance of 
an osteochondral cyst was observed in the condyle of one of the poor responders [Fig. 5.3g]. 
Trochlear repair tissues also expressed greater levels of collagen type II compared to condyles 
[Fig. 5.4a-h]. Among trochlea, Coll-II was more widespread in good responders while poor 
responders showed evidence of depleted Coll-II staining (Avg. % Coll-II -56.67+23.64% in good 
responders vs 20.6+2.29 in poor responders) [Fig. 5.4].   
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Figure 5.4: Representative Coll-II (a-h) staining of repair response in sections collected between 
holes (a,b,e,f) and through holes (c,d,g,h) in good (a-d) and poor (e-h) trochlear responders. 
Reduced Coll-II staining was observed in all condyles. Increased collagen expression was 
observed in good vs poor trochlear responders, more evident in sections taken from between 
holes. The arrow points to a subchondral cyst observed in the condyle of poor responder. Scale 
bar=1mm. Trochlear matrix was more abundant in collagen type II indicated by significantly 
higher % Coll-II (i) in repair tissues. 
 
Pellets cultured without TGF -III were distinctly smaller than TGF -III-stimulated cultures for 
both collagenase- and explant-derived BMSCs. Among the pellets stimulated with TGFβ-III, 
trochlea upper pellets had the largest diameter while condyles generated the smallest pellets for 
both collagenase- (p<0.0001) and explant-derived BMSCs (p=0.0013) [Fig. 5.5, 5.1S c,h; 5.2S-
b]. In general, trochlear pellets had increased GAG and Coll-II in collagenase- and explant-
derived BMSCs [Fig. 5.5]. Interestingly, trochlea lower pellets were smaller in poor trochlear 
responders for both collagenase- and explant-derived BMSCs [Fig. 5.5 and 5.2S]. Trochlea 
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upper pellets were associated with abundant GAG and coll-II in good as well as poor trochlear 
responders while trochlea lower pellets from poor trochlear responders had reduced Saf-O 
staining indicating low GAG deposition [Fig. 5.5]. As a further evidence of poor chondrogenic 
differentiation potential in cells derived from condylar subchondral bone, the matrix of condylar 
pellets was depleted in GAG and Coll-II as indicated by lower % Saf-O [Fig. 5.1S d,i] and % 
Coll-II [Fig. 5.1S e,j]. Trochlear pellet matrix had higher %Saf-O (collagenase-derived BMSCs, 
p<0.0001 and explant-derived BMSCs, p=0.0009) and %Coll-II versus condylar pellets 
(collagenase-derived BMSCs, p<0.0001 and explant-derived BMSCs p=0.0002).  
 
99 
 
 
 
 
Figure 5.5: Safranin-O/fast-green and collagen type II staining of pellets from good [a-n] and 
poor [a’-n’] trochlear responders. Negligible GAG and collagen type II expression was observed 
in condyles indicating inferior chondrogenic potential in vitro. GAG was low in trochlea lower 
pellets in trochlea poor responders. a-h, a’-h’ are collagenase-derived; i-n, i’-n’ are explant-
derived BMSCs. TGF- are from upper trochlea, while all other cultures had TGFβ-III. Scale 
bar=500 µm 
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Figure 5.1S: Summary of in vitro biological properties of collagenase- (a-e) and explant-
derived BMSCs (f-j). Higher values were observed for trochlea versus condyles for 
following properties -P0 cell yield (a,f); CFU-f (b,g); pellet size (c, h); % Saf-O_Pellets 
(d,i) and % Coll-II_Pellets (e,j). 
 
Figure 5.2S: Gross structure of pellets show an increase in size upon culture in presence of 
TGFβ-III. Pellets from trochlea upper were largest compared to condyles in good and poor 
trochlear responders. Trochlea lower pellets were smaller in poor trochlear responders. a). 
collagenase-derived; b). explant-derived BMSCs. Scale bar=1 mm 
5.3.2 Cell yield, clonogenic potential and expression of stem cell markers are higher in 
trochlear vs condylar BMSCs and these properties decreased in poor trochlear 
responders 
In vitro biological properties were found to be influenced by location as well as donor. In 
comparison to condyles, higher cell yield was observed in trochlea for both collagenase- 
(p=0.007) and explant-derived BMSCs (p=0.0008) [Fig. 5.1S a,f]. BMSCs from trochlear 
segments also had higher clonogenic potential indicated by higher CFU-f for both collagenase 
(p<0.0001) and explant-derived BMSCs (p=0.008) [Fig. 5.1S b,g]. In contrast, the two poor 
trochlea responders showed a noticeable reduction in cell yield and CFU-f in both trochlea upper 
and trochlea lower [Table 5.1S]. 
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Table 5.1S: Summary of average cell yield and CFU-f from good and poor trochlear responders 
for collagenase- and explant-derived BMSCs, highlighting the difference between good and poor 
trochlear responders. 
 
 
Expression of cell surface markers was similar between condyles and trochlea. However, 
expression varied as a function of donor and was found to be weaker for collagenase- [Fig. 5.3S 
a,b] as well as explant-derived BMSCs [Fig. 5.3S e,f] in both poor trochlear responders. This 
reduced expression was only observed for CD44 and not CD29 (data not shown) - the other stem 
cell marker analyzed. Expression of CD34 and CD45 was absent for all donors for collagenase- 
and explant-derived BMSCs indicating absence of any contamination by cells of hematopoetic 
origin [Fig. 5.3S]. 
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Figure 5.3S: CD 44 expression was reduced in trochlea lower in collagenase-derived BMSCs (a 
vs b) and in all samples in explant-derived BMSCs (e vs f). CD 34 expression was consistently 
absent (c,d,g,h). 
 
5.3.3 Moderate to strong positive correlations were observed between in vitro properties of 
collagenase-derived BMSCs and in vivo early repair responses and strong influence 
of cell yield, CFU, % Coll-II was observed 
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Significant correlations were found between in vitro BMSC properties and early repair response 
in condyle and trochlea. Robust positive correlations between cell yield, CFU-f and % Coll-II 
(pellets) of collagenase-derived BMSCs and all in vivo repair properties studied [Fig 5.6, 5.7] 
indicated a strong influence of these BMSCs properties on cartilage repair outcome (r
2
 values 
ranged from 0.48 to 0.73). Pellet size and % Saf-O (pellets) showed significant, positive but 
modest correlation with most of the in vivo repair parameters studied (r
2
 values ranged from 0.26 
to 0.44) [Figs. 5.6 and 5.7]. 
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Figure 5.6: Strong, positive correlation between in vitro biological properties of collagenase-
derived BMSCs-Cell yield, CFU, pellet size, % Saf-O (pellets), % Coll-II (pellets)- and repair 
response measured by ICRS macroscopic scoring and O’Driscoll Score in trochlea vs. condyles. 
n=8. C.I-95%; p<0.0001-0.0068. (RT-repair tissues. Blue circles-Condyles, Red triangles-
Trochlea Upper, Black squares-Trochlea Lower). 
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Figure 5.7: Strong, positive correlation between in vitro biological properties of collagenase-
derived BMSCs-Cell yield, CFU, pellet size, % Saf-O (pellets), % Coll-II (pellets)- and repair 
response measured by % Saf-O (RT) and % Coll-II (RT) in trochlea vs. condyles. N=8. C.I-95%; 
p<0.0001-0.0068. (RT-repair tissues. Blue circles-Condyles, Red triangles-Trochlea Upper, 
black squares-Trochlea Lower). 
In contrast, the in vitro biological properties of explant-derived BMSCs showed positive, 
significant (p<0.5) but weak correlations with in vivo characterization parameters (r
2
 ranged from 
0.1 to 0.3).  As an exception, % Coll-II (pellets) of explant-derived BMSCs demonstrated strong, 
positive correlations with all the in vivo parameters (r
2 
ranged from 0.38 to 0.56) [Fig 5.4S and 
5.5S].   
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Figure 5.4S: Weak, positive correlation between in vitro biological properties of Explant-derived 
BMSCs-Cell yield, CFU, pellet size, % Saf-O (pellets), % Coll-II (pellets)- and repair response 
measured by ICRS macroscopic scoring and O’Driscoll Score in trochlea vs. condyles. N=8. C.I-
95%; p<0.0001-0.0068. (RT-repair tissues. Blue circles-Condyles, Red triangles-Trochlea 
Upper, Black squares-Trochlea Lower). 
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Figure 5.5S: Weak, positive correlation between in vitro biological properties of explant-derived 
BMSCs-Cell yield, CFU, pellet size, % Saf-O (pellets), % Coll-II (pellets)- and repair response 
measured by % Saf-O (RT) and % Coll-II (RT) in trochlea vs. condyles. N=8. C.I-95%; 
p<0.0001-0.0068. (RT-repair tissues. Blue circles-Condyles, Red triangles-Trochlea Upper, 
Black squares-Trochlea Lower). 
GLM analysis confirmed that cell number, clonogenic and chondrogenic potential can serve as 
predictors of repair outcome. However, not all BMSC properties accounted for the variability in 
repair outcome to an equal extent [Table 5.1]. Macroscopic and O’Driscoll scores were better 
predicted by clonogenic and chondrogenic potential of pellets (% Saf-O and % Coll-II). On the 
other hand, matrix content of repair tissues- % Saf-O and % Coll-II- was more predicted by the 
initial cell population density (P0 cell yield) and chondrogenic potential of pellets (also defined 
by %Saf-O and % Coll-II). Taken together, cell yield, CFU and % Coll-II provided the 
maximum explanation for variability in different in vivo repair parameters. Consistent with these 
GLM analyses, these variables also presented the highest r
2
 values in the independent pair-wise 
Pearson correlation analysis [Table 5.1, table 5.2S and Figs 5.6, 5.7]. 
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Table 5.1: GLM analysis of dependent variables to determine the variables with maximum 
influence on repair outcome. First column denotes the variables with least influence on the 
repair outcome, removed sequentially in the order of significance.  The resulting r
2
 value 
after removal of each variable is outlined in column 3. Significant variables providing the 
maximum explanation for variability in repair outcome parameters are summarized in 
column 4 with their respective p values in column 5. 
 
. 
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Table 5.2S: Individual pair-wise correlation coefficients between independent and dependent 
variables with corresponding p values for condyles, trochlea upper and trochlea lower. Values 
highlighted in green denote significant correlations between in vivo parameters - ICRS score, 
O’Driscoll score, %Saf-O RT (repair tissue) and %Coll-II RT (repair tissue) – and in vitro 
parameters including cell yield, CFU-f, pellet size, Saf-O pellets and Coll-II pellets. (Saf-O and 
Coll-II denote % Saf-O and % Coll-II respectively). 
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5.4 Discussion 
For the first time, this study provides tangible evidence of a direct correlation between marrow 
stimulated repair outcome in condyle and trochlea and inherent biological properties of BMSCs 
present in these two locations. Variability in cell number, clonogenic and chondrogenic potential 
of trochlear BMSCs showed strong correlations with quality and quantity of repair tissue in a 
location- and donor-dependent manner. Cell number, clonogenic and matrix production potential 
of BMSCs were strong predictors of macroscopic and histological repair outcomes. We found 
sufficient evidence to substantiate our hypothesis that trochlear cartilage repair outcome is 
superior to condyles and correlates with in vitro biological properties of the BMSCs at the two 
sites in the contralateral knee. 
 
Bone marrow stimulated repair is mediated by recruitment of MSCs into access channels and 
cartilage defect followed by a complex multistep cascade of events including proliferation, cell-
cell interaction and differentiation finally leading to formation of a repair tissue with varying 
amounts of fibrous and hyaline cartilage [17, 18]. It is logical to speculate that properties of 
MSCs will have a profound impact on the repair outcome. We believe that the differences in the 
initial progenitor cell population have a strong bearing on the repair response. As shown by 
Mizuta et al in a rabbit full-thickness defect model, explicit chondrogenesis was preceded by an 
active phase of expansion in chondroprogenitor cell population [19]. Moreover, a high number of 
cells in the initial stages of chondrogenesis is a prerequisite since close interaction of closely 
packed cells during condensation phase is critical for initiation of chondrogenic differentiation of 
MSCs [20]. Fennema et al had reported that the differences in the original number of 
proliferative cells isolated were mirrored in the growth rate of corresponding BMSC cultures 
[21]. In the current study, lower cell yield indicated a depleted progenitor cell population in 
condyles having an impact on the onset and progress of downstream repair process. Low number 
accompanied with reduced clonogenic potential as indicated by CFU-f assay might attribute to 
diminished chondrogenic potential of condyles. It has also been shown that increasing population 
doublings escalate heterogeneity, reduces multipotency and repair potential [22]. Inferior 
chondrogenic potential of condylar pellets might also be attributed to poor response of BMSCs 
to chondrogenic stimulation due to molecular factors or being in different stages of lineage 
progression.  
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In vitro cultures of BMSCs provide limited insight into the complex and dynamic joint 
microenvironment during repair, however studies have shown that cellular behaviour of MSC 
cultures provide close estimation of their in vivo potency and allude to heterogeneity in the repair 
outcome [23]. Post et al characterized two murine MSC populations in vitro and found a pre-
existing propensity towards adipogenic or osteogenic differentiation which was consistent with 
in vivo behavior [24]. Moreover, MSC cultures have been shown to be heterogeneous with 
respect to morphology [25] and consist of rapidly dividing small cells and slower, larger cells 
reflecting correlation in proliferation rates and morphological heterogeneity. This morphological 
heterogeneity was later correlated to functional heterogeneity in vitro as well as in vivo [26]. Lee 
et al had demonstrated association between cell diameter, mechanical stiffness and fluctuations 
of nuclear membrane with clonogenic and proliferation potential in addition to potential for in 
vitro differentiation potency and repair in vivo [27]. Further, on comparison of stem cells from 
variety of niches, Woo et al revealed marked differences in their proliferation and differentiation 
propensity despite similar cell surface marker profiles [28]. Authors attributed these observations 
to cellular environment and genetic factors including epigenetic factors. Although the 
mechanism is not clear, epigenetic factors regulating stem cell differentiation alter fate of cells 
from different locations underlying the influence of location on their inherent nature [29]. Stem 
cells isolated from different locations have also shown differences in their propensities towards a 
particular lineage-such as preference for adipogenic and osteogenic differentiation in the case of 
adipose derived stem cells and BMSC respectively [28].  Furthermore, studies have shown that 
proliferative and functional profile of MSCs are altered in OA [30, 31]. Taking together these 
observations, we can conclude location-dependent variation in cartilage repair response is most 
likely due to inherent differences in the biological properties of subchondral BMSCs including 
their number and differentiation potential.   
 
In another observation, repair outcome in poor trochlear responders was associated with inferior 
number, clonogenic and differentiation potential of BMSCs isolated from trochlea of these 
donors.  Earlier studies have reported cultures obtained from different donors to be heterogenous 
with respect to number and differentiation [32, 33]. Interestingly, our data suggests that inferior 
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repair in poor trochlear responders may be a result of a depleted progenitor cell population 
further aggravated by a reduced clonogenic potential of BMSCs isolated from metaphyseal 
region of trochlea in these donors. These probably had a direct bearing on the chondrogenic 
potential indicated by depleted GAG expression in trochlea lower pellets. Smaller pellet size 
further suggests that inferior chondrogenic differentiation potential of metaphyseal BMSCs 
might be responsible for poor chondrogenic differentiation in poor trochlea responders.The poor 
potential of these donors seems to be at least partially intrinsic since the cells also had reduced 
expression of cell surface markers. These observations provide further evidence of correlation of 
cartilage repair response and inherent properties of local population of BMSCs in the region.  
 
Although moderate to strong positive and significant Pearson correlation coefficients were 
observed between all the biological properties analysed and corresponding repair outcome 
parameters, GLM analysis revealed that certain correlations were more strongly defined by 
trochlea data. Taken together, trochlea upper provided maximum explanation for the variability 
observed in vivo [Table 5.2S]. Weak correlations observed with explant-derived BMSCs might 
suggest a limited contribution of these cells in cartilage repair, likely restricted by their ability to 
migrate out of bone. Due to low initial yield, these cells might have undergone more population 
doublings in culture leading to loss in stemness and subsequent chondrogenic potential.   
 
It is important to bear in mind that repair of a cartilage defect does not occur in isolation and is 
affected by surrounding milieu which provides important signals by means of cellular 
interactions, growth and differentiation factors in addition to other mechanical and chemical 
stimuli. These factors impact the signaling pathways which control transcription of specific 
genes contributing to onset and progress of repair. For instance, Wnt proteins, TGF-β 
superfamily, BMPs, FGF, IGF are some of the several morphogenetic factors [34] which 
influence BMSCs possibly controlling the eventual repair outcome. Moreover, in vitro expansion 
and differentiation of BMSCs has been shown to be influenced by hydrostatic, compression and 
shear forces [35-39] in addition to mechanical loading and oxygen tension [40]. The downstream 
differentiation commitment of BMSCs may also be influenced by spatial dimensionality 
modifying the interaction of BMSCs in trochlea and condyle and their corresponding 
118 
 
 
 
microenvironment [41]. In addition, the mechanical environment plays a role in regulation of 
TIMPs and MMPs which have been implicated in the differentiation of BMSCs [42, 43]. 
Besides, ECM components regulate adhesion and survival of BMSCs and thus have an impact on 
the downstream commitment of BMSCs [44]. Taken together, there is a strong possibility that in 
vivo behaviour of BMSCs might be significantly influenced by location as a result of striking 
structural and anatomical differences between condyle and trochlea. This may alter the 
mechanical and chemical cues which have an important role in regulating the cellular behaviour 
of BMSCs in trochlea and condyle.  
 
5.5 Conclusion 
Through this study we found substantial evidence to suggest that clear differences exist in 
biological properties of BMSCs present in condyles and trochlea and that these differences 
are most likely the cause of variation in the repair outcome observed in these two 
locations. Although in vitro cultures of BMSCs can be coaxed into multiple phenotypes, 
they might not be an absolute reflection of their inherent potential. This might be further 
complicated by differences in the receptor profile of cells in vivo which might alter the 
response mediated by signaling pathways impossible to replicate in vitro. However, since 
precise methods for in vivo identification of BMSC and their behavioural patterns still 
elude us, it becomes imperative to carry out functional phenotype analysis both in vitro and 
in vivo in order to draw parallels between in vitro behaviour of BMSCs and corresponding 
repair outcome in an animal model. In the future, we plan to carry out detailed molecular 
profiling of BMSCs in order to identify the genetic mechanism of the location- and donor-
dependent differences. Here, we were able to discern important mechanistic insight into 
underlying cause of location- and donor-related variation observed with BMS repair 
outcomes. We speculate our results will advance our understanding of donor- and site-
specific variations in BMS repair response eventually helping in maximizing the efficiency 
of procedure in a more patient relevant basis.  
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CHAPTER 6   ARTICLE 3: FREEZE-DRIED CHITOSAN/PRP 
IMPLANTS IMPROVE MARROW STIMULATED CARTILAGE REPAIR 
IN A CHRONIC DEFECT RABBIT MODEL 
6.  
The previous studies enabled us to improve our understanding of characteristics of MSCs present 
in condyle and trochlea and present a likely mechanism of donor-, age- and location-dependent 
variability in marrow stimulated repair outcome. BMS has been known to be highly 
unpredicatable, and generate a fibrocartilagenous repair tissue with poor durability. Moreover, 
preclinical studies for cartilage repair strategies are generally performed in an acute model which 
is not an accurate representation of clinical situation leading to unsuccessful clinical translation of 
promising strategies. We recognised the need to develop a model with chronic, degenerative 
lesions for better clinical representation. Augmentation strategies have been shown to exert a 
positive impact in enhancing the outcome of BMS procedure. Platelet-rich-plasma (PRP) with its 
4-fold concentration of growth factors and cytokines promotes MSC proliferation and 
differentiation. However, burst release of factors and poor stability likely lead to inferior 
outcomes. Chitosan has been shown to increase the stability of blood clot formed in the defect 
and therefore improves the repair outcome. Combined with PRP, Chitosan is likely to form a 
voluminous, stable clot capable of sustained release of bioactive factors and superior retention of 
growth factors and MSCs in the defect. In this article, a chronic, bilateral model was developed 
using skeletally mature rabbits. BMS augmented with recalcified PRP and chitosan/PRP implants 
were compared. In addition to macroscopic assessment, two month repair was analyzed 
histologically to compare matrix composition. MicroCT analysis enabled understanding of 
subchondral bone regeneration and remodeling induced by two treatments. The conclusions from 
this study are expected to be of significant clinical relevance and eventually enable successful 
clinical translation of a promising approach. Submitted-Biomaterials.   
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Abstract  
Purpose 
Bone Marrow Stimulation (BMS) improves knee joint function but elicits incomplete repair. 
Liquid chitosan (CS)-glycerol phosphate/blood clots have been shown to improve BMS-based 
cartilage repair. Platelet-rich-plasma (PRP) – a rich source of growth factors and cytokines - 
improves recruitment and chondrogenic potential of subchondral mesenchymal stem cells. We 
hypothesized that repair response in a rabbit chronic defect model will improve when freeze-
dried chitosan/PRP is used to augment BMS. 
 
Methods  
Bilateral trochlear defects created in New Zealand White rabbits were allowed to progress to a 
chronic stage over 4 weeks. Chronic defects were debrided and treated by BMS in second 
surgery, then augmented with PRP (BMS+PRP) or chitosan/PRP implants (BMS+CS/PRP). The 
quality of 8 week repair tissue was assessed by macroscopic, histological and micro-CT analysis. 
  
Results 
ICRS macroscopic scores indicated fibrocartilaginous or fibrous repair in control defects that 
were improved in the BMS+CS/PRP group. An overall improvement in repair in BMS+CS/PRP 
group was further confirmed by higher O’Driscoll scores, %Saf-O and %Coll-II values. Micro-
CT analysis of subchondral bone indicated on-going remodeling with repair still underway. 
 
Conclusion 
Quality and quantity of cartilage repair was improved when chitosan/PRP implants were used to 
augment BMS in a chronic defect model.  
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6.1 Introduction 
 
Bone marrow stimulation (BMS) is a purely surgical process which initiates cartilage repair by 
fracturing or drilling into subchondral bone. BMS procedures initiate the formation of a blood 
clot around fractured bone followed by migration of subchondral progenitor cells which 
differentiate into a chondrogenic phenotype to form a repair tissue with variable amounts of 
hyaline and fibrous cartilage [1]. The repair tissue is typically characterized by low quality and 
compromised durability, and larger lesions in older patients are even more challenging to treat. 
One possible reason for the poor performance of BMS is that the blood clot rapidly shrinks to a 
fraction of its initial size due to platelet-mediated clot retraction, resulting in lack of defect filling 
and possible detachment from the tissue surface. One way to prevent clot retraction is to add 
chitosan (CS), a polymer of glucosamine and N-acetyl glucosamine units, to the blood [2]. Liquid 
CS-glycerol phosphate (GP)/blood implants can be applied over BMS-treated cartilage defects 
where they coagulate in situ and inhibit platelet-mediated clot retraction leading to the formation 
of a voluminous, adherent and physically stable clot with access to underlying marrow [3]. When 
used in conjunction with BMS procedures, CS-GP/blood implants promote cell recruitment, 
transient vascularization and subchondral bone remodeling leading to integrated repair and 
increased hyaline character of the repair tissue [2-5]. These implants were tested clinically [6, 7] 
and have now been approved in several countries to treat cartilage lesions (BST-CarGel, Smith 
and Nephew, USA). One drawback of this technology is that liquid CS solutions have limited 
stability during storage due to acid hydrolysis of CS and loss of viscosity [8]. A freeze–dried 
form of CS would not only overcome this limitation by increasing stability and shelf life but also 
permit easier sterilization.  
A microenvironment stimulating chondrogenic differentiation of marrow-derived mesenchymal 
stem cells (BMSCs) may be achieved by addition of platelet-rich-plasma (PRP) to the defect 
milieu. PRP is prepared by sequential centrifugation of whole blood and is a rich source of 
growth factors and cytokines such as PDGF, VEGF, IGF, EGF etc which play an important role 
in inflammatory and wound repair phenomena [9-11]. Earlier studies have shown that PRP can 
induce a significant improvement in BMSC recruitment, angiogenesis [12, 13], expression of 
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cartilage matrix [14], proliferation and viability of chondrocytes and BMSCs [15-16] as well as 
stimulate migration and chondrogenic potential of subchondral BMSCs [17]. Using an ovine 
chronic defect model, Milano et al showed that when used as an adjunct to BMS, PRP enhanced 
the repair response versus BMS alone [18]. Although the application of PRP improved the 
macroscopic and mechanical outcome, the hyaline nature of the repair tissue was still lacking. 
The efficacy of PRP in improving cartilage repair has been questioned due to multiple studies 
reporting less positive results in animal models [19-22]. We believe that inferior outcome with 
PRP could arise from the poor stability of PRP clots in vivo, which is even more pronounced than 
blood clots [23]. Combination of PRP with CS may help in overcoming this limitation thereby 
increasing residency and bioactivity of PRP.  
Progression to advanced stages of osteoarthritis (OA) may be prevented by early diagnosis and 
treatment. However, in cartilage lesions that are asymptomatic for longer times [24,25], BMS 
may have more severe limitations and therefore be less effective in treating older, chronic and 
extensive lesions. Chronic defects may alter joint homeostasis resulting in less favourable clinical 
outcomes [26-28]. To better represent this clinical situation, we developed a pre-clinical model to 
simulate degenerated chronic defects and examine the potential of BMS combined with CS/PRP 
in improvement of cartilage regeneration in chronic defects that are more challenging than acute 
lesions. It is already known that osteochondral defects smaller than 3 mm in young rabbits 
possess the potential for spontaneous regeneration [29] and several studies have reported a period 
of approximately 1 month to be adequate for development of chronic defect model in small 
animals [30,31]. Accordingly, we used skeletally mature rabbits with a defect size of 4 × 4 mm 
developed to chronicity over a period of four weeks. With these aspects in mind we carried out 
this study to test the hypothesis that augmentation of BMS with freeze-dried CS/PRP implants 
would improve repair response in a rabbit chronic defect model compared to BMS augmented 
with recalcified PRP.  
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6.2 Materials and Methods 
6.2.1 Preparation of freeze-dried chitosan formulation and PRP isolation 
 
Freeze-dried CS cakes consisted of 0.56% (w/vol) CS with 1% (w/vol) trehalose and 42.2 mM 
calcium chloride. To prepare, 0.056 g CS (Number average molar mass Mn 36.6 kDA and 80.2% 
DDA, produced in-house and characterized with NMR spectroscopy [32] and size-exclusion 
chromatography/multi-angle laser light scattering [33]) was mixed with 7.69 g water and 156 µl 
of 1 N HCl. Following overnight mixing, 1.56 ml of 3% (w/w) CaCl2 and 666 µl of 15% (w/v) 
trehalose solutions were added and the final solution was sterilized by filtration. Finally, 300 µl 
aliquots were prepared in 2 ml sterile glass vials and freeze-dried using the following conditions: 
1) Ramped freezing to -40
o
C in 1 hour then isothermal 2 hours at -40
o
C, 2) -40
o
C for 48 hours at 
100 millitorrs and 3) Ramped heating to 30
o
C in 12 hours then isothermal 6 hours at 30
o
C, at 100 
millitorrs.  
 
Autologous PRP was generated by sequential centrifugation of citrate-anticoagulated whole 
blood. Approximately 9 ml of autologous blood was extracted from rabbit and mixed with 1 ml 
of 3.8% (w/vol) sodium citrate before further processing. The whole blood was centrifuged at 
160g for 10 minutes. Following collection of the supernatant in addition to approximately the 
first 1-2 mm of erythrocytes, a second centrifugation was carried out at 400g for 10 minutes. 
Bottom 1.5 ml fraction containing PRP was isolated. Complete blood counts revealed that, on 
average, the ratio of platelets, leukocytes and erythrocytes in isolated PRP versus whole blood 
was 3X, 1X and 0.1X, respectively, which makes this a leukocyte-rich PRP. 
 
6.2.2 Experimental design and rabbit surgical model for cartilage repair in chronic lesions 
 
Canadian Council on Animal Care guidelines were observed and research protocol was approved 
by an institutional ethics committee for animal research. Using skeletally mature female New 
Zealand White rabbits, the chronic defect model was first validated in a pilot study utilizing a 
small number of animals (n=3) and short duration (4 weeks development to chronicity followed 
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by 3 weeks repair). The objective was to assess the feasibility of development of the model as 
well as compare fresh chronic defects (n=2 knees) to chronic defects after 4 weeks development 
(n=2 knees) and repair responses induced in chronic defects by BMS alone (n=1 knee) and BMS 
augmented with 1% (w/v) CS/PRP implants (n=1 knee). PRP controls were not included in this 
pilot study since the aim was to validate the chronic model rather than study the effect of 
treatments.  
 
A larger group (n=8) of skeletally mature (8-9 months old) female New Zealand White rabbits 
were then used in a bilateral model that limits the influence of inter-animal variation via a 
contralateral control. Two surgeries were performed to assess the development and repair of 
chronic cartilage defects. Following induction with xylazine-ketamine, animals were maintained 
under general anaesthesia using isofluorane-oxygen. Bilateral, parapatellar arthrotomies were 
performed to expose the synovial joint. Full-thickness chondral lesions measuring 4 × 4 mm were 
created in the trochlear central groove by scraping with 1.5 and 2.75 mm flat surgical blades 
taking care not to remove calcified cartilage. Knees were closed in sutured layers. A second 
surgery was performed four weeks later and the original lesion identified. Calcified cartilage 
(CC) and repair tissues (when present) were completely debrided using a flat blade to expose the 
underlying subchondral bone, without damaging the subchondral bone plate. Using a high speed 
microdrill, four subchondral perforations measuring 0.9 mm diameter and 6 mm deep were made 
on each trochlear defect in both knees, similar to what was done previously by our group in acute 
models [34,35]. Constant cooling irrigation was applied for removal of loose bone debris and 
prevention of heat necrosis [36]. The defect on one knee received treatment with one drop of 
CS/PRP mixture. Immediately before implantation, the CS cake (300 µL) was solubilized with 
300 µL autologous PRP. One drop of CS/PRP was applied to the drilled trochlear defect using a 1 
ml syringe and 18 gauge needle. The contralateral defect was treated with one drop of PRP 
recalcified with 42.2 mM calcium chloride. In both cases, knees were closed five minutes post 
application. The treatments were alternated between right and left knees [Fig. 6.1]. The patella 
was repositioned and knee was closed in sutured layers. No perioperative antibiotics were 
administered after either surgery but animals received extended analgesia with a fentanyl 
transdermal patch. Knees were allowed unrestricted motion and constantly monitored for 
infections and other complications following both surgeries. Animals were sacrificed eight weeks 
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later and knees were harvested for comparison of marrow stimulated repair response in presence 
of CS/PRP (BMS+CS/PRP group, n=8 knees) and recalcified PRP (BMS+PRP group, n=8 
knees).  
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Figure 6.1: Procedure of surgical manipulation to create and treat chronic defects using 
BMS+CS/PRP implants (left panels) or BMS+PRP (right panels). a,b: Creation of 4 × 4 mm 
defects by debriding all non-calcified cartilage from trochlea; c,d: Appearance of chronic defects 
four weeks after creation at the time of second surgery; e,f: Treatment of defects by debriding 
spontaneous repair tissue (when present) and calcified cartilage and drilling 4 holes measuring 
0.9 mm in width and 6 mm deep; g: Application of CS/PRP implant at defect site; h: Application 
of recalcified PRP at defect site. 
 
6.2.3 Characterization of repair 
 
Animals were sacrificed by overdose of pentobarbital and femoral ends were fixed in 4% 
paraformaldehyde /1%glutaraldehyde /0.1M Sodium cacodylate (pH 7.3). Low magnification 
images of fixed repair tissues were obtained with a dissection microscope equipped with digital 
camera to determine their gross structure and appearance using Northern Eclipse software 
(Empix Imaging). Images of repair tissues were scored by two independent, blinded readers using 
the ICRS macroscopic scoring system (ranging from 0, for severely abnormal to 12, for normal) 
[37]. Scores from two readers were averaged and used as an indicator of gross pathology of repair 
tissues.  
 
Samples were decalcified in EDTA with trace paraformaldehye and embedded in OCT and 
transverse sections were obtained from three levels: from the middle of the proximal and distal 
holes and from between holes. Sections were stained with Safranin O/Fast Green and scanned 
using a Nanozoomer RS system (Hamamatsu, Japan). Repair tissue was defined as all non-
mineralized tissue above the subchondral bone plate. Digital Saf-O stained sections were scored 
by two independent, blinded observers using a previously published O’Driscoll histological 
scoring method (ranging from 0, for worst tissue quality to 27, for best tissue quality) modified to 
assess subchondral bone health by an additional 3 point value [5]. Each Saf-O stained section was 
assessed for 10 criteria (Fig. 6.6c) to evaluate quality of repair tissue in addition to health of 
adjacent cartilage and subchondral bone repair. The scores obtained from three sections were 
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averaged for both readers and used for assessment of quality of fill in defects (ICC of 0.86 for 
total O’Driscoll score for both readers). 
 
Sections collected from each defect were also used to determine %Saf-O and %Coll-II in the 
chondral repair tissue using a previously described method [38]. Briefly, soft repair tissues were 
cropped by identifying projected articular surface and tidemark with the help of flanking articular 
cartilage and accounting for the curvature of the trochlear groove. Only the soft repair tissue 
above the tidemark was used to determine hue-saturation-value threshold limits for Saf-O and 
Coll-II. %Saf-O and %Coll-II positive region of repair tissues were measured using in-house 
Matlab routine software. 
 
6.2.4 MicroCT analysis of subchondral bone repair 
 
Micro CT scanning of fixed femur ends was done to characterize subchondral bone repair and 
remodelling (Skyscan x-ray microtomography 1172, Kontich, Belgium). Femurs were scanned 
with an aluminium filter at 14.1 µM pixel size resolution with an X-ray source voltage of 56 kV, 
1180 BMSec exposure, 0.45 rotation steps and 3 averaging frames. Trochlear micro CT image 
stacks were first reconstructed with NRecon software 1.6.1.5 using the following parameters: 
Smoothing of 2, Ring artifact reduction of 10, Beam hardening correction of 40%. Datasets were 
repositioned with DataViewer software 1.4.3 and region of interest were applied followed by 3D 
micro CT analysis. The regions of interest were of the rectangle adapted surface type [39] and 
measured 3 mm X 3 mm X 2 mm [Fig. 6.1S]. Bone morphometric parameters were calculated 
including bone surface density (BS/TV), bone surface (BS), bone volume (BV), porosity, 
connectivity density and number and thickness of trabeculae, by using the global thresholding 
procedure in CTAn software (version 1.9.3.0, Skyscan, Kontich, Belgium). 
 
6.2.5 Statistical Analysis 
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Statistical analyses were performed using SAS Enterprise Guide 7.1 and SAS 9.4. Since several 
sections were collected from both legs of each rabbit, a mixed model was used to account for the 
influence of donor. Fixed effects were treatments (BMS+PRP, n=8 knees and BMS+CS/PRP, 
n=8 knees), while donor was a random effect. Data in figures are presented as mean (diamond); 
median (line); Box: 25
th
 and 75
th
 percentile; Whiskers: Box to the most extreme point within 1.5 
interquartile range. p<0.05 was considered statistically significant. 
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6.3 Results 
6.3.1 Freeze dried chitosan/PRP implants induced inflammatory and wound bloom repair 
responses in chronic cartilage defects 
 
Although debridement appeared to have preserved the calcified cartilage intact due to absence of 
any punctuate bleeding at the time of initial surgery [Fig. 6.1a,b], the histological examination of 
Saf-O stained transverse sections of fresh defects showed that calcified cartilage had been partly 
debrided [Fig. 6.2e,i]. Chronic defects were noticeably distinct from the surrounding healthy 
tissue after 4 weeks [Fig. 6.1c,d], and residual calcified cartilage along with spontaneous repair 
response arising from the bone was occasionally observed [Fig. 6.2f,j]. Complete debridement 
down to subchondral bone was performed prior to BMS [Fig. 6.1e,f] and application of either 
CS/PRP [Fig. 6.1g] or recalcified PRP [Fig. 6.1h]. 
 
Defects treated with BMS+CS/PRP showed incomplete repair at 3 weeks [Fig. 6.2c] and 
histological examination of Saf-O stained transverse sections taken through holes revealed 
depressed repair tissues and enlarged remodeling drill holes [Fig. 6.2g,k], reminiscent of a wound 
bloom repair response [23]. Drill holes were devoid of subchondral cartilage and mostly filled 
with a polymorphonuclear cell-rich granulation tissue, where neutrophils colocalized with CS 
[Fig. 6.2g,k]. Contralateral defects treated with BMS alone also demonstrated incomplete repair 
at 3 weeks [Fig. 6.2d] and histological examination showed fibrocartilaginous and endochondral 
ossification repair responses, associated with chondrocyte hypertrophy and vascular invasion 
[Fig. 6.2h,l]. 
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Figure 6.2: Macroscopic and histopathological assessment of fresh defect (a,e,i), chronic defect 
after 4 weeks development (b,f,j), chronic defect treated with BMS+CS/PRP implant (c,g,k) and 
chronic defect treated with BMS alone (d,h,l). (e,i): Debridement was not homogenous and 
varying levels of calcified cartilage (CC) and debrided bone (DB) were seen in freshly debrided 
defects. (f,j): After 4 weeks, chronic defects showed evidence of partial spontaneous repair (SR) 
in some areas along with tufts of calcified cartilage (CC). (g,k): Granulation tissue formation 
(GT) and enlarged drill holes were seen in presence of CS/PRP implants. (h,l): 
Fibrocartilagenous repair and endochondral ossification (EO) process were seen in presence of 
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BMS alone, associated with chondrocyte hypertrophy (HT) and vascular invasion (VI). Red 
dotted lines in g & h represent original drill holes- hole enlargement and wound bloom effect is 
apparent in defect treated with BMS+CS/PRP (g). Scale bar (e-h):1 mm, (i-l): 100 µm. 
 
6.3.2 Chitosan/PRP implants solidified quickly in situ and improved the macroscopic 
repair appearance in chronic defects 
 
Clear differences in the solidification and stability of implants were observed at the time of 
surgery. On average, CS/PRP implants solidified in situ within 30-60 seconds. In contrast, in 
most cases, recalcified PRP implants did not coagulate even after passage of 5 minutes. In 
general, assessment of 8 week repair outcome was found to be generally poor [Fig. 6.3], most 
likely due to the chronic nature of the current defects. Incomplete fill and poor repair tissue 
integration to adjacent cartilage tissue were observed in both groups [Fig. 6.3]. Defect surfaces 
were significantly depressed with irregular surface [Fig. 6.3]. Appearance of repair tissues varied 
from dense white, glossy to reddish, spongy or tufty [Fig. 6.3]. Although higher for 
BMS+CS/PRP group (Mean score 4.75 ± 2.25) compared to BMS+PRP group (Mean score 3.25 
± 2.05), macroscopic ICRS scores did not show a significant difference between treatments 
(p=0.16) [Fig. 6.3e].  
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Figure 6.3: Best (a,b) and worst (c,d) repair response in defects treated with BMS+CS/PRP (a,c) 
and BMS+PRP (b,d). Scale bar=1 mm. (e): Mean macroscopic ICRS score was higher (non-
significant) in defects treated with BMS+CS/PRP versus defects treated with BMS+PRP. 
 
However, the BMS+CS/PRP group had the only instance of a nearly normal (grade II) repair 
response and only two severely abnormal (grade IV) repair outcomes, while the BMS+PRP group 
had 4 instances each of abnormal (grade III) and severely abnormal (grade IV) outcomes [Table 
6.1]. 
Table 6.1: Number of defects in each repair category for both treatments. Macroscopic repair 
scored according to the ICRS system. 
Grade of repair BMS+CS/PRP BMS+PRP 
I (12-Normal) 0 0 
II (8-11 Nearly Normal) 1 0 
III (4-7 Abnormal) 5 4 
IV (1-3 Severely Abnormal) 2 4 
 
6.3.3 Histological assessment showed superior repair in defects treated with chitosan/PRP 
implants 
 
Higher expression of GAGs and type II collagen was observed in defects with the best 
histological scores [Fig. 6.4 a,b,i,j,e,f,m,n], compared to defects with lowest scores [Fig. 6.4 
c,d,k,l,g,h,o,p]. Where present, repair tissues showed good integration to underlying bone, 
although bonding with adjacent cartilage was poor in both groups [Fig. 6.4].  
138 
 
 
 
 
 
Figure 6.4. Comparison of histopathological assessment of best and worst repair tissues generated 
by BMS+CS/PRP and BMS+PRP. (a-h): Saf-O staining for best (a,b,e,f) and worst (c,d,g,h) 
repair outcomes; (i-p): Coll-II immunostaining for best (i,j,m,n) and worst (k,l,o,p) repair 
outcomes; Scale bars 2.5mm (a-d & i-l) and 500 µm (e-h & m-p). 
 
Restoration of surface, structural integrity and thickness were all improved by BMS+CS/PRP 
treatment (p=0.05, p=0.0001 and p=0.002, respectively) [Fig. 6.5 a,b,c,d] and [Fig. 6.6 b]. 
Hypocellular tissue was less frequently observed in BMS+CS/PRP group and incidence of 
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chondrocyte clustering was more frequent in the BMS+PRP group (p=0.002 and p=0.009, 
respectively) [Fig. 6.5 g,h,i,j] and [Fig. 6.6b]. Margins of defects were recognizable and 
degenerative changes were observed in the adjacent cartilage, especially in the BMS+PRP group 
(p=0.004) [Fig. 6.5 e,f] and [Fig. 6.6 b]. Zonal organization and tidemark were not restored in 
any defect at this 8 week time point [Fig. 6.5 g,h,i,j]. One case of a cleft communicating with 
subchondral cyst was observed in both groups (Data not shown). Taken together, mean 
O’Driscoll score was significantly higher for BMS+CS/PRP group (Mean score 20.5±1.69) 
versus BMS+PRP group (Mean score 14.75±1.75) (p=0.0002), indicating superior quality of 
repair in presence of CS/PRP implants [Fig. 6.6a]. 
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Figure 6.5: Representative sections of repair tissues generated by BMS+CS/PRP and BMS+PRP. 
(a,b): Restoration of surface and structural integrity was better in presence of CS/PRP (a) versus 
PRP (b) (defect margins flanked by solid black arrows); (c,d): Missing repair tissue (line) in 
BMS+PRP (d) versus more uniform tissue in BMS+CS/PRP (c); (e,f): Comparison of adjacent 
cartilage (AC) showing improved appearance in the case of BMS+CS/PRP; (g,h): Best sections, 
(i,j): worst sections- all sections from same animal. Black arrows indicate zones of 
hypocellularity, yellow arrows indicate cell clusters, both more frequent in BMS+PRP. Scale 
bars=a,b: 1 mm, e-f: 250 µm, g-j: 100 µm. 
 
 
Figure 6.6: (a) Mean O’Driscoll score was significantly higher for repair tissues in defects treated 
with BMS+CS/PRP versus defects treated with BMS+PRP. (b). Significant differences (*) were 
observed between treatments, and scores for adjacent cartilage (p=0.004), cellular changes 
(p=0.002), cell clusters (p=0.009), structural integrity (p=0.0001), surface integrity (0.05) and 
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thickness of repair tissue (p=0.002) were significantly higher for defects treated with 
BMS+CS/PRP. (c). Criteria used in modified O’Driscoll scoring with respective score range. 
 
Quantitative histomorphometry revealed a significant increase in type II collagen staining in 
repair tissue matrix for BMS+CS/PRP group (Mean 57.37±12.43) compared to BMS+PRP group 
(Mean score 32±15.94), indicating a more hyaline repair (p=0.003) [Fig. 6.7a]. Safranin O 
staining was less widespread than type II collagen staining [Figs. 6.4, 6.5, 6.6]. A higher 
proportion of repair tissue was GAG-positive in the BMS+CS/PRP group (Mean 44.9±16.3) 
compared to BMS+PRP group (Mean 34.6±8.9), although this result was not significant (p=0.07) 
[Fig. 6.7b]. 
 
 
 
Figure 6.7: a). Mean %Coll-II was significantly higher for repair tissues in defects treated with 
BMS+CS/PRP versus defects treated with BMS+PRP. b). Mean % Saf-O was higher for repair 
tissues in defects treated with BMS+CS/PRP versus defects treated with BMS+PRP, although 
this difference was not significant. 
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6.3.4 Chitosan/PRP implants induced bone remodeling in BMS-treated defects 
 
In both groups at 8 weeks post-operative, subchondral bone underneath cartilage defects showed 
evidence of ongoing remodelling indicating repair was still underway [Fig. 6.4]. Quantitative 3-D 
micro CT analysis revealed high inter-individual variability in bone structural parameters, and no 
significant difference between treatments [Fig. 6.1S]. However, the values for bone surface 
density, bone surface, connectivity density, and trabecular number were all higher for 
BMS+CS/PRP group compared to BMS+PRP group (all p=0.01), indicating that CS/PRP 
implants increased bone remodeling [Fig. 6.1S].  
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Figure 6-1S: MicroCT 3-D analysis showed differences in structural parameters between defects 
treated with BMS+CS/PRP versus defects treated with BMS+PRP. Although the results were not 
significant, the values for bone surface density (a), bone surface (b), connectivity density (c), and 
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trabecular number (f) were trending high for BMS+CS/PRP group versus BMS+PRP group, 
suggesting an increase in bone remodeling. i. Schematic representing the region of interest (ROI) 
for micro CT analysis. 
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6.4 Discussion 
A chronic model was developed to test the efficacy of CS/PRP implants in augmenting marrow 
stimulated repair. Although chronic defects were found to be more challenging to treat than acute 
defects, CS/PRP implants improved the quality of repair tissues, which suggests that they would 
constitute a promising approach for treating chronic, degenerated lesions in older patients. Taken 
together, our data shows superiority of BMS+CS/PRP in repair of chronic defects compared to 
BMS+PRP, thereby affirming our starting hypothesis.  
 
The chronic defect model used here was intended to approach the degenerative and inflammatory 
processes concomitant with metabolic alterations in early OA due to cartilage injury. In line with 
this, we found that BMS by drilling to 6 mm induced much poorer repair in trochlear chronic 
defects [Figs. 6.3,6.4] than in similar acute defects in the rabbit model [34,35]. Recent studies 
have reiterated the chronic defect model to be more suitable to study pathogenesis of OA which 
is associated with multiple changes in the defect milieu with severe bearing on downstream repair 
processes. Altered joint homeostasis in old defects has been associated with inferior repair [40]. 
The difficulty in treating chronic defects has been recognized in multiple studies in the past 
[40,41]. Saris et al showed that cartilage repair outcome in groups receiving late treatment was 
significantly inferior compared to early treatment group and was comparable to untreated group 
[40]. Rodrigo et al suggested that synovial fluid may have a stimulatory effect in treatment of 
acute defects while may be inhibitory in chronic defect treatment [42].  
 
PRP is a rich source of growth factors and cytokines which play important roles in inflammatory 
and wound repair phenomena [9,10]. Although the exact mechanism of PRP action has not been 
understood, BMSC recruitment, expression of cartilage matrix [18] in addition to migration, 
proliferation and chondrogenesis of subchondral BMSCs have been shown to be positively 
influenced by PRP. In contrast, some studies report that PRP exerts a stimulatory effect on 
proliferation of chondrocytes and BMSCs, but has no effect on their chondrogenic differentiation 
[17, 47-49]. Reduced expression of lineage specific markers was observed in cells expanded in 
the presence of PRP [50]. Therefore, we believe that BMS augmented with recalcified PRP was 
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an appropriate baseline treatment to be compared with BMS repair outcome elicited in presence 
of CS/PRP implants. Our results indicate insufficient capability of PRP in enabling cartilage 
healing in a chronic defect [Figs. 6.3,4,5,6,7]. Similarly, in a previously published study, PRP 
was unsuccessful in regenerating the hyaline nature of repair tissue in a chronic defect treated 
with BMS [18]. In our study, PRP failed to solidify even after several minutes in most cases, 
suggesting impaired in vivo residency of a liquid implant, and providing a possible mechanism 
for reduced efficacy of PRP in cartilage regeneration. In our recent study, CS/PRP clots showed 
significant increase in viscosity vs PRP and reduced clotting time by 4 times compared to 
recalcified PRP [23]. Whereas CS/PRP clots remained voluminous even 1 hour after clotting, 
recalcified PRP clots had lost ~80% of their original volume as a result of serum exudation [23]. 
The resulting quick loss of platelet-derived bioactive factors could potentially limit repair in these 
defects. In our implants, CS inhibited the retraction observed in PRP clots and solid, voluminous 
CS/PRP implants increased stability in vivo, ensuring bioactivity for several weeks. Consistent 
with this hypothesis, CS/PRP implants have been shown to reside for several weeks in vivo and 
to possess significant bioactivity while recalcified PRP degraded in a day [23]. In addition, when 
implanted subcutaneously, the sustained presence of CS/PRP implants induced cell recruitment 
and angiogenesis in the local milieu. A similar increase in recruitment of progenitor cells 
combined with increased angiogenesis will greatly influence the cartilage tissue regeneration and 
subchondral bone remodeling.  Possibly through platelet activation, CS increases the 
concentration of bioactive factors including proangiogenic factors [61]. Our own in-house 
preliminary data [62] and other studies suggest that CS may stabilize platelets in PRP leading to 
sustained release of GFs [58]. Kim et al had shown improved chondrocyte proliferation and 
matrix synthesis induced by sustained release of TGF-βI from CS scaffolds [63]. Taken together, 
we believe that superior physical stability of CS/PRP implants leads to a significant increase in 
their biological activity arising from sustained residency and release of platelet-derived growth 
factors and inherent benefits of CS.  
 
Potentiating effects of CS in articular cartilage healing has been demonstrated in multiple studies 
[51-54]. While CS helped in maintenance of morphology and ECM synthesis by chondrocytes in 
vitro [53,54], a thermosensitive CS gel promoted chondrogenic differentiation of BMSCs [55]. 
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CS has been shown to be chemotactic and increase recruitment and proliferation of BMSCs into 
defect [4], impede loss and preserve viability of BMSCs [56]. Three-week analysis of repair 
tissues in our model revealed the presence of vascularized granulation tissue enriched with 
polymorphonuclear cells along with enlarged drill holes in CS/PRP group, similar to what was 
previously reported for CS-GP/blood implants [4,57]. In contrast, a typical fibrocartilagenous 
repair and endochondral ossification associated with hypertrophied chondrocytes and vascular 
invasion was observed in BMS only group, as previously reported [1, 4]. CS-GP/blood implants 
improve cartilage repair by, in part, increasing cell recruitment, vascularization and bone 
remodeling, polarizing the macrophage phenotype towards the alternatively-activated pro-wound 
healing lineage and stimulating secretion of anabolic wound repair factors [4, 5, 58-60]. Wound 
bloom effect as seen in previous studies was characterized by enhanced woven bone plate repair 
in the drill holes along with increase in volume and hyaline quality of cartilage tissue, likely due 
to increased recruitment of chondrogenic stem cells to the cartilage lesion [57]. Here, we showed 
that CS/PRP implants appear to induce similar mechanisms. Taken together, these factors may 
drive the superior repair response in presence of CS/PRP implants indicated by more hyaline 
nature of repair accompanied by better macroscopic regeneration and increased bone remodeling.   
 
One limitation of this study was its relatively short 8 week time point. Although increased 
hyaline nature of the repair tissue obtained with BMS+CS/PRP would be expected to provide 
long-term durability, this was not assessed here. In addition, we found high inter-individual 
variability in our results, which may arise due to immediate load bearing [64] further 
compounded by small sample size used in this study. Nevertheless, in spite of these limitations, 
CS/PRP implants show promise in augmenting the beneficial effects of BMS in chronic models. 
 
6.5 Conclusions 
We believe that this study will motivate earnest reassessment of pre-clinical cartilage repair 
models. Since prompt diagnosis and treatment of cartilage defects is rare, approaches aimed at 
improving repair in presence of altered joint hemostasis is warranted. The chronic model studied 
here is more comparable to human chronic defects than the corresponding acute model. Our 
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results show promising results in unveiling the positive role of CS/PRP implants for 
improvement of BMS mediated cartilage repair in chronic defects. In the future, a larger study 
with increased duration of repair and additional control groups will be undertaken to shed more 
light on the underlying mechanism of inflammatory and metabolic changes accompanying 
pathogenesis and repair of chronic defects using CS/PRP implants.  
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       CHAPTER 7       GENERAL DISCUSSION 
This study was carried out with a purpose to identify the underlying mechanism of variability in 
marrow stimulated repair outcome by identifying location-, age- and donor-dependent factors 
influencing the inherent properties of subchondral bone progenitor cells (or bone mesenchymal 
stem cells, BMSCs). Furthermore, efficacy of a novel biomaterial implant based approach in 
improving repair was tested in a challenging, degenerative cartilage lesion. Our initial hypothesis 
was that in vitro analysis of inherent properties of BMSC - such as number, clonogenicity and 
differentiation potential - will be influenced by location and age. Results showed that rabbit 
trochlear vs. condylar subchondral bone yielded a greater number of progenitors with superior 
cartilaginous matrix expression under chondrogenic conditions suggesting higher intrinsic 
capacity for cartilage repair compared to condylar subchondral bone. These properties declined 
with increasing age. Our second hypothesis was that inherent properties of progenitor cells are 
the underlying cause for donor and location dependent variability in cartilage repair outcome. 
Quality of trochlear repair was superior compared to condyles and correlated with number, 
clonogenic and differentiation potential of the stem cells analysed in vitro in a location- as well as 
donor-dependent manner. We also report data in support of third hypothesis that marrow 
stimulated cartilage repair will be improved when augmented with Chitosan and PRP in a 
skeletally mature, chronic defect model. The aggressive chronic model studied here was clearly a 
challenge to treat and closely depicted the clinical situation. When compared to PRP alone, 
Chitosan/PRP implants were found to be a promising approach to address the demanding and 
hard to treat cases including chronic, degenerative lesions in skeletally mature donors.  
Based on our data, number of BMSCs at the time of isolation is likely to exert the most 
significant influence on their cellular behaviour in vitro and a subsequent impact on the 
downstream differentiation process. Fewer BMSCs were isolated from condyles in young, 
skeletally mature and old animals. Since close interactions of cells is a critical requirement for 
chondrogenic differentiation of BMSCs, a lower population of these cells in condyles will likely 
attribute to reduced chondrogenesis eventually leading to poor repair. Evidence also suggests that 
paracrine effects of BMSCs are implicated in their therapeutic role [82]. Depleted BMSC 
population would diminish their beneficial paracrine effects and ultimately reduce their 
regeneration and repair potential. Stromal cells have also been shown to express angiogenins 
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which aid in bone remodelling due to their role in vessel growth, capillary proliferation and 
expansion of sinusoidal spaces [282]. In addition, they act to increase the local stem cell 
population by stimulating proliferation of tissue specific stem cells and inhibiting local apoptosis 
[282]. Since our current model engages lesser condylar stroma, both bone remodelling and stem 
cell proliferation may be negatively affected leading to inferior repair outcome in condyles. GLM 
analysis of biological properties enabled us to recognize that rabbit repair outcome is 
significantly influenced by resident population in subchondral bone and likely leads to location-
dependent variability. In vitro and in vivo variability observed in trochlea further strengthened 
our conclusion. A strong correlation between cell yield of trochlear BMSCs, surface marker 
expression, chondrogenic differentiation potential and repair outcome was unmistakably evident 
in poor trochlear responders. In addition, a significant reduction in progenitor cell population was 
observed in older animals. Although we did not study cartilage repair in an old animal, inferior 
cartilage repair outcome is a well known phenomenon in older patients. Age-related reduction in 
progenitor cell population possibly arises from senescence. It is highly likely that reduced 
progenitor cell population leads to inferior repair outcome in older individuals.  
Clonogenic potential of BMSCs demonstrated significant correlation with location of defect and 
age of donor. Colony forming potential of BMSCs determined by means of CFU-f assay is one of 
the parameter used to assess the stemness of a BMSC population and has been shown to have a 
direct bearing on differentiation potential. Trochlear BMSCs were consistently associated with a 
significantly higher colony forming potential indicating superior clonogenic potential. Multiple 
studies correlate the colony forming potential of BMSCs with multilineage differentiation 
potential. However, BMSC cultures are known to be highly heterogeneous and are prone to be 
influenced by method of isolation, culture conditions, media composition and passage number 
[77]. Inter-individual variability observed in poor vs good trochlear responders might also arise 
from the inherent heterogeneity of BMSCs, the exact mechanism for which is still poorly 
understood. Structural and anatomical differences along with ontogeny-dependent factors might 
contribute to variability in phenotypic profile of BMSCs studied under relatively similar 
conditions. In an important finding by Muraglia et al, it was observed that contrary to popular 
belief, only a fraction of BMSCs are indeed tripotential with capability to differentiate into 
osteogenic, chondrogenic and adipogenic lineage. Remaining cells are uni- and bipotent cells 
with much more defined propensity for a certain lineage [100]. Moreover, a difference in the rate 
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of proliferation between the clones was noted in further studies. Russell et al found that tripotent 
clones had higher rate of proliferation accompanied by a lower rate of apoptosis compared to 
unipotent clones [127]. Therefore, a difference in the proportion of tripotent clones would not 
only affect the differentiation potential but also cell number, both of which are expected to have a 
profound impact on the repair potency. Finally, cells may not be sensitive to inducing agents 
because of being in different stages of lineage progression [376]. Taken together, caution is 
required while analysing the colony forming potential of BMSCs as an indicator of 
differentiation potential of an individual cell.  
In addition to cell number and clonogenic potential, cell surface marker profiling was also carried 
out. An earlier study comparing the characteristics of stem cells isolated from different niches 
found mild location-dependent differences in their surface marker profile and differentiation 
potential. The authors believed the differences to stem from the influence of the local 
environment the cells are exposed to in their niche [119]. Donor-dependent correlation between 
cell surface marker expression and biological properties was identified in poor vs good trochlear 
responders, thus substantiating our understanding that inherent properties of BMSCs including 
their marker profile is likely to impact the corresponding repair potential to a certain extent. 
However, location-dependent variability in the cell surface marker profile was not evident. This 
observation might be an indicator of limitation of in vitro cultures in being a true reflection of the 
phenotypic profile of BMSC as found in situ. It is hard to ascertain if the marker profile was 
altered as result of in vitro culture since expression of markers is highly sensitive to culture 
conditions [282].  
Several factors contribute to the differentiation potential of BMSCs in vitro and in vivo. Even 
though rabbit MSCs (rbMSCs) and human MSCs (huMSCs) have been shown to bear close 
resemblance [100], rbMSCs might take longer for differentiation and have a greater propensity 
towards chondrogenic differentiation compared to huMSCs. Spontaneous repair potential and 
high inter-individual variability in rabbit repair models is a well known phenomenon. A study 
which directly correlates the properties of stem cells and in vivo repair outcome in an animal 
model might be the next step in understanding of pre-existing differences at the two locations. 
Characterization of BMSCs isolated from young trochlea and condyle revealed high inter-
individual variability. Differences in the surface receptor profile, interactions with growth factors 
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and cytokines, stages of lineage progression, epigenetic factors and posttranslational 
modifications are some of the factors likely implicated in the inherent variability of BMSC 
population [58]. The downstream differentiation commitment of BMSCs may also be influenced 
by spatial dimensionality modifying the interaction of BMSCs in trochlea and condyle and their 
corresponding microenvironment [377]. The outcome of differentiation assays was more 
consistent in skeletally mature and older individuals. This might be due to increase in number of 
progenitor cells with defined propensity for a certain lineage. An age related reduction in number 
of tripotential progenitors has been demonstrated in the past [378]. Studies have also shown that 
stem cell’s multipotentency is also influenced by the histone modification patterns of 
differentiation-associated genes [287]. A difference in these modifications arising due to 
anatomical differences, mechanical and chemical cues or some unknown inherent mechanism 
may also impact the differentiation potential of the stem cells and may lead to donor-, age- or 
location dependent variations [287]. 
In addition to stromal cells, we also carried out the characterization of cells migrating out of the 
bone explants. It is difficult to determine the niche of BMSCs due to lack of specific antigens or a 
specific phenotype. Nonetheless, they are hypothesized or postulated to be located in perivascular 
structures from where they can migrate to the site of need upon stimulation [379]. An alternative 
hypothesis in case of BMSCs is they migrate out of bone when cultured as explants over a period 
of time [380]. These cells are protected from the action of collagenase enzyme due to the 
presence of mineralized matrix and begin proliferating on being liberated later on. They are 
presumed to be undifferentiated/dedifferentiated cells possessing multilineage differentiation 
potential. They do not express any marker of bone except Col-I and are characterized by a weak 
expression of ALP [380]. In fact, Lin et al conducted an interesting experiment to show the 
migration of Stro-1+ cells from the bone chips to give rise to a culture of BMSCs bone chips and 
proposed that explants are richer source of BMSCs compared to any other source including BM. 
In our histological images of bone chips from day 7, presence of numerous lacunae in the bone 
was seen which could be a result of migration of cells or the death of osteocytes. If the cells 
indeed migrate out, these could revert to de-differentiate stage and regain multilineage 
differentiation potential. Lin et al provided evidence of this migration in their study indicated by 
reduction in percentage of Stro-1+ cells accompanied by an increase in number of lacunae in 
bone matrix [380]. We found remarkable similarities in most of the characteristics of collagenase 
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and explant derived BMSCs, providing further evidence that cells in bone have the potential to 
dedifferentiate into a more primitive and undefined phenotype.  
In an important observation, we found a strong influence of age of BMSCs on the corresponding 
biological properties including their number, stemness, expression of cell surface markers and 
differentiation potency. Reduced migration potential due to decreased response to 
chemoattractants might also contribute to inferior repair outcomes in older individuals. Ageing 
also induces changes in chondrocytes including senescence, reduced response to growth factors, 
accumulation of AGE and oxidative damage [287]. The resultant disturbance in the cartilage 
homeostasis makes the cartilage matrix vulnerable to further damage. Reduction in cell number 
and senescence in existing progenitor cell population are prevalent in older individuals. In 
addition to poor telomerase activity, the genes involved in DNA replication, cell cycle, mitosis 
and DNA repair are significantly downregulated with increasing age [381]. As a result of 
accumulation of DNA damages, cells enter senescent phase. According to Hayflick model of 
senescence, once the cells reach senescent limit, they switch from a rapidly dividing phenotype to 
a slow dividing one accompanied by a loss in differentiation potential [100]. There is a decline in 
anti-oxidants with increasing age which leads to escalation of levels of reactive oxygen species 
[382]. Moreover, the levels of growth factors decrease which might cause a shortfall in factors 
required critically for differentiation. Finally, Xin et al proposed that migratory ability of BMSCs 
towards chemoattractants reduces with increasing age [383]. This is an important consideration 
since it might lead to reduced migration and recruitment of BMSCs towards cartilage lesion in 
older individuals. The data from our study is consistent with the earlier findings of Payne et al 
and Zheng et al where a reduced chondrogenic potential was observed in older rats [220, 221]. 
This was confirmed in chondrogenic and osteogenic differentiation assays. Older animals had 
negligible Col-II and Saf-O and Alizarin Red-S staining denoting poor cartilaginous and osseous 
matrix. On the other hand, BMSCs from young animals synthesized a matrix rich in cartilaginous 
and osseous proteins. 
In situ characterization of BMSC is currently lagging due to several challenges such as the lack 
of markers for their in vivo identity as well as markers to distinguish multipotent BMSCs and 
committed progenitor cells. As a result, it becomes imperative to draw information from the in 
vitro cultures of BMSCs. However, the conditions in vitro are far different from the in vivo niche 
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of BMSCs. Moreover, in vitro cultures are vulnerable to be affected by the heterogeneous nature 
of BMSCs [120]. Nonetheless, in vitro characterization of BMSCs is our best bet to understand 
the mechanism of inconsistency in the cartilage repair response and deliberate the approaches to 
address them. Our second study (chapter 5) aimed to provide further understanding of underlying 
mechanism of inherent variability in cartilage repair response, thus bringing us one step closer to 
developing approaches to reduce the unpredictability in marrow stimulated repair outcomes. 
Cartilage repair does not occur in isolation and is bound to be influenced by factors generated by 
defect milieu including synovium, synovial fluid and subchondral bone. Therefore, our bilateral 
model aimed at parallel study of repair outcome and properties of BMSCs was a more ideal 
approach for a better understanding of correlation between in vivo repair outcome and in vitro 
biological properties of BMSCs. Such a model would also be more suitable for enhancing our 
understanding of heterogeneous behaviour of BMSCs which might explain the influence of 
donor, age and location on repair outcome. A better understanding of mechanism of inter-
individual variability will likely enhance predictability of MS repair outcomes. Although multiple 
studies have reported correlation of biological properties of BMSCs and their impact on repair 
outcome, our study was the first to provide valuable insight into mechanism of inter-individual 
variability observed in marrow stimulated repair outcome. We found direct evidence of a 
correlation between number, clonogenic potential and differentiation potential of BMSCs and 
healing induced by BMS. Animals of similar age and sex profile demonstrated clear differences 
in repair outcome and properties of BMSCs as a function of both location and donor. While this 
may be a factor contributing to the reduced differentiation potential of older BMSCs, it might 
also add to reduced variability between BMSC populations. By applying suitable statistical 
model, we were able to recognize the factors with maximum impact on the cartilage repair 
outcome in a location- and donor-dependent manner. Macroscopic appearance of repair tissues 
showed strongest association with clonogenic (CFU) & early chondrogenic potential (Coll-II) of 
BMSCs. O’Driscoll scores in repair tissue were most strongly related to clonogenic (CFU) & 
matrix production (Saf-O and Coll-II) by BMSCs. %Saf-O &% Coll-II in repair tissues were 
most strongly associated with cell number (cell yield) & early chondrogenic potential (Coll-II) of 
BMSCs. As a result, cell number, clonogenic and chondrogenic potential of BMSCs were 
identified as strong predictors of macroscopic and histological outcomes in rabbit cartilage repair. 
In conclusion, the pre-existing properties of progenitor cells may have a critical role in 
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influencing donor- (good vs poor responders in trochlea) and location-dependent (condyle vs 
trochlea) variation observed in marrow stimulated repair outcome.  
Several groups are working towards challenging the limitation of BMS in older individuals with 
chronic, degenerative lesions. Based on our characterization studies we recognized that cell 
number and inherent differentiation potential of subchondral progenitor cells has a critical impact 
on the repair outcome. Moreover, differentiation of BMSCs is likely to be influenced by changes 
in joint capsule, composition of matrix and interaction with bioactive factors released by synovial 
fluid and subchondral bone [384]. Studies have shown that the migratory ability of BMSCs is 
affected by the receptors and adhesion molecules expressed by them including chemokine 
receptor type 4 (CXCR4) and its binding protein stromal-derived factor 1-α (SDF-1α) [285]. The 
expression of these mediators is vulnerable to being influenced by the changes in the 
environment of the BMSCs, such as presence of inflammation. Moreover, levels of MMPs are 
also affected by the levels of inflammatory mediators IL-1β, TNF-α and TGF-1 β thereby 
affecting the BMSC migration [385-387]. The chronic model used here is more likely to 
accurately represent the alterations induced in a degenerated joint versus the commonly used 
acute animal model. It has been reported that the proliferative and chondrogenic capacities of 
BMSCs are affected by disease stage of donor and BMSCs obtained from patients with OA are 
reduced compared with those from healthy individuals [53]. Chronic defects may involve altered 
joint biomechanics or alteration in the subchondral bone progenitor cell population thus reducing 
the repair potential in this model. Although no alterations were observed upon macroscopic 
examination of patellofemoral and tibiofemoral compartments, further investigation may reveal 
factors affecting the nature of repair. More specifically, changes in subchondral bone 
revascularization or remodelling may adversely affect cartilage repair in this rather aggressive 
model and need to be further explored. Since the model requires two surgeries within a short span 
of four weeks, it will be worth deliberating the influence of local inflammation on the efficacy of 
treatment strategies. In this study, we explored the beneficial effect of chitosan/PRP in improving 
the cartilage repair outcome.  
Earlier studies have shown that application of PRP causes a significant improvement in BMSC 
recruitment, angiogenesis [348, 349], expression of cartilage matrix [25], proliferation and 
viability of chondrocytes and BMSCs [388, 389], migration and chondrogenic potential of 
164 
 
 
 
subchondral BMSCs [26]. However, most of the growth factors are released quickly from PRP 
leading to loss in their activity and clinical efficacy [305]. It has previously been shown that 
platelet-mediated retraction is inhibited in CS/PRP hybrid clots and that CS/PRP implants have a 
superior residency and bioactivity compared PRP only implants in vivo [390]. The observations 
have been described in more detail in chapter 6, article 3. The positive impact of chitosan and 
PRP on the recruitment, proliferation and differentiation of BMSCs is multifactorial. Chitosan is 
a biocompatible polycationic hemostat and promotes cell recruitment and transient 
vascularization, improves subchondral bone remodeling and repair [13] and escalates number and 
area of mature chondrogenic foci [18]. Most importantly, chitosan ensures a more sustained 
release and retention of growth factors in the defect milieu which has a direct bearing on the 
cellular behaviour of BMSCs recruited to the defect [294].  It has previously been shown that 
release of EGF and PDGF-AB from CS-PRP hybrid clots in vitro increased compared to release 
from PRP-only clots [391]. Moreover, chitosan can aid in overcoming the negative impact of 
reduced proliferation and migration observed in BMSCs of older individuals thereby generating a 
repair tissue with superior quality and quantity. Based on our observations in a chronic model, we 
believe that chitosan/PRP implants hold immense potential in improving cartilage repair 
outcome, especially in challenging conditions.  
Inter-individual variability in repair response was prevalent. Although significant improvement in 
the macroscopic appearance was not observed, lesser instances of grade IV degeneration was 
observed in presence of chitosan/PRP implants. Integration with adjacent cartilage was poor in 
both groups which may be explained by aggressive nature of the defect. Evidence of degeneration 
was more prominent on defect edges and increased chondrocyte clustering was more prevalent in 
PRP group suggesting a worse repair response. Additionally, chitosan has been shown to induce 
superior, albeit delayed repair in previously published study [13, 19]. It is likely that repair 
response in poor responders may be improved over time and longer repair durations might result 
in better repair. While 8 weeks’ time point was considered to be suitable in this preliminary 
study, this might still be a relatively early repair point and increased GAG deposition might be 
observed in a model with longer sacrifice time point. An earlier study reported improved repair 
outcome in 26 weeks compared to 13 weeks in a chronic partial thickness rabbit model [392]. 
Moreover, any growth factors or cytokines released after initial injury will not have any lasting 
effect by the time of second surgery. Although the meniscus appeared normal, there may be 
165 
 
 
 
microscopic changes with profound impact on cartilage repair since cartilage degeneration has 
been found to be concomitant with meniscus degradation in humans. Besides, despite our best 
efforts, the complete removal of calcified cartilage cannot always be ensured and the presence of 
residual CC has been shown to be one of the barriers in marrow stimulated cartilage repair. There 
is also an immediate load bearing in animals with no physiotherapy during recovery phase. 
Appropriate physiotherapy and gradual increase in weight bearing may also improve repair 
outcome in humans. Finally, although this model is aimed at closely simulating advance stages of 
OA, an accurate reflection of alterations in matrix metabolism and accompanying cartilage 
degeneration seen in OA may not occur. In the light of these factors, it is reasonable to propose 
that selective modifications in the future will likely generate even more promising preclinical 
results with application of chitosan and PRP implants, thus paving way for successful clinical 
translation.  
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 CHAPTER 8   CONCLUSIONS AND RECOMMENDATIONS 
 
The immense potential of BMS in cartilage repair is well recognized; even with certain 
limitations including poor quality of repair and high-inter individual variability. Despite several 
pre-clinical and clinical studies, a clear identification of source of strong age dependence and 
significant inter-individual variability in BMS remains unclear. This thesis presents a method of 
comprehensive analysis of properties of subchondral bone progenitor cells. Intricate techniques 
for isolation of progenitor cells from condyles and trochlea were optimized followed by their in-
depth analysis using in vitro biological assays. Progenitor cells originating from marrow spaces 
and cortico-spongious bone showed mesenchymal stem cell phenotype as defined by ISCT 
guidelines for stem cell characterization. Rabbit trochlea yielded a greater number of progenitors 
with higher clonogenic and osteogenic potential versus condyle. A greater manifestation of 
cartilaginous phenotype was confirmed by superior cartilage matrix production in trochlea. The 
mechanism for significant inter-individual variability in chondrogenic potential of young animals 
warrants further perusal. In contrast, subchondral progenitor cells isolated from distal femur of 
old animals were characterized by significant reduction in yield, clonogenic and surface marker 
expression. Combined with significantly reduced chondrogenic potential, these observations 
point towards a strong age-dependent decline in properties of progenitor cells making older 
individuals more susceptible to unsuccessful cartilage healing. Taken together, our observations 
led us to conclude that inherent biological properties of progenitor cells are prone to be 
influenced by their location and age of individual. These observations motivated us to further 
verify if superior inherent properties of trochlear progenitor cells are the likely cause of improved 
repair in rabbit trochlea.  
Since BMS procedures rely on cellular behaviour and downstream differentiation of BMSCs for 
cartilage regeneration, it is highly likely that pre-existing properties of progenitor cells may have 
a critical role in age-, donor- and location-dependent variation observed in the repair outcome. It 
is important to bear in mind that rabbit repair procedures are extremely sensitive to inter-
individual variability and notable spontaneous repair potential. With these issues in mind, 
skeletally mature rabbits with more consistent repair outcomes were used to develop bilateral 
models. We designed a study to investigate the dependence of inter-individual variability on 
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location- and donor-dependent variables. Subchondral bone parameters in one knee of each 
animal was correlated with marrow stimulated repair capacity in second knee from same animal. 
Full thickness defects were created in condyle and trochlea of one knee and treated by 
microdrilling to induce marrow stimulated repair. Bone marrow stimulation induced superior 
repair in trochlea with tangible evidence of inter-individual variability leading us to recognize 
good and poor trochlear responders. Negligible repair tissue volume was observed in all eight 
condyles. ICRS score indicated significantly higher macroscopic restoration in trochlear defect. 
Histological and histomorphometrical examination provided further evidence of superior repair in 
trochlea indicated by significantly higher GAG and collagen content of matrix in repair tissue. In 
vitro characterization of progenitor cells isolated from contralateral knee confirmed our earlier 
findings and trochlea exhibited increased number, clonogenic potential and chondrogenic potency 
compared to condyles. In an important finding, we showed that the intrinsic difference in the 
repair potential of trochlea may be a result of lower number, reduced surface marker expression 
and low clonogenic and chondrogenic potential of progenitor cells present in metaphyseal 
marrow. We believe that reduced cell number with lower clonogenic potential causes a reduction 
in the downstream differentiation potential in vitro as well as in vivo. Linear regression analysis 
of univariate scatter plots revealed moderate to strong positive correlation between repair 
outcome parameters as dependent variables and biological properties as independent variables. 
GLM analysis with forward selection of variables enabled us to identify cell number, clonogenic 
and collagen expression of trochlear cells as most important variables in predicting repair 
outcome in an individual. These studies have allowed us to provide substantial evidence of 
location-, age and donor-dependent variability in marrow stimulated cartilage repair outcome. 
Our extensive characterization and robust analysis protocol showed that intrinsic biological 
properties of subchondral bone progenitors strongly influence in vivo repair potential.  
While our analyses of subchondral bone parameters provide new avenues to improve BMS 
cartilage repair, it also stressed upon the need for development of approaches for successful 
functional repair, especially in challenging cases. Classical and augmented BMS has been tested 
in several pre-clinical studies. Unfortunately, promising strategies fail to translate successfully 
into a clinical practice since acute defect preclinical defect models are an inaccurate 
representation of clinical pathology. Our studies have led us to conclude that presence of 
voluminous, stable and adherent blood clot is a critical factor in ensuring superior quality and 
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quantity of regenerated tissue. Chronic defects created in adult animals were clearly more 
challenging to treat and were evidently distinct from fresh, acute defects. Increased biological 
stimulation provided by PRP stabilized by the CS implants showed superior repair potential in 
treatment of chronic, degenerative lesions. We believe that increased bioactivity achieved by the 
application of PRP along with beneficial properties of CS in cartilage regeneration stimulated 
better matrix restoration in chronic defects treated with BMS and augmented with CS/PRP 
implants. Histological analysis confirmed an overall improvement in repair in BMS+CS/PRP 
knees as indicated by higher O’Driscoll scores and histomorphometric assessment. Although not 
significant, CS/PRP implants also increased subchondral bone remodeling compared to defects 
treated with BMS augmented with PRP. Taking synthesis of these observations, we believe that 
chitosan/PRP clots have a significant potential for use in cartilage repair because of their superior 
handling properties as well as their increased bioactivity due to the concentration of platelets and 
associated growth factors. 
The comprehensive analysis of diverse factors studied in this research project reveal underlying 
mechanism of individual-to-individual variability in BMS repair. In addition, method to further 
stimulate BMS with a bioactive implant has been tested. Upon combination with structural 
imaging, these results may be applied in development of methods for identification of factors 
which influence repair and assist clinicians in modifying their treatment on a more patient 
relevant basis, especially in demanding cases. At this point, we realize that we have made 
noteworthy critical progress in the field of cartilage repair; however, these conclusions only give 
rise to more questions which when answered can make further contribution towards providing 
relief from osteoarthritic pain and discomfort.    
Although beyond the scope of this research, following recommendations are worth considering in 
future: 
1. Biochemical and molecular analysis of BMSCs. One of the deficits of our characterization 
assays was the lack of a biochemical and molecular analysis. We carried out 
immunohistopatholgical analysis to assess the chondrogenic potential of pellets from 
condyles and trochlea. While the assessment was sufficient for us to conclude superior 
properties of trochlea, it will be interesting to investigate the biochemical and molecular 
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changes occurring in temporal evolution of pellets over three week culture period. 
Transcriptional and translational profiling do not always concur and detailed analysis of 
genetic expression profile might provide valuable insights. Pellets can be harvested at 
multiple time points during differentiation in order to reveal the molecular mechanisms 
responsible for differences in cellular behaviour of cells present in different locations. 
While expression of Coll-II and aggrecan genes can explain the differences in the matrix 
composition, analysis of Sox-9 may reveal important mechanism of these differences. 
Biochemical analysis of spent media can further aid in determining the differences in the 
biochemical composition of condylar and trochlear pellets and help us advance our 
current understanding of location-dependent variability in chondrogenic differentiation. 
 
2. Characterization of huBMSCs. Although this was beyond the scope of this project, 
detailed characterization of huBMSCs must be carried out in future. Differences between 
rbBMSCs and huBMSCs explored in the past have been discussed in chapter 7. 
Consequently, the results from this study provide an initial understanding of the 
mechanism of inter-individual variability observed in humans. Extrapolation of these 
results would require careful consideration of anatomical, mechanical and biophysical 
components of cartilage repair.  
 
3. Correlation studies in young animals. Correlation of properties of BMSCs and cartilage 
repair outcome in young rabbits will likely be complicated due to their high spontaneous 
repair potential. We observed high inter-individual variability in biological properties of 
BMSCs isolated from young condyle and trochlea. A study aimed at correlating the repair 
outcome with biological properties of underlying BMSCs in a young rabbit might further 
elucidate the mechanism for these variations.  
 
4. Test the expression of Col-I. Deposition of collagen type II and GAG indicate the hyaline 
nature of repair tissue and pellets. In order to understand the nature of matrix 
composition, it is important to study the expression of Col-I. Fibrocartilagenous repair is 
characterized by matrix with varying amounts of Col-I. Matrix composition of repair 
tissue has a critical bearing on the mechanical and structural durability of repair tissue. 
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We could not carry out analysis of col-I in these studies due to discontinuation of anti-
Col-I antibody being used in our lab. We were unable to identify an alternative Col-I 
antibody that performed reliably in rabbits. Identification of new antibody epitope and 
optimization of histological protocol for application of new antibody are in progress. 
Meanwhile, we were able to derive meaningful conclusions about the hyaline nature of 
repair tissues generated in current studies.  
 
5. In depth analysis of OA pathology in chronic model. The analysis of changes during 
progress of OA in the chronic model developed here was beyond the scope of this 
proposal. Multiple pro-inflammatory cytokines and growth factors are known to 
aggravate the OA pathology in chronic lesions. Several challenges with an adverse effect 
on success of cartilage repair in a degenerative and inflammatory environment of chronic 
lesion have been discussed in chapter 6 and 7. Detailed understanding will help us 
identify responders which can serve as targets for novel repair strategies to improve repair 
outcome in challenging conditions.  
 
6. Mechanical testing of repair tissue. Mechanical strength is an important parameter in 
determination of the durability and functional behaviour of repair tissue. Studies aimed at 
determining the mechanical strength of the repair tissues generated with different 
treatments might suggest successful approaches for cartilage repair in future.  
 
7. Additional time points for chronic model. We chose duration of development of chronic 
lesion and cartilage repair based on our understanding from existing studies. Although we 
find one month to be sufficient time for development of OA pathology, additional time 
points must be studied in order to evaluate the long-term repair outcome. More often than 
not, BMS leads to formation of a fibrocartilagenous repair tissue with severely 
compromised mechanical durability. A long term study help will likely improve the 
quality and volume of repair outcome and enable a more meaningful testing of its 
durability and stability. 
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8. MFX alone group. The study presented in this research proposal compared the effect of 
treatments including CS/PRP and recalcified PRP. A group treated with BMS alone was 
conspicuously absent. The rationale for choice of PRP alone as control treatment has been 
discussed in chapter 6. However, in order to improve our understanding of bioactive 
stimulation provided by individual components of the proposed treatment, it will be 
imperative to conduct a study with a control group receiving treatment with BMS alone. 
Now that we have provided a proof of concept, a larger study with more number of 
animals can be planned in future with statistically powered groups to compare all 
treatments.  
 
9. Dosage analysis of CS/PRP. Small scale studies designed to test multiple concentrations 
of CS after deliberate consideration might be carried out in future, specifically to suit the 
needs of different animal models. We need to strike a balance between efficient cartilage 
repair and extensive immune response leading to formation of granulation tissue which 
might delay repair process.    
 
10. Chronic model studies in a larger animal. Structural variations in the joint anatomy have 
profound impact on mechanical profile of repair tissue. Application of CS/PRP must be 
tested in larger animals such as sheep in order to evaluate the role of denser subchondral 
bone in large animal taking us one step closer for eventual clinical translation. 
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Scientific challenges 
Variability in cellular behaviour of BMSCs during in vitro characterization. Earlier studies 
have shown that drilling deep to 6 mm (D6) improved the repair outcome in trochlea when 
compared to drilling to 2 mm (D2). The likely cause was that deep drilling provided access to 
metaphyseal marrow which is richer in progenitor cell population. As a result more cells are 
recruited to the defect thereby improving the repair response. However, results in the current 
study led us to conclude that chondrogenic potential of trochlea lower BMSCs isolated from 
metaphyseal marrow was inferior to that of epiphyseal trochlear BMSCs. It is likely that the 
superior repair with D6 arises because the volume of bone participating in repair is three times 
the volume of bone participating in D2. This would eventually lead to an increase in the number 
of cells participating in the repair thus improving the repair outcome. In vitro culture makes this 
difference inconsequential and would likely be a true reflection of inherent potential of these 
cells. However, trochlea lower BMSCs did demonstrate highest clonogenic potential which was 
not reflected in the chondrogenic potential. We observed similar results with progenitor cells 
isolated from young and old animals. The mechanism for this observation still remains unclear. A 
possible explanation can be attributed to heterogeneity in multipotency of progenitor cells. Only a 
fraction of progenitor cells are really tripotential while a majority of population is either uni- or 
bipotential. It is possible that metaphyseal marrow is richer in uni-or bipotent cells while 
progenitor cells in epiphyseal marrow may possess propensity towards chondrogenic lineage. 
Also, it is impossible to determine the influence of culture conditions on the accuracy of assays 
as the properties of progenitor cells have been shown to be influenced by culture conditions in a 
profound manner.  
Challenge of bilateral model in study 2. Study 2 was designed with an aim to correlate the 
repair outcome with inherent properties of progenitor cells present in condyle and trochlea in 
order to reveal a likely mechanism of variability observed in marrow stimulated repair outcome. 
In order to be able to draw parallels, it was important to characterize the cells with maximum 
phenotypic similarity to those participating in the repair process. A bilateral model was used to 
correlate the repair outcome in a donor-dependent fashion and also reduce inter-individual 
variability. This led to a difference of three weeks between the induction of repair and 
characterization of cells in vitro. We would be remiss if we did not recognize that the 
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modifications induced by defect generated in one knee might have an influence on the properties 
of BMSCs in the contralateral knee. However the model was most suitable given our limitations. 
Moreover, since the repair duration was limited to three weeks, we do not expect a significant 
influence on the properties of BMSCs in the contralateral knee and believe that their 
characterization provides a close approximation of their inherent properties in native state. 
Chronic model in study 3. In order to better represent the clinical situation, a chronic defect 
model was developed in study 3. We realized that chronic defects are certainly harder to treat and 
present inferior outcomes than those observed in acute defects in previously published studies. 
Chronic defects may involve altered joint biomechanics or variations in the subchondral bone 
progenitor cell population thus reducing the repair potential in this model. Although no 
alterations were observed upon macroscopic examination of patellofemoral and tibiofemoral 
compartments, further investigation may reveal factors affecting the nature of repair. More 
specifically, changes in subchondral bone revascularization or remodelling may adversely affect 
cartilage repair in this rather aggressive model and need to be further explored. Since the model 
requires two surgeries within a short span of four weeks, it will be worth considering the 
influence of these treatments on local inflammation which may in turn influence the efficacy of 
chitosan/PRP implants. Although the meniscus appeared normal, there may be microscopic 
changes with profound impact on cartilage repair since cartilage degeneration has been found to 
be concomitant with meniscus degradation in humans. Finally, although this model is aimed at 
closely simulating advance stages of OA, an accurate reflection of alterations in matrix 
metabolism and accompanying cartilage degeneration seen in OA may not occur.  
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